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1.0 Introduction 
In the past 5 years, the introduction of targeted therapy has dramatically changed the 
treatment armamentarium of advanced and metastatic renal cell cancer (mRCC) and has 
significantly improved the perspectives of patients with this disease. In December 2005, 
the Food and Drug Administration approved the first targeted agent, sorafenib, for the 
treatment of patients with cytokine-refractory disease. Thereafter, five other targeted 
agents have been registered for treatment of mRCC, including sunitinib, temsirolimus, 
everolimus, bevacizumab in combination with interferon-????????????????????????????????
Currently, sunitinib is the most widely prescribed targeted drug in patients with mRCC. 
Although sunitinib has gained remarkable success in mRCC, a number of issues still 
needs to be addressed to better understand the pharmacodynamics of this effective drug. 
Then, the management of patients with mRCC can be further improved. In this chapter, 
the literature on renal cell cancer (RCC) is summarized and the current treatment 
strategies for patients with mRCC in the era of targeted therapy are reviewed. 
Thereafter, sunitinib is discussed in more detail and the other chapters of this thesis are 
introduced.   
 
2.0 Renal cell cancer 
 
2.1 Epidemiology 
Kidney tumors comprise 2% of all adult malignancies and account for 208,000 new 
diagnoses and 102,000 deaths worldwide per year (1). RCC represents the vast majority 
of all kidney tumors. Over the last years, the incidence of all stages of RCC has increased 
(2;3), leading to a rising mortality rate. Men have a two times higher risk of developing 
RCC than women (1). The disease is most frequently diagnosed in the sixth and seventh 
decades of life (4). Most patients with RCC do not have an identifiable risk factor. Few 
risk factors for RCC have been established such as cigarette smoking, obesity, and 
hypertension (5-9), whereas fruit and vegetable consumption may have a protective 
effect (10;11). Approximately 2-3% of cases are familial and several hereditary RCC 
syndromes have been described including von Hippel-Lindau syndrome, hereditary 
papillary RCC, hereditary leiomyomatosis RCC, Birt-Hogg-Dubé, and tuberous sclerosis 
(12). Among these, the von Hippel-Lindau syndrome is most notable. A defect in one 
allele of the von Hippel-Lindau (VHL) gene, a tumor suppressor gene on the short arm of 
chromosome 3 (3p25–26), is responsible for this autosomal dominant syndrome, which is 
characterized by several vascular tumors including RCC, central nervous system 
hemangioblastoma and pheochromocytoma (13). Most people with the von Hippel-Lindau 
syndrome inherit a germline mutation of the VHL gene from the affected parent and a 
normal wild type gene from the unaffected parent. People who have already inherited 
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one mutated copy of the gene have a high probability of developing a second mutation in 
at least one other cell in their organs. According to the two-hit hypothesis, tumorigenesis 
occurs when both VHL alleles are inactivated (13). 
 
2.2 Clinical presentation  
Patients with RCC can present with local or systemic symptoms. However, most patients 
with localized disease are incidentally diagnosed with RCC, as a result of the extensive 
use of abdominal imaging. Local symptoms of RCC comprise hematuria, flank pain or a 
palpable abdominal mass, whereas systemic symptoms can be caused by metastases or 
paraneoplastic symptoms, such as weight loss, fatigue, fever, hypertension, hyper-
calcemia and erythrocytosis (14). Computed tomography (CT) scans are mainly applied 
for staging of RCC and to allow determination of local invasion, involvement of lymph 
nodes and distant metastases (15). Approximately 30% of all patients with RCC have 
metastatic disease at presentation (16). After complete resection of the primary tumor, 
recurrence develops in another 30% of patients (16). Metastatic disease is most 
frequently found in lungs (50-60%), followed by bone (30-40%), liver (30-40%) and 
brain (5%) (16). In addition, metastases from RCC can be detected at unusual sites such 
as thyroid gland, skin and underlying soft tissue.  
 
2.3 Pathology 
Histopathological examination of tumor tissue is necessary to confirm the diagnosis of 
RCC. Then, RCC is classified histologically into different subtypes (Figure 1). Clear cell 
carcinoma is the most common subtype and accounts for 75% of the cases (17). Clear 
cell refers to the high lipid content in cytoplasm that is dissolved during histological 
preparation, resulting in a lucent or clear cytoplasm. In the remaining cases, papillary 
carcinoma, chromophobe carcinoma and collecting duct carcinoma are described, which 
represent 10-15%, 5-10% and 1% of the cases, respectively (17).   
 
 
 
Figure 1. Representative examples of (A) clear cell, (B) papillary, and (C) chromophobe renal cell 
carcinoma. Haematoxylin and eosin staining, 20 × [Reprinted with permission; (18)]. 
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2.4 Staging  
Table 1A displays the tumor-node-metastasis (TNM) classification applied for staging RCC 
(19). Based on this classification RCC is further categorized into four stages of disease 
(Table 1B).  
 
Table 1A. Definition of TNM classification for renal cell cancer 
 
Tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor ????????????????????? ?????????? ?????????????????? 
T1a Tumor ? 4 cm in greatest dimension, limited to the kidney 
T1b Tumor > 4 cm but not > 7 cm in greatest dimension, limited to the kidney 
T2 Tumor > 7 cm in greatest dimension, limited to the kidney 
T2a Tumor > 7 cm but ? 10 cm in greatest dimension, limited to the kidney 
T2b Tumor > 10 cm, limited to the kidney 
T3 Tumor extends into major veins or perinephric tissues but not into the 
ipsilateral adrenal gland and not beyond Gerota’s fascia 
T3a Tumor grossly extends into the renal vein or its segmental (muscle containing) 
branches, or tumor invades perirenal and/or renal sinus fat but not beyond 
Gerota’s fascia 
T3b Tumor grossly extends into the vena cava below the diaphragm 
T3c Tumor grossly extends into the vena cava above the diaphragm or invades the 
wall of the vena cava 
T4 Tumor invades beyond Gerota’s fascia (including contiguous extension into the 
ipsilateral adrenal gland) 
Regional lymph node (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastases in regional lymph node(s) 
Distant metastasis (M) 
MX Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
Table 1B. Stage grouping for renal cell cancer 
 
Stage T N M 
I T1 N0 M0 
II T2 N0 M0 
III T1 or T2 N1 M0 
 T3 N0 or N1 M0 
IV T4 Any N M0 
 Any T Any N M1 
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2.5 Prognosis 
The prognosis of RCC is related to the stage of the disease. When applying the TNM 
classification to predict the prognosis, the 5-year cancer specific survival is 78%, 73%, 
55% and 17% for TNM stages I,II, III, and IV, respectively (20). In case of metastatic 
disease (stage IV), the prognosis is poor. Nevertheless, the prognosis among patients 
with distant metastases is highly variable. In 2002, Motzer et al (21) have introduced the 
Memorial Sloan-Kettering Cancer Center (MSKCC) criteria to predict the prognosis in 
patients with distant metastases. To date, these criteria (21) are still applied for risk 
stratification of mRCC patients. The MSKCC criteria are based on five risk factors 
including low Karnofsky performance status (< 80%), high lactate dehydrogenase (> 1.5 
times the upper limit of normal), low serum hemoglobin, high corrected serum calcium 
(> 10 mg/dL), and time from initial diagnosis to systemic treatment < 1 year. When 
patients have none of these risk factors they are categorized into the favorable risk 
group, whereas patients with 1-2 and ?? ?? ????? ???????? ???? ???????????? ????? ????
intermediate and poor risk groups, respectively. Accordingly, the MSKCC criteria are 
highly prognostic for survival in patients with mRCC when treated with first-line 
interferon-??? ??? ????? ?????????? ???? ??????? ???????? ????????? ???? ???? ??? ???? ?????????
when belonging to the favorable, intermediate and poor risk groups, respectively (21).  
 
3.0 Surgical treatment  
 
3.1 Localized disease 
The primary treatment of RCC consists of surgical excision of the primary tumor. The 
surgical procedure is mainly determined by the size and location of the primary tumor as 
well as the TNM stage. Therefore, careful physical examination, routine laboratory tests 
and adequate tumor staging are required before surgery. Radical nephrectomy is the 
gold standard curative operation for patients with localized RCC. For primary tumors with 
a size less than 4 cm, a nephron-sparing partial nephrectomy is generally recommended 
(15), as the recurrence-free and long-term survival are similar to those of patients 
treated with radical nephrectomy (22). In addition, partial nephrectomy may be 
considered in case of bilateral RCC, a solitary kidney, renal cell insufficiency or other 
situations in which radical nephrectomy is contraindicated. To decrease surgery-
associated morbidity, laparoscopic nephrectomy and minimally invasive percutaneous 
ablative approaches (e.g., radiofrequent heat ablation and cryoablation) for small tumors 
can be considered (15).   
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3.2 Primary metastatic disease 
When mRCC patients present with potentially resectable primary tumors and/or a solitary 
metastasis, nephrectomy and/or metastasectomy should still be considered, as long-term 
survival has been reported in some patients (23). In the cytokine era, responses of the 
primary tumor were very rare (24) and patients presenting with primary metastatic 
disease and a resectable primary tumor usually underwent cytoreductive nephrectomy. 
This strategy was based on the results of two randomized phase III trials, which had 
shown that nephrectomy followed by interferon-?? ? ??????? overall survival (OS) as 
compared with interferon-?? ?????? (25;26). A combined analysis of these two trials 
demonstrated a median OS benefit of 5.8 months in patients who underwent 
nephrectomy (27). In the era of targeted therapy however, the current role of 
cytoreductive nephrectomy has not yet been defined.  
 
4.0 Systemic therapy for metastatic disease 
 
4.1 Cytokine-based therapy 
Until the last decade, the treatment options for patients with metastatic RCC have been 
disappointing, since mRCC is resistant to standard cytotoxic chemotherapy (28). As some 
RCC tumors are able to evoke an immune response, immunotherapy was usually applied 
to treat patients with mRCC. The most consistent antitumor effects have been observed 
with cytokine-based therapy consisting of interferon-????????????????????-2. Although few 
mRCC patients, especially those with lung metastases and a previous nephrectomy, may 
achieve a long-lasting complete remission, cytokine-based therapy results in modest 
response rates and provides modest survival benefit (29). Interferon-??? ???? ?????
frequently administered cytokine, leads to an objective response of 7.5% and a median 
OS of 13 months (30). Currently, the targeted agents (Table 2) have replaced 
immunotherapy in the majority of mRCC patients. 
 
4.2 Biological pathways for targeted therapy in renal cell cancer 
An increased understanding of the biology of RCC has identified relevant targets for 
molecular therapy in RCC tumor cells and their microenvironment (Figure 2). Discovery 
of the VHL gene in families affected with the von Hippel-Lindau syndrome has clarified 
the pathogenesis of hereditary RCC (43). The VHL gene is a tumor suppressor gene of 
which biallelic inactivation promotes a phenotype at risk to develop malignancies. Of 
interest, in more than 90% of sporadic RCC, in particular the clear cell subtype, one VHL 
allele is inactivated through a deletion (loss of heterozygosity) (44). The other VHL allele 
is inactivated through either gene mutation (in approximately 80% of clear cell tumors) 
or through gene silencing by methylation [in approximately 19% of cases; (45;46)].  
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Figure 2. Biological pathways in renal cell cancer and its therapeutic targets. 
RCC, renal cell cancer; PI3K, phosphoinositide-3 kinase; mTOR, mammalian target of rapamycin; 
VHL, von Hippel-Lindau; HIF, hypoxia-inducible factor; VEGF, vascular endothelial growth factor; 
PDGF, platelet-derived growth factor; VEGFR, vascular endothelial growth factor receptor; PDGFR, 
platelet-derived growth factor receptor. 
 
Defective VHL gene function leads to overexpression of a series of proteins that can be 
used as targets for treatment. The VHL gene encodes the von Hippel-Lindau protein that 
is required for degradation of the crucial transcription factor hypoxia-inducible factor 
(HIF) (47). Under hypoxic conditions in tumors, the HIF protein is usually upregulated. 
When VHL is inactivated, the HIF protein cannot be degraded and the amount of HIF is 
increased even under normoxic conditions. Activated HIF translocates to the nucleus of 
tumor cells and results in transcription of a large repertoire of genes including vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) (48). VEGF is 
a potent proangiogenic protein which plays a key role in tumor angiogenesis [Figure 3; 
(49)] and exerts its effects by binding to the VEGF receptor (VEGFR) on endothelial cells 
(50). The high angiogenic potential of RCC, especially in tumors in which VHL is 
inactivated, results in highly vascularized tumors. Several drugs affecting VEGF signaling 
have been approved for treatment of mRCC. The activity of VEGF can be inhibited by 
bevacizumab (51), which is a monoclonal antibody that binds circulating VEGF, thereby 
preventing binding of VEGF to its receptor. 
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Figure 3. Tumor-induced angiogenesis. VEGF, vascular endothelial growth factor.  
 
The tyrosine kinase inhibitors (TKIs) sunitinib (35), sorafenib (37), and pazopanib (39) 
inhibit VEGF signaling by targeting the intracellular domain of its receptor on tumor-
associated endothelium, leading to reduced tumor angiogenesis. In addition, these TKIs 
are able to inhibit PDGFR in the microenvironment of tumors, thereby enhancing the 
anti-angiogenic effects of these drugs (52).  
Next to the VHL gene, HIF expression is regulated by signaling through the mammalian 
target of rapamycin (mTOR) pathway (53). This name is based on the precedent that the 
pathway was first discovered through genetic and molecular studies using the 
immunosuppressant drug rapamycin, also known as sirolimus (54). Activation of mTOR, 
which is a serine-threonine protein kinase, is regulated through a series of complex 
signaling interactions that link growth factor receptor signaling and other cell stimuli to 
activation of the phosphoinositide-3 kinase and Akt/protein kinase pathway (55). The 
mTOR pathway regulates cell proliferation, cell survival, cell motility, transcription, and 
protein synthesis. In RCC, mTOR is frequently activated (53;56). Presently, temsirolimus 
and everolimus, which are rapamycin derivatives or rapalogues, have been approved for 
treatment of mRCC. Temsirolimus and everolimus bind to an intracellular protein, FKBP-
12, forming a complex that inhibits the mTOR serine-threonine kinase (57). 
Consequently, these drugs induce cell cycle arrest and inhibition of tumor angiogenesis 
by reducing synthesis of VEGF (58).  
 
Growth factors
(e.g., VEGF)
Small tumor
Metastatic spread
Sprouting vasculature Growing tumor
Nutrients from blood
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4.3 Inhibitors of VEGF signaling  
 
4.3.1 Bevacizumab 
Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes the 
circulating VEGF protein without affecting VEGF bound to its receptor (51). The drug is 
administered intravenously (IV). In RCC, bevacizumab is usually administered at 10 
mg/kg with an interval of 2 weeks. Initially, bevacizumab has shown clinical benefit as 
compared to placebo in patients with cytokine-refractory mRCC (59). In this setting, the 
median progression-free survival (PFS) in patients receiving bevacizumab (10 mg/kg IV 
every 2 weeks) was significantly longer than that in the placebo group (4.8 versus 2.5 
months). The response rate of monotherapy bevacizumab was low (10%). As a next 
step, bevacizumab was added to interferon-α (9 million U subcutaneously 3 times a 
week) and was compared with interferon-α alone in the first-line setting (31;33). In two 
phase III randomized trials, the combination resulted in an improved objective response 
rate as compared to that in patients receiving interferon-α alone (26-31% versus 13%). 
Furthermore, adding bevacizumab significantly improved median PFS (8.5-10.2 versus 
5.2-5.4 months). The combination did not significantly improve OS, the primary endpoint 
of these studies (32;34), which may be the result of second-line treatment with TKIs 
confounding the OS analysis. 
Combination of bevacizumab with interferon-α is more toxic than either drug alone. Most 
frequently reported toxicities [> 20% of all grades according to Common Terminology 
Criteria for Adverse Events (CTCAE)] include fatigue (33-93%), proteinuria (18-71%), 
anorexia (36-71%), nausea (58%), pyrexia (45%), neutropenia (43%), bleeding (33%), 
asthenia (32%), hypertension (26-28%), influenza-like illness (24%), and headache 
(23%) (31;34). Of these toxicities, fatigue is a frequently reported grade 3 side-effect (> 
20%). Hypertension and proteinuria are predominantly associated with the 
administration of bevacizumab. In particular, the development of hypertension is a 
commonly reported side-effect after administration of drugs that target VEGF signaling. 
The underlying mechanism of the rise in blood pressure has not yet been fully clarified 
yet, but is sought in a reduction in microvascular density of the peripheral 
microcirculation (60).  
 
4.3.2 Sunitinib 
Sunitinib targets several receptors including VEGFR-1, -2, and -3, PDGFR-α and -β, c-Kit 
protein (c-Kit), and FMS-like tyrosine kinase-3 (FLT-3). Sunitinib is an oral TKI that is 
routinely administered at 50 mg once a day in a treatment cycle of 6 weeks consisting of 
a 4 weeks-on/2 weeks-off schedule. In a randomized phase III trial, sunitinib showed 
significant benefit as compared to interferon-α in first-line treatment of 750 patients with 
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mRCC (35). In the final analysis, the response rate was 47% in mRCC patients treated 
with sunitinib, whereas the objective response rate was 12% in patients treated with 
interferon-α (36). In addition, sunitinib improved PFS (11 versus 5 months) and OS (26.4 
versus 21.8 months) (36). This improvement in OS did not achieve statistical significance 
(36), which is most likely due to cross-over of interferon-α treated patients to sunitinib 
and/or other active targeted therapy at the time of disease progression. In this phase III 
trial, the median OS was extended as compared with historical controls, implying that 
targeted therapy has significantly improved the survival of patients with mRCC. In 
addition, sunitinib has shown efficacy as second-line drug in mRCC patients progressive 
on previous cytokine-based therapy (61;62). In 168 cytokine-refractory mRCC patients, 
sunitinib treatment was associated with a response rate of 42% and a median PFS of 8.1 
months (61). 
In some patients, intermittent dosing of sunitinib may cause flare-up symptoms in the 2-
week rest period. Therefore, Escudier et al (63) have evaluated the efficacy and 
tolerability of sunitinib when administered continuously at 37.5 mg daily in cycles of 6 
weeks. In this phase II study, mRCC patients who had failed previous cytokine therapy 
were enrolled. When administered continuously, the efficacy and tolerability of sunitinib 
were similar to the findings with the intermittent schedule (61;62); the median PFS and 
OS were 8.2 and 19.8 months, respectively. A meta-analysis of pharmacokinetic and 
efficacy data from all clinical studies with single-agent sunitinib in mRCC, however, has 
shown that the probability of greater response and survival increased with higher drug 
exposure (64). Therefore, dosing of 50 mg in a 4 weeks-on/2 weeks-off schedule is still 
recommended in patients who tolerate sunitinib well and do not experience clinical 
deterioration during the rest-period. 
Non-hematological toxicities that are most frequently (> 20% of all grades) associated 
with sunitinib treatment are diarrhea (53%), fatigue (51%), nausea (44%), stomatitis 
(25%), vomiting (24%), and hypertension [24%; (35)]. Clinically relevant hematological 
toxicities include leucopenia (78%), neutropenia (72%), and thrombocytopenia (65%). 
Although sunitinib-induced toxicities can be severe and may significantly impede patients 
in their daily activities, the incidence of grade 3 and 4 toxicities is low. 
 
4.3.3 Sorafenib 
Sorafenib was originally developed as a RAF kinase inhibitor, targeting the RAS-RAF-
MEK-ERK pathway, but was subsequently discovered to target other tyrosine kinases 
including VEGFR-2 and -3, PDGFR-α and -β, c-Kit, FLT-3, and RET (65;66). Sorafenib is 
an oral TKI and is administered at 400 mg twice a day. The efficacy of sorafenib has 
been demonstrated in a phase III randomized trial (37). In this study, 903 patients with 
cytokine-refractory mRCC were assigned to sorafenib or placebo. At a preplanned interim 
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analysis, the PFS of sorafenib-treated patients was superior to that of patients assigned 
to receive placebo. On the basis of these data, the protocol was amended to offer 
sorafenib to patients assigned to placebo. Although a partial response was reported in 
only 10% of patients, sorafenib significantly improved PFS as compared with that of 
placebo (5.5 versus 2.8 months) (37). However, sorafenib-treated patients did not have 
a significantly better OS than placebo-assigned patients (17.8 versus 15.2 months) (38). 
This lack of substantial improvement in OS was probably due to the cross-over design of 
the study (38). 
Sorafenib can induce rather severe toxicities, especially of the skin and gastrointestinal 
tract. Often (> 20% of all grades), sorafenib treatment is associated with diarrhea 
(48%), rash and desquamation (41%), alopecia (31%), hand-foot syndrome (33%), and 
fatigue (29%) (38). For specific toxicities, the incidence of grade 3 toxicities is low       
(< 10%). Nevertheless, grade 3 and 4 toxicities have been reported in 29% of patients. 
 
4.3.4 Pazopanib 
Pazopanib is a novel TKI and has more recently been approved for the treatment of 
mRCC. This drug inhibits VEGFR-1, -2, and -3, PDGFR-α and -β, and c-Kit (67). In 
general, pazopanib is orally administered at 800 mg once a day. A randomized, double-
blind, placebo-controlled phase III trial was the basis for drug approval (39). Initially, the 
study inclusion was restricted to patients progressive on previous cytokine-based 
therapy. The protocol was amended to include treatment-naïve patients, as the use of 
cytokines had decreased. In the overall study population, the independently assessed 
objective response rate was 30%. In the treatment-naïve and cytokine-pretreated 
population, response rates were 32% and 29%, respectively. Pazopanib showed an 
overall PFS benefit as compared with that of placebo (9.2 versus 4.2 months). In the 
treatment-naïve subpopulation, the PFS benefit was 8.3 months for pazopanib as 
compared to placebo (11.1 versus 2.8 months), whereas the PFS benefit was 3.2 months 
over placebo in the cytokine-pretreated subpopulation (7.4 versus 4.2 months). These 
favorable objective response rates and PFS benefits of pazopanib are comparable with 
those of sunitinib (35;36). Currently, the results for OS have not yet been published.     
The toxicity of pazopanib is similar to, if not less severe than, that of similar molecules 
such as sunitinib (35) and sorafenib (37). Diarrhea (52%), hypertension (40%), hair 
color changes (38%), nausea (26%), anorexia (22%), and vomiting (21%) account for 
the most frequently (> 20% of all grades) reported non-hematological side effects (39). 
Among the hematological toxicities, leucopenia (37%), neutropenia (34%), and 
thrombocytopenia (32%) are commonly reported. Grade 3-4 diarrhea and hypertension 
are reported in 3% and 4% of patients, respectively. 
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4.4 Inhibitors of mTOR signaling 
 
4.4.1 Temsirolimus 
Temsirolimus is an inhibitor of mTOR. The drug is administered IV at 25 mg per week. 
The efficacy of temsirolimus was first demonstrated in a phase II trial in patients with 
treatment-refractory mRCC. In a retrospective analysis of this study, the benefit of 
temsirolimus seemed pronounced in a subset of patients with poor prognosis (68). 
Hence, a randomized phase III trial (40) was conducted in 626 treatment-naïve mRCC 
patients having at least three out of six poor prognostic factors, which were defined as 
more than two metastatic sites of involvement plus five criteria according to the MSKCC 
prognostic criteria (21). Patients were randomized to either temsirolimus (25 mg weekly) 
or temsirolimus (15 mg weekly) plus interferon-α subcutaneously 3 times a week (3 
million U with escalation to 6 million U) versus interferon-α alone subcutaneously 3 times 
a week (3 million U with escalation to 18 million U) (40). The objective response rates 
among patients receiving interferon-α (4.8%), temsirolimus (8.6%), and combination 
therapy (8.1%) did not differ significantly. Temsirolimus treatment improved median PFS 
as compared with that of interferon-α alone (5.5 versus 3.1 months). In addition, 
temsirolimus-treated patients had a better OS than patients treated with interferon-α 
alone (10.9 versus 7.3 months). However, when patients on the combination regimen 
were compared with the interferon-α group, PFS and OS were similar, being 4.7 and 8.4 
months, respectively. 
Temsirolimus is well tolerated as compared with interferon-α. After administration of 
temsirolimus, asthenia (51%), rash (47%), nausea (37%), anorexia (32%), dyspnea 
(28%), hyperlipedemia (27%), infection (27%), diarrhea (27%), peripheral edema 
(27%), hyperglycemia (26%), hypercholesterolemia (24%), and fever (24%) are most 
frequently (> 20% of all grades) observed (40). Among these toxicities, most common 
grade 3 and 4 side effects are asthenia and hyperglycemia (both in 11% of patients). 
 
4.4.2 Everolimus 
The mTOR-targeting agent everolimus can be given orally; it is administered at 10 mg 
per day. In a double-blind randomized trial, the efficacy of everolimus has been 
investigated in 416 mRCC patients who had progressed on sunitinib, sorafenib, or both 
(41;42). Patients were assigned in a 2:1 ratio to receive everolimus (N = 277) or placebo 
(N = 139). At disease progression, patients were unblinded and those assigned to 
placebo were offered open-label everolimus. The objective response rate of everolimus 
was very low and almost similar to that in the placebo group [1.8 % versus 0%; (41)]. 
Treatment with everolimus significantly improved median PFS as compared with that of 
placebo (4.9 versus 1.9 months), but did not result in improved OS (14.8 versus 14.4 
22
months). Lack of increased OS was likely the result of the cross-over design of the study. 
A subsequent phase II study showed efficacy of the combination of bevacizumab (10 
mg/kg IV every 2 weeks) plus everolimus (10 mg per day) in treatment-naïve and 
previously treated mRCC patients (69); overall response rates were 30% and 23%, 
respectively. Additionally, median PFS was 9.1 and 7.1 months in these patients, 
respectively. These favorable results require further study of this promising combination 
and phase III studies are ongoing. 
Everolimus-induced toxicities are comparable with those associated with temsirolimus 
treatment (40). Stomatitis (44%), infections (37%), asthenia (33%), fatigue (31%), 
diarrhea (30%), rash (29%), nausea (26%), anorexia (25%), peripheral edema (25%), 
vomiting (24%), thrombocytopenia (23%), hypercholesterolemia (77%), hypertri-
glyceridemia (73%), and hyperglycemia (57%) are commonly (> 20% of all grades) 
described after treatment with everolimus (41). Among these toxicities, grade 3 and 4 
toxicities are rather rare. Grade 3 hyperglycemia is the most often reported grade 3-4 
toxicity and is observed in 15% of patients. In addition, everolimus-induced pneumonitis 
is a remarkable side-effect, of which grade 3 pneumonitis develops in 4% of patients.  
 
5.0 Targeted drugs in renal cell cancer: focus on sunitinib 
 
5.1 Chemistry 
Sunitinib malate (SU11248, Sutent®) is small molecule with a molecular weight of 398.5 
g/mol (532.6 g/mol as malate salt). The chemical name of sunitinib is 5-[5-Fluoro-2-oxo-
1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino 
ethyl)amide (70). The chemical structure of sunitinib is shown in Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chemical structure of sunitinib. 
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5.2 Mechanism of action 
As mentioned earlier, sunitinib inhibits several receptor tyrosine kinases including 
VEGFR-1, -2, and -3, PDGFR-α and –β, c-Kit, and FLT-3 (71). In biochemical tyrosine 
kinase and cellular proliferation assays, inhibition of these receptor tyrosine kinases was 
shown in the low nano-molar range (72-75). In addition, sunitinib targets RET (76) and 
colony-stimulating factor 1 receptor (CSF-1R) (77). Receptor tyrosine kinases are 
transmembrane proteins at the cell surface and transduce extracellular signals to the 
cytoplasm (78) (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Sunitinib interacts with the adenosine triphosphate (ATP) binding site of the tyrosine 
kinase receptors and prevents autophosphorylation, thereby inhibiting the downstream signaling of 
proteins. L, extracellular ligand; R, receptor; TK, tyrosine kinase; P, phosphorylation site. 
 
These proteins have extracellular domains, which enable binding of ligands, and 
intracellular catalytic domains. Some receptors act as monomers, whereas others (e.g., 
PDGFR-β) dimerize on ligand binding. When a ligand binds to the extracellular domain of 
the receptor, it results in autophosphorylation of the cytoplasmatic domain and 
stimulation of the tyrosine kinase activity. Then, tyrosine kinase activation stimulates 
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multiple downstream signaling pathways that are involved in DNA synthesis, 
proliferation, growth, migration and cell death (78). Sunitinib acts through competitive 
inhibition of adenosine triphosphate at its binding site, preventing autophosphorylation 
and kinase activity in the catalytic domain. As a result, transmembrane signaling is 
blocked, thereby affecting multiple downstream processes involved in tumor growth, 
metastasis formation and angiogenesis.   
 
5.3 Targets in renal cell cancer 
In RCC, the main targets for sunitinib are thought to be located in the microenvironment 
of tumor cells (Figure 2). The VEGF and PDGF pathways are supposed to be the most 
important pathways for sunitinib in RCC. VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) are 
expressed on vascular endothelial cells, whereas VEGFR-3 (Flt-4) is present on lymphatic 
endothelium. In addition, PDGFR-β is expressed on pericytes and smooth muscle cells 
covering blood vessels. Inhibition of VEGFR on tumor-associated endothelium is assumed 
to be the major therapeutic effect of sunitinib (79;80). As a result, sunitinib impedes 
tumor angiogenesis which is stimulated by VEGF that is produced by tumor cells. 
Furthermore, inhibition of PDGFR signaling might enhance the anti-angiogenic effects of 
sunitinib by targeting pericytes, which are able to protect endothelial cells from apoptosis 
(81). Although indirect actions of sunitinib on cells in the microenvironment seem to 
prevail, there is increasing evidence that sunitinib also modulates tumor growth of RCC 
by direct actions on tumor cells (82). Apart from VEGF and PDGF signaling, sunitinib 
targets other pathways that may contribute to its efficacy in RCC. Although FLT-3, c-KIT 
and RET are assumed to be effective targets in other specific malignancies including 
acute myelogenous leukemia (83), gastrointestinal stromal tumors (84), and thyroid 
cancer (85), the additional value of targeting these receptors in RCC has not been 
clarified yet. In normal tissue, FLT-3 is usually expressed on immature hematopoietic 
progenitor cells, mature myeloid and lymphoid cells and controls the proliferation and 
survival of hematopoietic progenitor cells (86). Inhibition of FLT-3 may be associated 
with sunitinib-induced bone marrow toxicity (87). In addition, c-KIT is expressed on 
hematopoietic progenitor cells, mast cells, germ cells and the interstitial cell of Cajal in 
the gastrointestinal tract (88). At the level of melanocyte function, inhibition of c-KIT is 
associated with hair depigmentation (89), which is frequently reported after sunitinib 
treatment (90). Furthermore, CSF-1R is activated by the osteoclastogenic factor CSF, 
which is produced by tumor cells, thereby stimulating osteoclasts and increasing 
osteoclastic activity of osteoclasts (77). As a result, targeting CSF-1R may inhibit bone 
metastases. The clinical value of inhibiting CSF-1R has not yet been elucidated.  
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5.4 Preclinical activity 
In preclinical studies, sunitinib has shown growth inhibition and tumor regression in 
various human cell lines and human xenografts models including RCC (72;80). In vitro 
studies in cell lines of clear cell RCC have demonstrated that pharmacologically relevant 
concentrations of sunitinib (~ 0.1 μmol/L) inhibited the phosphorylation of VEGFR and 
PDGFR-β (71;80) and blocked endothelial cell proliferation and invasion, but did not 
affect the viability of RCC cell lines in vitro (80). Studies in RCC xenografts have shown 
that sunitinib could also inhibit tumor angiogenesis in vivo, but may not affect 
proliferation or apoptosis of RCC cells. The results of a previous study indicated that 
sunitinib inhibits RCC growth primarily through an anti-angiogenic mechanism (80). In 
contrast to these results, Xin et al (82) have reported that sunitinib induces apoptosis in 
clear cell RCC cells through inhibition of signal transducer and activator of transcription 3 
(Stat3). In that study, however, IC50 values required to inhibit RCC cell viability and 
proliferation in vitro were in the range of 5 μmol/L and above, which are much higher 
than the clinically relevant plasma concentrations of sunitinib, which are in the range of 
50 to 100 ng/mL or 0.1 to 0.2 μmol/L (72;90). 
 
5.5 Human studies 
 
5.5.1 Dosing and schedule 
Although initial phase I studies were planned to administer sunitinib continuously, a 
resting period was incorporated to allow patients to recover from potential severe bone 
marrow and adrenal toxicity that was observed in animal studies (71). Therefore, 
sunitinib was administered in a 4 weeks-on/ 2 weeks-off schedule in phase I studies 
(83;90). At doses of 75 mg daily or above, dose-limiting toxicities of fatigue, 
hypertension and bullous skin toxicity were encountered (83;90). As a result, the 
recommended phase II dose was set at 50 mg daily on a 4/2 schedule. Dosing of 
sunitinib is not based on body surface area (BSA), since a phase I study showed that 
BSA-normalized dosing would not improve the variability of sunitinib exposure (90).  
 
5.5.2 Pharmacokinetics 
After oral administration, sunitinib is mainly metabolized by the liver and eliminated by 
biliary excretion into the feces (91). Metabolism occurs primarily by the cytochrome P450 
(CYP) 3A4 isoenzyme in hepatic microsomes (92). Sunitinib undergoes two N-de-
ethylation steps (93). First, CYP3A4 N-de-ethylates sunitinib to the active metabolite 
SU12662. This metabolite appears to be equipotent to the parent compound in 
biochemical and cellular assays for inhibition of VEGFR, PDGFR and c-KIT (94). The active 
metabolite SU12662 is further metabolized by CYP3A4 to the inactive metabolite 
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SU14335 (93). This N-de-ethylation step occurs at a slower rate than the first step. As 
pharmacokinetic studies showed that inhibitors and inducers of CYP3A4 significantly 
affect the metabolism of sunitinib (92), it is recommended to avoid these drugs in 
patients treated with sunitinib. Consumption of grapefruit juice, which is a potent 
intestinal cytochrome CYP3A4 inhibitor, however, resulted in a marginal increase in 
sunitinib exposure (95). In addition, it was demonstrated that food did not affect the 
bioavailability of a single dose sunitinib of 50 mg in healthy volunteers (96). In a phase I 
study, the peak plasma concentration of sunitinib was reached at five hours after oral 
administration of 50 mg sunitinib (90). The steady state concentrations of sunitinib and 
its active metabolite SU12662 were achieved within 10 to 14 days (97). In a pharmaco-
kinetic meta-analysis, the terminal half-lives of sunitinib and its active metabolite 
SU12662 were estimated at 69 and 80 hours, respectively (98). Daily administration of 
sunitinib led to accumulation of the drug. On day 28, the accumulation of sunitinib and 
SU12662 were respectively 3.0-5.5 and 7-15 times higher than on day 1 (90). Daily 
dosing of sunitinib 50 mg resulted in sufficient plasma concentrations above 50 ng/mL, 
as required for adequate inhibition of VEGFR-2 and PDGFR-β (72).  
 
5.5.3 Pharmacodynamics 
As mentioned in paragraph 4.3.2, sunitinib has proven efficacy with an acceptable 
toxicity profile in mRCC patients. In the main study (35), a randomized phase III trial 
comparing sunitinib with interferon-α in first-line treatment, sunitinib showed a response 
rate of 47% as well as an improved PFS (11 versus 5 months) and OS (26.4 versus 21.8 
months) as compared with interferon-α (36). Since then sunitinib is the first-line 
treatment of choice for mRCC patients. Although most patients will benefit from sunitinib, 
a number will demonstrate progressive disease (PD). In addition, PD will occur in 
patients at a certain stage of sunitinib treatment. Some patients have difficulties to 
tolerate the drug due to a series of toxicities occurring simultaneously. At present, 
several other targeted drugs are available and may be more suitable for specific patients. 
As a result, sunitinib treatment in mRCC patients can be challenging for patients as well 
as their treating physicians. Therefore, a better understanding of the efficacy and toxicity 
of sunitinib is necessary to improve the management of mRCC patients. To this end, 
specific tools are required to predict the efficacy and toxicity of sunitnib in individual 
patients with mRCC. Then, individual mRCC patients can be appropriately selected for 
treatment with sunitinib.  
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6.0 Outline of the thesis 
 
The current chapter gives a summary of the literature on the approved targeted drugs for 
treatment of mRCC, thereby focusing on sunitinib. In this thesis, a number of clinical 
issues concerning sunitinib treatment in mRCC patients is investigated.  
 
Part I of the thesis is related to the efficacy of sunitinib in patients with mRCC. In chapter 
2, the efficacy of sunitinib is evaluated in patients with a primary RCC tumor in a 
compassionate use programme. In chapter 3, the surgical implications of sunitinib for 
patients with primary metastatic disease are studied. In chapter 4, the efficacy of 
sunitinib in patients with newly diagnosed brain metastases is reported. The role of 
genetic polymorphisms for prediction of PFS in mRCC patients treated with sunitinib is 
explored in chapter 5.  
 
Part II includes chapters in which the side-effects of sunitinib treatment are described. In 
chapter 6, factors that may predict severe toxicity in unselected patients with advanced 
RCC are investigated. In chapter 7, it is discussed whether severe cognitive disorders can 
develop after sunitinib treatment in elderly patients and whether these mental changes 
may be associated with preexisting arteriosclerotic leukoencephalopathy. In chapter 8, a 
multicenter study, that examines whether genetic polymorphisms are associated with 
sunitinib-induced toxicity, is described.  
  
Part III reports clinical studies on the pharmacodynamic effects of sunitinib treatment in 
mRCC patients. In chapter 9, it is evaluated whether computed tomography (CT) based 
criteria, previously developed by Choi et al (99), are of additional value for early 
prediction of clinical outcome in mRCC patients treated with sunitinib. In chapter 10, the 
relation between the dosing schedule of sunitinib and the changes in hemoglobin levels 
during sunitinib treatment is explored. In chapters 11 and 12, the effects of sunitinib on 
respectively endothelial progenitor cells and circulating proteins are investigated. In 
chapter 13, the association between the sunitinib-induced rise in blood pressure and a 
change in microvascular density in the skin is examined. Finally, in Chapter 14 and 15, 
the results described in this thesis will be summarized and put into perspective.  
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Abstract Purpose: Nephrectomy before immunotherapy in patients with metastatic renal cell cancer
(RCC) will improve patient outcome. In addition, the primary tumor is known to be refractory to
cytokines. Sunitinib is nowapproved for treatment of advanced RCC, but its effect on the primary
tumor has yet to be reported.
Experimental Design: All patients treated with sunitinib for advanced RCC without prior
nephrectomy were reviewed and sequential computed tomography scans were evaluated for
response in the primary tumor as well as metastases according to Response Evaluation Criteria
in Solid Tumors.Volumes of primary tumors and central necrotic areas were measured with the
perimeter method.
Results: Computed tomography scans were available for evaluation of response in 17 of 22
patients with a primary tumor in situ (1patient with two primaries). According to Response
Evaluation Criteria in Solid Tumors, 4 patients had a partial response, 12 had stable disease, and
1had progressive disease.The one-dimensional longest diameter of the primary tumor correlated
with the volumetric measurements both at baseline and at the time of evaluation of response.
Excluding the patient withprogressive disease, themedian volume reductionwas 31%associated
with a median increase in the volume of necrosis of 39%.Three patients underwent nephrectomy
and tumors showed extensive necrotic areas next to small fields of vital tumor cells.
Conclusions: Sunitinib can induce a significant reduction in volume of primary renal cell tumors.
Further trials need to address the role of nephrectomy in advanced RCC patients on sunitinib
treatment.
Until recently, cytokine therapy was the only treatment for
metastatic renal cell cancer (mRCC), but less than 20% of
patients benefit from a response (1). Responsiveness of the
primary tumor to immunotherapy is very rare (2–4). For that
reason, patients with synchronous metastases and a resectable
primary tumor in situ will undergo a nephrectomy as part of a
multimodality approach. This approach is largely supported by
data from two randomized phase III clinical trials showing a
longer overall survival in patients with nephrectomy followed
by IFN-a versus patients on IFN-a alone (5–7). An additional
feature in favor of nephrectomy is the rare phenomenon of
spontaneous regression of metastases (8). It has also been
argued that nephrectomy may improve the response to
immunotherapy by reduction of immunosuppressive factors
produced by the primary tumor.
There are several subtypes of renal cell cancer (RCC), of
which f75% contain clear cell carcinoma histology. At least
60% of these tumors is associated with inactivation of the von
Hippel-Lindau tumor suppressor gene. This leads to elevated
protein levels of hypoxia-inducible factor a and consequent
overexpression of vascular endothelial growth factor and
platelet-derived growth factor (9). These growth factors
promote tumor angiogenesis, which likely contributes to the
hypervascularity of RCC. Inhibitors of angiogenesis have
proven efficacy in RCC, and among them is sunitinib
(SU011248 or Sutent; Pfizer Pharmaceuticals Group). Sunitinib
is an oral tyrosine kinase inhibitor of the vascular endothelial
growth factor receptors, the platelet-derived growth factor
receptors, flt-3, and c-Kit, and has been approved for the
treatment of advanced RCC. In a randomized phase III clinical
trial, sunitinib has shown an objective response rate of 31%,
which was significantly higher than the 6% in patients that
received IFN-a (10). The progression-free survival of the
sunitinib treatment group was 11 months, whereas that of
the IFN-a group was only 5 months (10). Based on current data
available, sunitinib is now the preferred drug for first-line
treatment of most mRCC patients (1).
Presently, there is little experience with the effects of
sunitinib on the primary tumor in patients that present with
mRCC. Therefore, we conducted a retrospective analysis of the
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drug-induced response in the primary tumor and also
addressed the radiologic changes in contrast enhancement
associated with the increase in central necrosis.
Patients andMethods
Patients and treatment. Medical records were reviewed of patients
treated with sunitinib for advanced RCC in two centers in the
Netherlands (VU University medical center and the Netherlands Cancer
Institute) from December 2005 to June 2007. Patients were selected that
received sunitinib without prior nephrectomy. Most of the patients had
been included in an expanded access program until September 2006,
after which sunitinib was registered and available on doctor’s
prescription. Each participant signed an institutional review board–
approved protocol-specific informed consent in accordance with
national and institutional guidelines.
Sunitinib was administered orally at a dose of 50 mg daily, consisting
of 4 wk of treatment followed by a 2-wk rest period in cycles of 6 wk. A
dose reduction of sunitinib (to 37.5 mg and then to 25 mg) was allowed
depending on the type and severity of adverse events. If patients had
symptoms of progressive disease during the rest period, there was the
possibility for continuous dosing of sunitinib at 37.5 mg/d.
Tumor response was assessed by computed tomography (CT) scans
every two to three cycles of treatment according to the Response
Evaluation Criteria in Solid Tumors (RECIST; ref. 11). Tumor measure-
ments were calculated separately for the response in the primary tumor
and in themetastatic sites. Progression-free survivalwas the time between
the first day of sunitinib and the date of progressive disease on the CT
scan or clear clinical evidence of progressive disease. Survival was the
time between the first day of treatment and the date of death or the date at
which patients were last known to be alive. For progression-free survival
and survival analysis, data collection was closed on November 1, 2007.
Image analysis. Portovenous phase CT scans of the abdomen were
acquired f70 s after i.v. injection of a low-osmolar nonionic contrast
agent (Omnipaque or Ultravist 300). All series were reconstructed in
5-mm contiguous axial slices. Because volumetric measurements are
considered as the reference standard for the assessment of the objective
response, volumes of the primary tumors as visualized on CT scans
were calculated using the perimeter method (12). Image viewing and
manipulation were controlled with Centricity RA 600 version 6.1
software (GE Healthcare, Inc.), which allows the radiologist to draw
perimeters around the regions of interest. The software then automat-
ically calculates the area enclosed by the perimeter and the mean
density of this area in Hounsefield units (HU).
An independent radiologist (M.R.M.) blinded to the patients’
outcome examined the CT scan images. On each CT scan section in
which the primary tumor was visible, the radiologist drew a line along
the perimeter of the tumor to assess the area. The total volume (V) of
the primary tumor was then calculated by summing the separate cross-
sectional areas (A), multiplied by the section increment in millimeters
(I), as follows: V = I(A1 + A2 + . . .An), where n is the number of
sections containing tumor and V is expressed in cubic centimeters.
Primary tumors of RCC are known for central heterogeneity that is
associated with intratumoral necrosis or hemorrhage on histologic
assessment (13). Therefore, the volumetric measurements were repeated
for the central hypodense nonenhancing part of the tumor. Non-
enhancing areas at a density <40 HU were arbitrarily defined as most
compatible with necrosis.
Statistical analysis. The total volume of the primary tumor, the
volume of the hypodense nonenhancing part, and the volume of the
solid part were calculated. The relation between volumetric measure-
ments and the longest tumor diameter was assessed by Spearman
correlation test. The Wilcoxon signed rank test was used to compare the
tumor measurements at baseline and between 1.2 and 3.9 mo of
sunitinib treatment. Two-tailed P < 0.05 was considered significant.
Table 1. Antitumor effects of sunitinib in patients with advanced RCC without prior nephrectomy
Pt no. Diameter
baseline (cm)
RECIST Volume PFS
(mo)
Survival
(mo)
Primary
(%)
Metastases
(%)
Overall
(%)
Overall Tumor
baseline
(cm3)
Tumor
# (%)
Necrosis*
baseline
(cm3)
Necrosis*
# (%)
Solid
# (%)
1 13 -31 -34 -33 PR 695 -64 131 -43 -68 18+ 18+
2 7 -12 -27 -21 SD 138 -51 61 -13 -81 4 5
3 6 -6 -27 -15 SD 131 -24 14 195 -50 11 20+
4 13 -16 -14 -15 SD 536 -27 189 39 -63 3 4
5 7 0 c 0 SD 189 -18 28 109 -40 15+ 15+
6ab 11 -19 -9 -22 SD 773 -58 124 34 -75 13+ 13+
6b 5 -33 -9 -22 SD 49 -60 3 359 -87
7 7 -17 -42 -35 PR 133 -31 51 7 -54 5 6
8 8 1 8 5 SD 227 12 4 -14 13 7 12
9 15 -18 -56 -32 PR 1715 -46 642 29 -90 10 15
10 8 -11 -45 -32 PR 281 -38 208 -43 -24 14 15+
11 10 10 77 41 PD 439 53 271 39 77 0.2 4
12 9 -20 -100 -29 SD 293 -30 45 129 -59 10 14+
13 6 -8 -55 -20 SD 116 -37 22 5 -47 13 14+
14 6 -2 -32 -27 SD 158 -42 22 245 -88 9+ 9+
15 7 7 -16 -10 SD 174 14 28 53 7 6 8+
16 16 -12 -28 -17 SD 1651 -25 228 158 -54 12+ 12+
17 5 11 50 18 SD 57 8 16 163 -52 1 4
Abbreviations: RECIST primary, RECIST applied for primary tumor only; RECIST metastases, RECIST applied for metastases only; RECIST
overall, overall RECIST applied for both primary tumor and metastases; PR, partial response; SD, stable disease; PD, progressive disease;
Volume tumor, total volume of primary tumor; Volume necrosis, volume necrotic part of the primary tumor; Volume solid, volume solid part of
the primary tumor; D (%), change in percentage; PFS, progression-free survival.
*The hypodense nonenhancing part of the tumor is referred to as necrosis.
cMetastases were present but not measurable.
bPatient no. 6 had bilateral primary tumors in situ.
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Results
Patients and treatment response. Eighty-two patients with
advanced RCC had been treated with sunitinib in the expanded
access program, and an additional 13 patients received the drug
on doctor’s prescription following registration. Of these 95
patients, 22 patients had a primary tumor in situ. There were 17
males and 5 females, and the median age was 61 years (range,
48-77 years); 21 patients had clear cell carcinoma and 1 patient
had non-clear cell carcinoma. According to the Memorial Sloan-
Kettering Cancer Center criteria [based on the five risk factors:
low Karnofsky performance status (<80%), high lactate dehy-
drogenase (>1.5 times the upper limit of normal), low serum
hemoglobin, high corrected serum calcium (>10 mg/dL), and
time from diagnosis to treatment <1 year; ref. 14], 16 patients
were categorized into the intermediate-risk group and 6 patients
into the poor-risk group. According to the prognostic criteria for
vascular endothelial growth factor – targeted therapy by
Choueiri et al. (ref. 15; based on the five risk factors: time
from diagnosis to treatment <2 years, baseline platelet count
>300 109/L, neutrophil count >4.5 109/L, corrected calcium
<8.5 or >10 mg/dL, and initial Eastern Cooperative Oncology
Group performance status >0), 1 patient had no adverse
prognostic factor, 3 patients had 2, and 18 patients had >2
adverse prognostic factors. In 16 patients sunitinib was given as
first-line treatment, and in 6 patients, as second-line treatment.
The primary decision not to perform a nephrectomy was based
on a surgically unresectable primary tumor (n = 10), extensive
metastatic burden defined as the sumof the diameter of themeta-
stases exceeding the diameter of the primary tumor (n = 6), poor
Memorial Sloan-Kettering Cancer Center prognosis (n = 2), soli-
tary kidney (n = 2), high age (n = 1), and doctor’s choice (n = 1).
At baseline, the median performance status according to
Eastern Cooperative Oncology Group was 1 (range, 0-3).
During sunitinib treatment, the physical condition of 8 of 22
patients improved remarkably. Three patients had an obvious
deterioration of their performance status due to progressive
disease. Four patients presented with symptoms related to the
primary tumor consisting of flank pain and hematuria, which
gradually disappeared in all of them. Four patients required a
dose reduction to 37.5 mg/d because of adverse events and five
switched to a continuous dosing schedule.
Four of 22 patients could not be evaluated for treatment
response because of early termination of sunitinib due to
progressive disease. In 18 patients, a follow-up CT scan was
available. One of these 18 patients was excluded because he
required embolization of the primary tumor within the first
cycle due to extensive hematuria already present at the start of
sunitinib. One patient had bilateral primary tumors. Summa-
rized, 17 patients with 18 primary tumors were included in the
image analyses.
According to RECIST, 4 of 17 patients reached a partial
response, 12 had stable disease, and 1 had progressive disease
(Table 1). Only in patient no. 15 the response of the primary
tumor was not in line with the response of the metastases.
Excluding the patient with progressive disease, RECIST calcu-
lations were analyzed for the primary tumor only, themetastases
only, and the overall response, resulting in a median change of
-12%, -28%, and -21%, respectively. Progression-free survival and
survival of the individual patients are also depicted in Table 1.
Imaging. The median volume of the 18 primary tumors was
208 cm3 at baseline. There was a high correlation between the
volumetric measurements and the longest diameter of the
primary tumors at baseline (Spearman’s q = 0.968, P = 1e-006;
Fig. 1A) and at the time of response evaluation (Spearman’s
q = 0.956, P = 1e-006; Fig. 1B). At baseline, large tumors
seemed to have larger necrotic areas; the necrotic volume
correlated well with the tumor volume (Spearman’s q = 0.805,
P = 5.51e-005). The patient with progressive disease was
excluded from further analysis.
During sunitinib treatment, the median density of the solid
part decreased from 82 HU (range, 54-130 HU) to 66 HU
(range, 49-116 HU; P = 0.028), whereas that of the hypodense
nonenhancing, necrotic part was not altered. The changes in
Fig. 1. Relationbetweenvolumetricmeasurements and the size of the longest diameter of the primary RCCat baseline (A) and at first evaluation after the start of sunitinib (B).
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volumetric measurements of the primary tumor after 1.2 to 3.9
months of sunitinib are listed in Table 1. The volume of the
primary tumor decreased in 13 of 17 patients (Fig. 2). In
patients with partial response or stable disease (n = 16), the
volume of the primary tumors (n = 17) significantly decreased
with a median reduction of 31% (P = 0.001). The decrease of
the volume of the solid part was also significant (median, 54%;
P = 0.001). In contrast, a significant increase in the volume of
the central necrosis was measured (median, 39%; P = 0.035).
Changes in the volume of the solid part were significantly
correlated with changes in the total volume of the primary
tumor (Spearman’s q = 0.850, P = 1.52e-005) and changes in
the necrotic volume (Spearman’s q = -0.645, P = 0.005).
Follow-up CT scans were available to evaluate the long-term
effects of sunitinib in seven patients with an initial decrease in
the primary tumor volume. Although six of these patients had a
further decrease in the primary tumor volume during contin-
uation of sunitinib, the largest response was observed within
the first 4 months (Fig. 3A). During follow-up, the volume of
the necrotic part remained more or less stable in most tumors
(Fig. 3B), whereas the solid part decreased slightly further in six
of eight tumors (Fig. 3C). Separate follow-up measurements of
the longest diameter of the primary tumor and metastases
during sunitinib treatment showed parallel decreases in size.
Nephrectomy after sunitinib treatment. Three patients (nos.
9, 10, and 12) with mRCC had their kidney removed during
sunitinib treatment. Initially, all presented with large right-
sided primaries that seemed to be surgically unresectable
because of suspected liver invasion. In patient no. 9, the
primary tumor volume decreased by 46%. After 3 months on
sunitinib, nephrectomy was carried out after discontinuation
of the drug for 3 weeks. Patient no. 10 had 38% reduction of
the primary tumor and underwent surgery after 11 months.
Sunitinib was stopped 1 week before the operation. Patient
no. 12 had 30% tumor volume reduction, and after 4 months
surgery was done after withdrawal of sunitinib for only 2 days.
Pathology revealed necrotic areas next to vital tumor cells
(Fig. 4).
In the three patients there was no regrowth of disease in the
treatment-free perioperative interval. No negative effects on
hemostasis or wound healing were observed and the postop-
erative course was uneventful. After surgery, sunitinib was
withheld in patient nos. 10 and 12 based on the excellent
response in metastatic sites. Both patients presented with
progressive disease 4 and 6 months after surgery, respectively.
Patient no. 9 continued sunitinib after surgery until progressive
disease, 6 months thereafter.
Discussion
This is the first analysis on the effects of sunitinib on the
primary tumor in 17 patients with advanced RCC expressed
both according to RECIST and in volumetric measurements.
Partial response or stable disease was measured in 16 of these
Fig. 2. Primary tumor of patient no. 6 at baseline (A) and after two cycles of sunitinib showing a decrease in size and an increase in necrosis (B). Perimeters were drawn
around the tumor as well as around the necrotic part at baseline (C) and at the time of response (D). ROI, region of interest.
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patients. Thirteen patients had a volumetric reduction of the
primary tumor of 18% to 64% associated with decrease of the
longest diameter of 0% to 33%. The decrease in tumor volume
was accompanied by an increase of central necrosis and a
decrease of the vital solid part. In three patients with low
metastatic tumor load, the primary tumor became surgically
resectable. Apart from vital tumor cells, pathology showed
extensive areas of necrosis. Our findings are of interest because
outcome of advanced RCC patients without nephrectomy
would have been poor in the cytokine era. Nowadays, when
primary nephrectomy does not seem to be a valid option,
patients may experience marked clinical benefit from sunitinib.
Primary tumors of RCC can grow to an enormous size as
compared with their metastases, with longest diameters up to
20 cm (16). On sunitinib treatment, the longest diameter of
the primary tumor shows a relatively smaller drop than that
of the metastases (see Table 1). For this reason, large primary
tumors will have an important effect on the overall objective
response when these are included in RECIST measurements.
Hence, the overall response may be underestimated because a
relatively large reduction in primary tumor size is necessary to
achieve a partial response as exemplified in patient nos. 12, 13,
and 14. Therefore, it could be considered to exclude primary
tumors in calculating the overall response according to RECIST.
Volumetric measurements, although cumbersome, may be
preferred because tumor growth or shrinkage can be asymmet-
rical in one or even three dimensions. Fortunately, in our study,
volumetric changes of the primary tumor of RCC showed a
high correlation with the calculations according to RECIST.
This indicates that the changes in size of the primary tumors
can be considered symmetrical and that RECIST measurements
reflect the response to sunitinib. Note that according to one-
dimensional (RECIST), two-dimensional (WHO definition),
and volumetric measurements, the response criteria are
different and that a partial response is reached on a decrease
in tumor size of 30%, 50%, and 65%, respectively (11).
Similar to findings in primary RCC, extensive necrosis can
also be induced by sunitinib in hepatocellular carcinoma,
reflected by a decrease in contrast enhancement on follow-up
CT scans (17). Other tyrosine kinase inhibitors, such as
sorafenib in RCC and imatinib in gastrointestinal stromal cell
tumors, are known to cause early and extensive necrosis as well
(18, 19). Treatment-induced necrosis is not part of standard
criteria to assess tumor response. Because the necrotic part of
primary tumors of RCC is often heterogeneous, very irregular,
and asymmetrical, measuring necrosis by the longest diameter is
Fig. 4. Pathology of a primary tumor of RCC (patient no.12) after sunitinib
treatment showing large necrotic areas (A) with preexistent blood vessels (B) next
to vital tumor cells (C).
Fig. 3. Follow-up measurements during sunitinib treatment in seven patients
with a reduction in volume of the primary tumor. Colored lines belong to the same
patients. One patient had bilateral primary tumors (two dark blue lines).
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difficult. Therefore, other methods to quantify necrosis are
required. Here, we applied volumetric measurements and
revealed an increase in necrosis in primaries. Another approach
to include necrosis as part of tumor response has recently been
described by Choi et al. (20, 21). In patients with gastrointes-
tinal stromal cell tumors treated with imatinib, Choi response
criteria (a z10% decrease in one-dimensional tumor size or a
z15% decrease in tumor HU) seemed to be more accurate than
RECIST and correlated significantly with time-to-tumor pro-
gression and disease-specific survival (20, 21). Faivre et al. (17)
have also addressed the inadequacy of RECIST and used
volumetric measurements for sunitinib-induced necrosis in
hepatocellular carcinoma expressed as minor (<50%) and
major (50%) posttreatment tumor necrosis. We show that
RECIST criteria are well applicable to evaluate the response of
metastases as well as of the primary RCC to sunitinib treatment.
The increase in necrosis and the reduction of the solid part,
however, might be a more consistent indicator for the extent of
response. Note that increase of necrosis as well as tumor size
would likely reflect progression of disease (patient no. 11). It
remains to be investigated in mRCC treated with sunitinib
whether other response criteria and functional imaging techni-
ques will add to information already acquired by contrast-
enhanced CT scans for measurements according to RECIST (22).
The pros and cons of cytoreductive nephrectomy in the
presence of metastatic disease have long been a subject for
debate (23–25). Historically, the nonresponsiveness of the
primary tumor to cytokine therapy and the palliation of
symptoms were arguments for a nephrectomy (2–4, 26).
Increased perioperative and postoperative morbidity and
mortality (27) in patients with incurable disease and a limited
life expectancy were postulated as arguments against cytor-
eductive nephrectomy. Furthermore, surgery could lead to a
potential delay or even cancellation of systemic therapy due to
progression in metastatic sites, postoperative morbidity, or
decreased performance status (25). The present responses of the
primary tumor to sunitinib are very encouraging and put
the role of a nephrectomy in a different light as compared with
the guidelines in the cytokine era.
The observed responses in the primary tumor and the
alleviation of symptoms on sunitinib treatment seem to have
made the historical arguments for a nephrectomy defective
reasoning. In our patients, sunitinib also improved the
performance status in those with a response. Successful resection
of the primary tumor directly invading adjacent organs and
structures in three patients suggests that sunitinibmay be used to
improve surgical resectability in doubtful cases. Whether this is
beneficial for patient outcome cannot be answered on the basis
of these three cases. Prospective randomized phase III clinical
trials in patients presenting with mRCC are warranted to define
which patients treated with sunitinib will benefit from nephrec-
tomy, to analyze whether nephrectomy has an effect on survival,
and to determine the optimal timing of a nephrectomy (28).
Such trials will lead to new guidelines on the role of
nephrectomy in mRCC patients in the sunitinib era.
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Abstract
Objective To evaluate neoadjuvant sunitinib in patients
with synchronous metastatic renal cell cancer (mRCC) to
downsize surgically complex tumours and reconsider cyto-
reductive surgery.
Patients and methods Retrospective analysis of ten con-
secutive mRCC patients treated with sunitinib in an
expanded access program who presented with surgically
complex primary tumours or bulky locoregional metasta-
ses. Surgery-limiting tumour sites (SLTSs) were deWned as
primary or retroperitoneal lesions with direct invasion of
adjacent organs or encasement of vital structures on imag-
ing. Patients received sunitinib 50 mg/day for 4 weeks on
and 2 weeks oV to be followed by cytoreductive surgery
after downsizing and individual reassessment. Response
was measured according to Response Evaluation Criteria in
Solid Tumours (RECIST).
Results Six out of ten SLTSs revealed a reduction of
tumour size with a median of 14% according to RECIST.
None of the ten SLTSs had a partial response (PR), whilst
at distant metastatic sites one complete remission and two
PRs occurred. Downsizing of SLTSs appeared most promi-
nent in the Wrst 2–4 months, which resulted in reconsider-
ing cytoreductive nephrectomy in three patients. These
three tumours invaded the liver on imaging and were
reduced by 11, 18 and 20%.
Conclusions In this patient group with mRCC and surgi-
cally complex primary tumours or locoregional metastases,
downsizing of SLTSs by neoadjuvant sunitinib was limited.
Cytoreductive surgery was reconsidered in three patients.
Given the overall reduction in tumour burden by sunitinib
alone, further investigation to deWne the role of cytoreduc-
tive surgery is warranted.
Keywords Renal cell cancer · Primary tumour ·
Sunitinib · Nephrectomy
Introduction
Oral tyrosine kinase inhibitors targeting vascular endothe-
lial growth factor (VEGF) and platelet-derived growth fac-
tor (PDGF) receptors have altered the management of
metastatic renal cell carcinoma (mRCC) [1]. Compared
with cytokine therapy, sunitinib at a dose of 50 mg daily for
4 weeks on and 2 weeks oV induces a high partial response
(PR) rate of up to 40% at metastatic sites [2]. We have
recently demonstrated that the same regimen of sunitinib
leads to responses in the primary tumour [3] at a rate previ-
ously unknown for cytokine treatment [4]. Recently four
cases have been described in which neoadjuvant-targeted
therapy altered the surgical management in advanced RCC
[5]. These and our results support to reinvestigate the con-
cept of neoadjuvant therapy to achieve downsizing of the
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tumour that may facilitate debulking surgery of residual
masses. In particular, neoadjuvant sunitinib may change the
surgical management of mRCC patients with bulky surgi-
cally complex primary tumours or locoregional metastases
and an otherwise good or intermediate prognosis with a low
distant metastatic load. Historically, cytokines had little
eVect on the primary tumour and cytoreductive surgery was
often not an option in these particular patients. Within the
frame of a sunitinib expanded access program, we oVered
upfront sunitinib to patients with mRCC to downsize surgi-
cally complex primary tumours and/or bulky locoregional
metastases followed by cytoreductive surgery if feasible.
We reviewed patient characteristics and our experience
with this approach.
Patients and methods
Patient population
Medical records of patients treated with sunitinib for
advanced RCC from December 2005 to November 2007
were reviewed. Most of the patients (n = 52) had been
included in an expanded access program until September
2006 after which sunitinib was available through an
extended registration protocol (n = 15). In the expanded
access program, each participant signed an institutional
review board-approved protocol-speciWc informed consent
in accordance with national and institutional guidelines. Of
67 patients treated, 10 patients with primary metastatic
RCC received sunitinib without prior nephrectomy due to
surgically complex primary tumours or bulky locoregional
metastases with the aim to downsize the tumour and allow
cytoreductive surgery. Memorial Sloan-Kettering Cancer
Center (MSKCC) criteria were evaluated based on the Wve
risk factors: low Karnofsky performance status (<80), high
LDH (>1.5 times the upper limit of normal), low serum
haemoglobin, high corrected serum calcium (>10 mg/dL),
and time from initial diagnosis to sunitinib treatment of less
than 1 year [6].
Surgery-limiting tumour sites (SLTSs)
Surgically complex disease was deWned as a primary
tumour or retroperitoneal locoregional metastases for
which removal was deemed technically not feasible or
potentially associated with morbidity outweighing the ben-
eWt. This decision was exclusively based on imaging with
computed tomography (CT) scans supported by magnetic
resonance imaging (MRI) or ultrasound if required. This
analysis does not contain patients in whom cytoreduction
had been aborted because the lesions proved unresectable
during explorative surgery. The lesions were summarised
under the term SLTSs. The following imaging criteria
applied: (a) direct and extensive invasion of the primary
tumour to adjacent tissues (n = 5 with 4 liver and 1 soft tis-
sue invasion) (Fig. 1a); (b) extensive retroperitoneal meta-
static burden (n = 4 with bulky encasement of the caval
vein, aorta, coeliac axis or superior mesenteric artery)
(Fig. 2a); and (c) mRCC with a primary tumour in a solitary
kidney inaccessible to nephron-sparing surgery or other
ablative procedures (n = 1). The decision to perform cyto-
reductive surgery after treatment with sunitinib was taken if
Response Evaluation Criteria in Solid Tumours (RECIST)
measurement showed a reduction of tumour size and imag-
ing suggested a technically feasible resection.
Treatment and eYcacy
Sunitinib was administered orally at a dose of 50 mg daily,
consisting of 4 weeks on treatment followed by a 2-week
rest period in cycles of 6 weeks. A dose reduction of suniti-
nib (to 37.5 mg and then to 25 mg) was allowed depending
on the type and severity of adverse events. If patients had
symptoms of progressive disease (PD) during the rest
period, there was a possibility of continuous dosing of suni-
tinib at 37.5 mg/day.
At baseline, tumour burden was assessed according to
RECIST by one-dimensional measurement of the largest
diameter of the primary tumour and the sum of diameters
of target lesions. Bone lesions were considered truly
i 1F g. Sections demonstrating 
liver invasion of patient no. 4 at
baseline (a) and after 10 months
sunitinib treatment (b).
Cytoreductive surgery was
reconsidered and the primary
tumour removed with resection
of adjacent liver tissue
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non-measurable. To determine the overall metastatic load
in relation to the primary tumour size, the sum of all
measurable metastatic lesions was recorded additionally.
Clinically, tumour response was assessed by CT scans every
two to three cycles of treatment according to RECIST. To
evaluate how a potential diVerence in response between pri-
mary tumour site and metastases may aVect overall RECIST
measurements, these lesions were calculated separately and
together (overall). In addition, separate RECIST measure-
ments were performed for the SLTSs to evaluate the eVect
of sunitinib on these unresectable lesions over time.
The progression-free survival (PFS) was the time
between the Wrst day of sunitinib and the date of PD on the
CT scan or clear clinical evidence of PD. Overall survival
(OS) was the time between the Wrst day of treatment and the
date of death or the date at which patients were last known
to be alive. For PFS and survival analysis, data collection
was closed on 1 November 2008. PFS and OS were calcu-
lated with the Kaplan–Meier method. PFS and OS of the
ten patients treated with the primary in situ were compared
to the PFS and OS of mRCC patients with nephrectomy
prior to sunitinib treated at our institution (n = 54). Patients
treated with sunitinib for extensive distant metastasis but a
small resectable primary which was not removed because
nephrectomy would have no substantial impact on the
tumour burden were excluded from the analysis (n = 3).
Results
Patients and treatment
Patient characteristics are summarised in Table 1. Of ten
patients the SLTSs were primary tumours in six patients
and bulky locoregional metastases in four. All patients had
histologically proven RCC of clear cell subtype. MSKCC
criteria disclosed an intermediate risk for all but one patient
with a poor prognosis. Four patients reduced sunitinib dos-
ing: patient nos. 3 and 5 reduced to a continuous dose of
37.5 mg/day due to symptomatic progression in a 2-week
rest period preceding the second cycle; patient nos. 8 and 9
reduced to 37.5 mg/day for 4 weeks on and 2 weeks oV
after, respectively, 10 months and 6 weeks due to grade III
hand-foot syndrome and other grade III adverse events.
Adverse events are summarised in Table 2.
EYcacy
According to RECIST, two out of ten patients reached an
overall PR, six had stable disease (SD) and one had PD
(Table 3). One patient could not be evaluated for response
because of early termination due to PD. Excluding this
patient, RECIST calculations were analysed for the primary
tumour only, the metastases only and the overall response,
resulting in a median reduction of, respectively, 10% (range
¡20 to +11%), 22% (range ¡100 to +50%) and 14% (range
¡32 to +18%). Between 1.2 and 3.9 months, the median
reduction of the SLTSs was 11% (range ¡20 to +46%). Six
out of nine patients had a reduction of the SLTS (median
¡14%, range ¡20 to ¡9%) (Figs. 1, 2, 3). None of the
reduction in SLTSs was qualiWed as PR. Downsizing of
the SLTSs appeared to be most prominent in the Wrst
2–4 months. Median PFS was 6 months (range 0.2–
15 months) and the median OS was 15 months (range
2–22 months). The PFS and survival of the individual
patients are shown in Table 3. In addition, the median PFS
for patients with a previous nephrectomy (n = 54) was
9 months (range 1–30 months, P = 0.031) (Fig. 4). Cur-
rently, the median OS has not reached patients with previ-
ous nephrectomy (range 0.5–32 months).
Cytoreductive nephrectomy
In three patients, cytoreductive nephrectomy was per-
formed following downsizing by sunitinib and response at
metastatic sites.
Patient no. 3 had been diagnosed with lung, bone and
subcutaneous metastases of RCC. Surgery of the primary
Fig. 2 Surgery-limiting tumour 
site (SLTS) of patient no. 7 at
baseline (a) and after 5 months
sunitinib treatment (b). Despite a 
21% reduction of the longest
diameter of the retroperitoneal 
metastases, encasement of vital
structures remained
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tumour was expected to be complex because of liver inva-
sion on imaging. The patient experienced a PR on sunitinib
treatment with a 56% decrease of the metastases. The pri-
mary tumour decreased by 18% on one-dimensional mea-
surement according to RECIST which was accompanied by
an increase in necrosis. During sunitinib, the performance
status improved from 2 to 0. Sunitinib was discontinued
3 weeks before surgery. Nephrectomy was feasible
although the tumour invaded the liver capsule. Pathology
revealed vital tumour cells and large areas with necrosis,
but no direct invasion into the liver parenchyma. Sunitinib
was restarted, but 6 months thereafter patient had PD.
Patient no. 4 was diagnosed with lung, liver and lymph
node metastases of RCC. Cytoreductive nephrectomy was
considered complex because of liver invasion (Fig. 1). Ini-
tially, interferon alpha was started which was discontinued
after 2 months because of a mixed response. Sunitinib was
initiated which induced an overall PR; the metastases had
decreased by 45% and the primary tumour by 11%. Liver
invasion was reduced on imaging. During sunitinib the per-
formance status improved from 2 to 1. After 10 months the
patient underwent nephrectomy and partial liver resection
after 1 week oV sunitinib. Pathology revealed a largely
necrotic tumour with remnants of direct liver and inferior
Table 1 Patient’s characteristics at baseline
2 = intermediate, 3 = poor, PS Eastern Cooperative Oncology Group (ECOG) performance status, SLTS surgery-limiting tumour site, BLRM bulky
locoregional metastases
a Risk groups according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria associated with shorter survival [based on Wve risk factors:
low Karnofsky performance status (<80%), high LDH (>1.5 times the upper limit of normal), low serum haemoglobin, high corrected serum
calcium (>10 mg/dL), and time from initial diagnosis tot treatment of less than 1 year] [12]
Pt no. Age Gender PS MSKCC 
risk groupa
Metastatic sites Diameter 
primary 
(cm)
Diameter 
metastases 
(cm)
Site SLTS Diameter 
SLTS 
(cm)
Primary reason not 
to perform 
nephrectomy
1 68 M 1 2 Lung, liver 12 18 Primary tumour 12 Soft tissue invasion
2 63 M 1 3 Lung, bone, liver 15 22 BLRM 15 Encasement
blood vessels
3 53 M 2 3 Lung, bone, subcutis 15 10 Primary tumour 15 Liver invasion
4 60 M 2 3 Lung, liver, 
lymph nodes
8 12 Primary tumour 8 Liver invasion
5 50 M 0 2 Lung, lymph nodes 10 10 BLRM 7 Encasement 
blood vessels
6 72 M 2 2 Lung, lymph nodes 9 7 Primary tumour 9 Liver invasion
7 69 F 0 2 Lymph nodes 7 19 BLRM 12 Encasement
blood vessels
8 66 M 0 2 Lung, liver 16 10 Primary tumour 16 Liver invasion
9 60 F 0 2 Skin, bowel 5 3 Primary tumour 5 Solitary kidney
10 52 M 0 2 Lung, pleura,
lymph nodes
14 12 BLRM 6 Encasement
blood vessels
Table 2 Adverse events during 
sunitinib treatment Pt no. Adverse events
1 Thrombocytopenia gr I, lymphocytopenia gr II, anaemia gr II, fatigue gr I,
stomatitis gr I, anorexia gr II, diarrhoea gr I esophagitis gr I, hand-foot syndrome gr I
2 Anaemia gr I, stomatitis gr II, nausea gr II, vomiting gr II, hand-foot syndrome gr I
3 Stomatitis gr II, nausea gr I, vomiting gr I, heartburn gr I, hand-foot syndrome gr I,
discoloration hair gr I
4 Taste alteration gr I, nausea gr I, vomiting gr I, diarrhoea gr I, oedema gr I
5 Nausea gr I, vomiting gr I, hand-foot syndrome gr I
6 Thrombocytopenia gr I, lymphocytopenia gr I, fatigue gr II, stomatitis gr II, nausea gr I,
vomiting gr I, petechiae gr I
7 Thrombocytopenia gr II, taste alteration gr I, stomatitis gr II, hypertension gr I
8a Hand-foot syndrome gr III
9b Thrombocytopenia gr I, stomatitis gr III, nausea gr III, vomiting gr III, diarrhoea gr III, 
hand-foot syndrome gr III
10 Fatigue gr I
a Pt no. 8 had a dose reduction 
because of grade III hand-foot 
syndrome
b Pt no. 9 had a dose reduction 
because of several grade III 
adverse events
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caval vein invasion. Four months after surgery, patient had
PD and sunitinib was resumed.
Patient no. 6 was diagnosed with metastases to the lungs,
mediastinal and locoregional lymph node metastases of
RCC. The primary tumour invaded the liver on imaging.
Sunitinib as Wrst-line treatment resulted in complete
response of the metastases and a decrease of the primary
tumour of 20% with an increase of the necrotic area. The
performance status improved from 2 to 1. The patient
underwent a successful nephrectomy after sunitinib was
discontinued 2 days before surgery. The tumour invaded
the liver capsule, but not the parenchyma, which was con-
Wrmed histologically. Based on the excellent response at the
metastatic sites, sunitinib was withheld. Follow-up CT
scans, 6 months after surgery, demonstrated PD of the
small lung lesions.
Discussion
This retrospective analysis suggests that downsizing SLTSs
of RCC by neoadjuvant sunitinib may be of limited beneWt
for the surgical management. Although in none of the ten
SLTSs a PR was reached, cytoreductive surgery was recon-
sidered in three after a reduction of the longest diameter of
Table 3 Tumour measurements after initiating sunitinib treatment
RECIST Response Evaluation Criteria in Solid Tumours, SLTS surgery-limiting tumour site, RECIST SLTS RECIST performed for SLTS only,
RECIST primary RECIST performed for primary tumour only, RECIST metastases RECIST performed for metastases only, RECIST overall over-
all RECIST performed for both primary tumour and metastases, PR partial response, SD stable disease, PD progressive disease, PFS progression-
free survival
Pt no. RECIST PFS 
(months)
Survival
(months)
SLTS (%) Primary (%) Metastases (%) Overall (%) Overall
1 ¡9 ¡9 +4 ¡1 SD 10 18+
2 – – – – – 1 2
3 ¡18 ¡18 ¡56 ¡32 PR 10 15
4 ¡11 ¡11 ¡45 ¡32 PR 14 15+
5 +46 +10 +77 +41 PD 0.2 4
6 ¡20 ¡20 ¡100 ¡29 SD 10 14+
7 ¡16 +7 ¡16 ¡10 SD 6 14
8 ¡12 ¡12 ¡28 ¡17 SD 15 22
9 +11 +11 +50 +18 SD 1 4
10 +13 ¡1 +11 +4 SD 4 15+
Fig. 3 Change in the longest diameter of SLTS during sunitinib treat-
ment. Patient nos. 3, 4 and 6 underwent cytoreductive surgery (Wlled
triangles)
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11–20%. It cannot be concluded, however, that the success-
ful resection was technically facilitated by sunitinib pre-
treatment in those patients. The decision to pretreat patients
with surgically complex primary mRCC was based on
imaging and not on unresectability at explorative surgery.
Despite downsizing, histology suggests that local down-
staging does not occur. It appears that the eVect of downsiz-
ing is most prominent in the Wrst 2–4 months (Fig. 3).
Remarkably, in none of the four patients with retroperito-
neal encasement of major blood vessels, such as the caval
vein, aorta, coeliac axis and superior mesenteric artery, did
this approach led to reconsidering resection. Although
reduction in size was observed, it was too limited to safely
attempt surgery.
Sunitinib was given at the standard dose of 50 mg/day,
though it was reduced to 37.5 mg in four patients. It was
noticed recently that by starting the dose at 37.5 mg/day, a
similar time to progression could be achieved at the cost of
half of the response rate [7]. Whether the increase of the
dose of sunitinib over 50 mg for a short upfront period will
lead to a higher rate of PR still needs to be investigated.
In one patient, sunitinib was discontinued 48 h before
surgery, suggesting that even a short-time interval may be
suYcient to safely perform surgery. The half-life of suniti-
nib is relatively long and is approximately 40 h, whereas
that of the active metabolite SU012662 is approximately
80 h [8]. It is known that after discontinuing sunitinib,
some patients, especially those with an initial tumour
response, may experience a rapid clinical deterioration.
This rebound phenomenon may be due to early regrowth of
the tumour vascularisation [9] or to tumoural oedema [10].
Maintaining an interval as short as possible between with-
drawal of sunitinib and surgery may be of importance in
view of the observed rebound phenomenon with acceler-
ated tumour growth in the rest period.
Within the community of urological surgeons, there is
no uniformly accepted deWnition of unresectable tumour
lesions. A tumour that may be deemed unresectable in one
centre may be judged accessible in another. This reXects
diVerent levels of expertise and often multidisciplinary
approaches are required. To account for this lack of deWni-
tion, we chose the term of complex surgery. Some common
criteria to deWne surgically complex tumours hold for the
majority of centres performing cytoreductive surgery
[11, 12]. These are direct extensive invasion of the liver in
right-sided renal masses or involvement of the coeliac axis
or superior mesenteric artery in the case of left-sided renal
masses or bulky retroperitoneal lymph node metastases
[13, 14]. If not revealed at explorative surgery, these criteria
are usually based on clinical imaging. For the majority of
urological surgeons, they represent hallmarks of unresecta-
bility or resectability leading to excessive morbidity in the
setting of mRCC. Generally, the acceptance of morbidity
associated with surgery is closely related to the overall
outcome of the disease. As an example, in testicular cancer,
complete post-chemotherapy resection of bulky retroperito-
neal metastases including complex surgery with resection
of the caval vein or aorta often results in deWnite cure
[15, 16]. In patients with RCC and synchronous distant
metastases, however, the morbidity of such extensive surgery,
even if technically feasible, appears imbalanced against the
limited survival beneWt that may be achieved [12, 17–20].
Assessment of resectability may be further biased by the
fact that invasion on imaging does not always reXect inva-
sion at pathological examination [21]. We are aware that in
our series, the decision whether or not a lesion was resect-
able was based on these clinical criteria rather than explor-
ative surgery. This may bias the interpretation of true
unresectability, although the decision at explorative surgery
may in turn be biased by a diVerence in surgical skills.
However, this reXects current clinical practice. It is impor-
tant to note that the conclusion of limited downsizing fol-
lowing neoadjuvant therapy remains unaVected by the
deWnition of resectability.
There is an ongoing discussion whether the current
response assessment by RECIST is suYcient to decide
whether treatment with targeted therapy is beneWcial [22].
From a surgical endpoint, however, reduction of the longest
diameter on imaging is relevant for the assessment of
downsizing and ultimately for the resectability of a primary
tumour or large metastatic lesion. In this analysis, the
reduction in tumour size was more profound in the meta-
static lesions than in the primary tumour. Whilst two PRs
and one CR according to RECIST were observed at meta-
static sites, none of the primary tumour sites or bulky retro-
peritoneal lesions qualiWed as PR.
There have been very recent observations that neoadju-
vant-targeted therapy may reduce the extent of surgery in
advanced RCC cases with thrombi in the caval vein [23],
nodal involvement, renal fossa recurrence and tumour
within a solitary kidney [5]. In line with these positively
selected cases, this analysis of a consecutive series of
patients suggests that some may beneWt from neoadjuvant
therapy to reconsider surgery. However, it remains
unknown whether this approach will alter the outcome for
patients with distant metastases. Neoadjuvant sunitinib may
therefore have a limited future role in selected patients with
advanced disease of doubtful resectability in whom a sub-
sequent surgically complete resection might be achieved.
Ultimately, only few patients presenting with mRCC will
have primary tumours or locoregional metastases of doubt-
ful resectability. In a series reported by Kassouf et al. [13] in
498 patients who underwent cytoreductive surgery for
primaries in the case of mRCC, only 23 patients were identi-
Wed with cT4NxM1 disease. The median survival of these
23 patients was poor, being 7.1 months for those receiving
54
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additional systemic therapy, but only 2.5 months for those
who had not. Although these data have been collected retro-
spectively in the pre-sunitinib era, surgery seemed only
justiWable in those few with symptomatic tumours.
Therefore, for patients presenting with primary mRCC,
the fundamental question remains if survival will be
improved by removing a partially responding asymptom-
atic primary tumour in the face of partially and temporarily
responding systemic disease [24]. In fact, high-level evi-
dence from randomized trials only supports cytoreductive
nephrectomy in conjunction with interferon alpha [25, 26].
Neoadjuvant sunitinib may have impact on surgical man-
agement. However, it is premature to conclude that cytore-
ductive surgery is required either prior to or after sunitinib
in these patients. Randomized studies investigating cytore-
ductive surgery and its sequence in combination with suni-
tinib or other targeted therapies are needed.
ConXict of interest statement There is no conXict of interest.
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To the Editor
Oral tyrosine kinase inhibitors (TKIs) and the mono-
clonal antibody bevacizumab have signiﬁ cantly
changed the management and perspectives of patients
with metastatic renal cell cancer (mRCC). Especially 
patients with a clear cell histological subtype gain ben-
eﬁ t from therapies targeted against signalling of the
vascular endothelial growth factor (VEGF) and plate-
let-derived growth factor. Sunitinib has been regis-
tered as ﬁ rst- and second-line therapy for mRCC. This
TKI can induce high partial response (PR) rates of up 
to 40% at metastatic sites and can prolong progres-
sion-free survival (PFS) and overall survival (OS) as
compared to interferon-alpha (11 and 26 months ver-
sus 5 and 22 months, respectively) [1]. In primary
tumours, sunitinib-induced responses as well as
responses induced by the VEGF-directed monoclonal 
antibody bevacizumab have been described at a rate
previously unknown for cytokine-based treatment
[2–4]. Therefore, presurgical targeted therapy might
facilitate nephrectomy by downsizing primary tumours.
In addition, responses have been reported in bulky 
retroperitoneal lymph nodes and even in tumour 
thrombi with caval vein extension, which may improve
the surgical management of these tumour sites [5–11].
In contrast to these promising reports, we describe
two patients with mRCC of a clear cell subtype who
developed a progressive caval vein thrombus during 
sunitinib, which resulted in a negative impact on sur-
gical management.
Case reports 
Two patients were treated in accordance with a
phase II trial in which sunitinib-induced responses
in primary tumours were investigated. The main
inclusion criteria of this trial were histologically con-
ﬁ rmed mRCC of the clear cell subtype with a resec-
table asymptomatic primary tumour in situ, extensive
metastatic disease deﬁ ned as non-resectable metas-
tases in case of one metastatic site ortwo metastatic
sites, a World Health Organization (WHO) perfor-
mance status of 0 or 1, an intermediate risk proﬁle
according to Memorial Sloan-Kettering Cancer 
Center (MSKCC) criteria, and no prior systemic
treatment with biological response modiﬁers, TKIs, 
monoclonal antibodies or chemotherapy. Patients
were treated with sunitinib 50 mg/day four weeks on
and two weeks off for two cycles. At completion of 
the second treatment cycle, a computed tomography
(CT) scan was performed for response evaluation
and patients were admitted for surgery within
one week.
Case 1
A 49-year-old male patient presented with a primary
RCC tumour in the right kidney with thrombus
extension into the infrahepatic caval vein up to the
liver. The patient had metastatic disease in lungs and
para-aortic lymph nodes. Metastatic burden was 
limited and the sum of the longest diameter of all
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metastatic lesions was only 2.8 cm. Resection of the 
primary and thrombus was feasible, but it was decided
to include the patient in the protocol and take
advantage of potential downsizing of the thrombus.
The patient started sunitinib 50 mg/day (four weeks
on and two weeks off) as ﬁ rst-line treatment. During
the ﬁ rst week of the second cycle the patient was
admitted with fatigue grade 3, dyspnoea and ascites.
The CT scan revealed extension of the thrombus
into the right atrium with liver congestion. The size
of the primary tumour and metastases, however, had
remained stable (Figure 1). The performance score
deteriorated rapidly from WHO 0 to 3 and nephrec-
tomy could not be performed anymore. The patient
died two months after the start of sunitinib due to
thrombus-induced backward and liver failure.
Case 2
A 35-year-old male patient was diagnosed with resec-
table primary RCC in the left kidney, one liver 
metastasis and bone metastases. After pain-alleviat-
ing radiotherapy for metastases in spine and hip, the
patient initiated ﬁ rst-line sunitinib treatment at
50 mg/day (four weeks on and two weeks off). At
response evaluation in the last week of the second
cycle, the liver metastasis showed a minor reduction
of 19% in size, while the primary tumour had not
changed. In addition, the CT scan revealed a newly
developed thrombus in the caval vein (Figure 2).
Nephrectomy was performed in a trans-abdominal
approach requiring extension of the surgical ﬁeld to
safely perform a cavotomy. The adjacent tissues to
Figure 1. CT scans of the ﬁ rst patient at baseline (A) and after (B) one cycle of sunitinib. A1 and B1: The primary tumour has decreased
in size. A 2-3 and B 2-3: The caval vein thrombosis has increased in size (A2 and B2) and extends from infrahepatic (A2) towards the
right atrium (B3). Note the absence of the thrombus in the right atrium before treatment (A3).
Figure 2. CT scan of the primary tumour of the second patient at baseline (A) and after two cycles of sunitinib demonstrating a newly 
formed thrombus in the caval vein (arrows) (B).
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the renal vein were adhesive due to a reaction of the
thrombotic material. Histopathological examination
demonstrated a primary tumour of 10 cmin diameter 
with clear cell histology and a necrotic centre. The 
thrombus contained tumour cells as well (Figure 3).
The patient recovered and continued on sunitinib 
until progressive disease (PD) in liver and bone
lesions ﬁ ve months thereafter. He died from disease
after a survival period of 12 months from the time
of diagnosis. 
Discussion
We here describe two mRCC patients on presurgical
sunitinib to facilitate secondary nephrectomy who
developed a progressive caval vein thrombus while
on treatment. In the ﬁ rst patient, an initially resect-
able caval vein thrombus progressed into the right
atrium and surgery could not be performed due to
rapid clinical deterioration as a result from backward
and liver failure. In the second patient, a tumour 
thrombus developed with extension into the caval 
vein which required extended surgery, while the liver 
metastasis demonstrated regression. It cannot be
excluded that progression of the thrombus in the ﬁrst
patient may have been related to venous thrombotic
events [12], but histology revealed a tumour throm-
bus in the second patient.
In the cytokine era, responses in primary tumours
and caval vein thrombi were rare. mRCC patients with 
primary tumours in situ were more likely to die from
distant metastases than from local progression [13].
Therefore, initial cytokine therapy was used to select 
patients for nephrectomy that showed a response in
metastases. For two reasons, however, this strategy 
may be less logical in mRCC patients treated with
targeted agents, such as sunitinib. First, mixed
responses in the primary tumour and metastases may
occur, indicating the risk of progression of initially
resectable primaries to inoperable tumours despite a
sunitinib-induced response in metastases. Second,
after development of PD during sunitinib and subse-
quent discontinuation of this drug, a resectable pri-
mary tumour may rapidly progress or may cause
severe symptoms requiring palliative treatment.
The effect of downsizing primary tumours is
most prominent in the ﬁ rst three months, suggesting
that a few cycles of sunitinib may be sufﬁcient to
facilitate the subsequent surgical procedure. In previ-
ous reports on sunitinib, however, the PD rate in
primary tumours varied from 0 to 47% [4,14]. The
study by Thomas et al. [14] and the present cases
indicate that initially resectable primaries and tumour 
thrombi can progress to inoperable tumours within
a few months. The wide range of the PD rate may
reﬂ ect a high variability in sunitinib sensitivity of 
primary tumours and indicates that biomarkers are
warranted to early identify mRCC patients with
failure of downsizing primaries. Since a 24 hour 
discontinuation period of sunitinib appears to be safe
to perform surgery [15], the management plan can
be changed rapidly in case patients develop PD in
resectable primaries or tumour thrombi in the pres-
ence of stable disease in metastases.
Combined therapy of presurgical sunitinib fol-
lowed by nephrectomy in mRCC patients might
improve the quality of life and even prolong PFS
and OS. Several patients have been described in
whom sunitinib could be discontinued during a
disease-free period after this treatment procedure
[16]. Since there is no evidence from randomized
controlled trials, the role and sequence of cytore-
ductive surgery in combination with targeted ther-
apy in mRCC are open for debate. Currently, a
number of trials have been initiated to investigate
the efﬁ cacy of presurgical sunitinib in mRCC
patients with a primary tumour in situ. The present
two cases illustrate, however, that not each patient
beneﬁ ts from this approach. Whether caused by
thrombotic events or true tumour growth, caval vein
thrombi can develop and progress under targeted
therapy. Physicians should be aware of progressive
primary tumours and tumour thrombi to avoid
missing an opportunity for nephrectomy.
Figure 3. Histology of the primary tumour (A) (H&E, 200×) and the caval vein thrombus which contains vital tumour cells of clear cell
histology (B) (H&E, 100×).
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Brain Metastases in Patients With Renal Cell
Cancer Receiving New Targeted Treatment
In December 2005, a 45-year-old man with progressive meta-
static renal cell cancer (mRCC) started palliative treatment with
sunitinib malate (Sutent; Pﬁzer, New York, NY) 50 mg daily oral
dosing for 4 weeks followed by a 2-week rest period in cycles of 6
weeks. Right-sided nephrectomy had been performed for stage III
clear cell carcinoma in March 2001. In October 2002, he was diag-
nosedwith symptomaticmediastinal lymphadenopathy and lungme-
tastases. He received ﬂuorouracil, interleukin-2a, and interferon alfa,
later followed by anti-interleukin-6, according to two different trial
protocols. Both treatments resulted in a relatively long period of dis-
ease stabilization. At initiation of sunitinib, he was dyspneic on exer-
tion and had a cough, but was otherwise in good general health. He
was not using any medications. During the ﬁrst ﬁve treatment cycles,
he developed National Cancer Institute Common Terminology
Criteria of Adverse Events (version 3.0) grade 2 skin rash, itch, fa-
tigue, and stomatitis not requiring supportive medications or dose
A B
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reduction. Response evaluation with thoracic and abdominal com-
puted tomography scan after the ﬁrst and ﬁfth cycle showed stable
disease according to Response Evaluation Criteria in Solid Tumors1
(Figs 1A: before treatment; and 1B: after 6 months of sunitinib).
During the 2-week rest period of the ninth cycle, he presented with
right-sided headache and pain at the back of his right eye, accompa-
nied by nausea and vomiting and sensory neuropathy in the left arm.
All vital signswere normal. Amagnetic resonance imaging scan of the
brain showed three brain lesions with perilesional edema (Fig 2)
suggestive of brain metastases. Neurologic symptoms disappeared
promptly after initiation of dexamethasone, which was followed by
whole-brain radiotherapy (ﬁve times; 4 Gy). Dexamethasone was
tapered but not discontinued, despite possible drug interaction
through cytochrome P450 isoenzyme 3A4 metabolism, because of
relapsing headache.2 Disease evaluation conﬁrmed previously docu-
mented stable disease (Fig 1C: after 12months of sunitinib and at the
time of brain metastases). Therefore, sunitinib treatment was reiniti-
ated shortly after radiotherapy. Stable diseasewasmaintained as dem-
onstrated on a computed tomography scan 3 months after resuming
sunitinib (Fig 1D). Unfortunately, 3 weeks later, he deteriorated with
signs of brain herniation, which did not respond to corticosteroids,
and died.
Sunitinib, a novel oral tyrosine kinase inhibitor (TKI) targeting
multiple receptors involved in angiogenesis, is approved for the treat-
ment of mRCC. It is not known whether sunitinib can prevent the
occurrence of brain metastases. The incidence of brain metastases as
the onlymetastatic site inmRCC is less than 1%3-5 and occurs as part
of the ﬁrst presentation of mRCC in approximately 3% of the pa-
tients.5,6 The cumulative incidence is approximately 10% in
mRCC,4,6-8 andthemedianoverall survival is3 to6months,9 although
a longer survival has been reported.10 We performed a retrospective
analysis of 91 mRCC patients treated with sunitinib on a
compassionate-use basis in our centers during the last 2 years and
identiﬁed nine patients (10%; age 45 to 77 years) who developed
symptomatic brain metastases. This incidence conﬁrms previous re-
sults and suggests that sunitinib does not inﬂuence the incidence of
brainmetastases. Seven patients developed stable disease and two had
partial response lasting 2 to 9 months until progression within the
CNS. In all patients, CNS disease was the ﬁrst sign of progression, but
in six patients, including our patient described here, this was the only
progressivemetastatic site.After radiotherapyor surgery, the sunitinib
waseffectively continued in threepatients.This suggests adifference in
the pharmacokinetic behavior and less activity of sunitinib within the
brain, compared with another registered TKI for mRCC, sorafenib,
which has been suggested to reduce the incidence of brain metasta-
ses.11 No CSF measurements of sunitinib concentration have been
performed in humans, but animal studies indicate that sunitinib pen-
etrates the blood-brain barrier to some extent.12 Sunitinib could also
be a substrate forP-glycoprotein–mediated efﬂux, similar to imatinib,
whichwould limit its distributionwithin thebrain.13Of interest, six of
ninepatientsdevelopedCNSsymptomsduring the2-week rest period
of the treatment cycle. One explanation for this observation could be
that sunitinibhas antiedemaactivity, asobserved for themultitargeted
TKI,14 therebymasking pre-existent brainmetastases. Our case series
suggests that sunitinib is inadequate for control of brain metastases
and may temporarily mask their existence.
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Leptomeningeal Carcinomatosis Due to
Squamous Cell Carcinoma of the Uterine
Cervix Associated With HPV-45
A 58-year-old African American woman with a history of Me´-
nie`re’s disease and gastric bypass was diagnosed with squamous cell
carcinoma of the uterine cervix, conﬁrmed by a positive endocervical
curettage, in December 2003. She received concurrent chemoradio-
therapy with cisplatin and radiation therapy (45 Gy, fractions of 1.8
Gy). She remained disease free until April 2006, when she presented
with a palpable left supraclavicular lymph node. Fine-needle aspira-
tion biopsy of the node showed malignant cells morphologically and
immunohistochemically (CK 5/6 and p63 positive) compatible with
metastatic nonkeratinizing squamous cell carcinoma. Computed to-
mography (CT) scan imaging of the chest, abdomen, and pelvis also
showed retroperitoneal lymphadenopathy. She then received chemo-
therapy with cisplatin and vonorelbine beginning in April 2006.
Sixmonths after diagnosis of recurrence, thepatient presented to
the emergency department with intermittent headaches, dizziness,
and photophobia. Physical examination revealed an obese African
American woman in no apparent distress. She had no signiﬁcant
lymphadenopathy of the supraclavicular, axillary, or inguinal areas.
Neurologic examinations, including cranial nerve function, and mo-
tor and sensory systems were normal, with the exception of slight
memory loss. Computed tomography scan of the brain was unre-
markable for any acute process. CSF cytology revealed numerous
discohesive neoplastic cells with similar cytomorphology and immu-
nohistochemical staining characteristics as the prior ﬁne-needle aspi-
ration of the supraclavicular lymph node (Figs 1A, lower power; and
1B, higher power; Papanicolaou stain). There was no evidence of
systemic disease recurrence.
Given her excellent performance status, anOmaya reservoir was
placed and she received intrathecal chemotherapy with methotrexate
(6 mg two times per week for 10 doses). This was followed by 12 mg
alternatingwith thiotepa (10mgfor threedoses). She responded to the
intrathecal chemotherapy with reduction in headaches, but the CSF
remained positive on cytology. After only 2.5 months, she clinically
deteriorated with decreasing cognitive function and awareness, so
intrathecal therapy was discontinued.
The patient was readmitted to the hospital with seizures and
headache in February 2007.At that time,magnetic resonance imaging
of the brain revealed intense enhancement of the meninges over the
bilateral occipital lobes and cerebellum(Figs 2Aand2B). Shewas then
given whole-brain radiation. Despite the radiation, the patient had
progressive cognitive and neurologic decline and ultimately died as a
result of leptomeningeal disease within 26 weeks of diagnosis. No
postmortem examination was performed; however, human papil-
loma virus (HPV) subtyping by nested polymerase chain reactionwas
performed on the parafﬁn block of the original endocervical biopsy
and conﬁrmed HPV subtype 45.
There are believed to be fourmechanisms bywhich leptomenin-
geal spread occurs: meningeal seeding from a previous metastasis,
direct extension from subdural or extradural tumors, direct extension
from sites outside but adjacent to the CNS, or hematogenous
spread.1,2 Prior reviews and case reports have supported the concept
that leptomeningeal metastases from cervical cancer occur via hema-
togenous spread,3 whereas those secondary to oropharyngeal cancer
occur via direct extension or perineural spread.4-7 It has been found
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Genetic Polymorphisms Associated with a Prolonged Progression-Free
Survival in Patients with Metastatic Renal Cell Cancer Treated
with Sunitinib
Astrid A.M. van der Veldt1, Karel Eechoute2, Hans Gelderblom3, Jourik Gietema5, Henk-Jan Guchelaar4,
Nielka P. van Erp4, Alfons J.M. van den Eertwegh1, John B. Haanen3,6, Ron H.J. Mathijssen2, and
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Abstract
Purpose: The objective of this study was to identify genetic polymorphisms related to the pharmaco-
kinetics and pharmacodynamics of sunitinib that are associated with a prolonged progression-free survival
(PFS) and/or overall survival (OS) in patients with clear-cell metastatic renal cell cancer (mRCC) treated
with sunitinib.
Experimental design: A retrospective multicenter pharmacogenetic association study was performed in
136 clear-cell mRCC patients treated with sunitinib. A total of 30 polymorphisms in 11 candidate genes,
together with clinical characteristics were tested univariately for association with PFS as primary and OS as
secondary outcome. Candidate variables with P < 0.1 were analyzed in amultivariate Cox regressionmodel.
Results:Multivariate analysis showed that PFS was significantly improved when an A-allele was present
in CYP3A5 6986A/G [hazard ratio (HR), 0.27; P ¼ 0.032], a CAT copy was absent in the NR1I3 haplotype
(5719C/T, 7738A/C, 7837T/G; HR, 1.76; P ¼ 0.017) and a TCG copy was present in the ABCB1 haplotype
(3435C/T, 1236C/T, 2677G/T; HR, 0.52; P¼ 0.033). Carriers with a favorable genetic profile (n¼ 95) had
an improved PFS and OS as compared with noncarriers (median PFS and OS: 13.1 versus 7.5 months and
19.9 versus 12.3 months). Next to the genetic variants, the Memorial Sloan-Kettering Cancer Center
prognostic criteria were associated with PFS and OS (HR, 1.99 and 2.27; P < 0.001).
Conclusions: This exploratory study shows that genetic polymorphisms in three genes involved in
sunitinib pharmacokinetics are associated with PFS inmRCC patients treated with this drug. These findings
advocate prospective validation and further elucidation of these genetic determinants in relation to
sunitinib exposure and efficacy. Clin Cancer Res; 17(3); 620–9. 2010 AACR.
Introduction
For decades, the treatment options of metastatic renal
cell cancer (mRCC) have been limited and systemic treat-
ment primarily consisted of immunotherapy with cyto-
kines. Increasing knowledge of the underlying biology of
renal cell cancer (RCC), in particular the clear-cell subtype,
has expanded the treatment options for patients with
mRCC (1). RCC is characterized by an inactivated von
Hippel–Lindau (VHL) tumor suppressor gene. Inactivated
VHL leads to elevated protein levels of hypoxia-induced
factor-a which upregulates VEGF and platelet-derived
growth factor (PDGF) genes and proteins. The develop-
ment of targeted therapy against signaling of these proteins
has significantly improved the perspectives of patients with
mRCC.
Currently, sunitinib is the most widely prescribed drug
for the treatment of mRCC and has been registered as first-
line and second-line therapy. Sunitinib is an oral tyrosine
kinase inhibitor (TKI) which targets several receptors in-
cluding VEGF receptors-1,-2,-3, PDGF receptors (PDGFR)-
a and –b, c-KIT, and FLT-3. In a randomized controlled
trial, sunitinib significantly prolonged the progression-free
survival (PFS) and overall survival (OS) as compared with
interferon-a (2, 3). Although sunitinib can achieve partial
response rates of up to 40% (3–5), approximately 35%
of mRCC patients do not benefit from sunitinib treatment
(4, 5). Because sunitinib treatment may also result in
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unnecessary toxicities (6, 7), pretreatment markers to iden-
tify mRCC patients with a favorable outcome to sunitinib
treatment are warranted.
Sunitinib efficacy may be dependent on its exposure
which is regulated by efflux pumps and metabolizing
enzymes. After oral administration, the systemic exposure
of sunitinib is initially determined by its absorption in the
gastrointestinal tract (Fig. 1). This process may be regu-
lated by active drug transport over the intestinal wall, as
sunitinib may be a substrate for polyspecific efflux trans-
porters, expressed on enterocytes (8, 9). The efflux trans-
porters ABCB1 (ATP binding cassette member B1,
formerly known as P-glycoprotein or MDR1) and ABCG2
[ATP binding cassette member G2, formerly known as
breast cancer-resistance protein (BCRP) or mitoxantrone
resistant protein (MXR)] are expressed in the intestine
and liver, and are involved in the oral absorption
and biliary secretion of several anticancer drugs (10).
Therefore, expression levels and functionality of these
drug transporters may have important consequences for
the efficacy of sunitinib.
The cytochrome P450 (CYP) 3A (CYP3A) family is the
predominant drug metabolizing enzyme and CYP3A4 is
thought to be the key enzyme for the biotransformation of
sunitinib (11). CYP3A4 is predominantly found in the liver
and its expression is regulated by the ligand-activated
nuclear receptors NR1I2 [pregnane X receptor (PXR)]
and NR1I3 [constitutive androstane receptor (CAR)]
(12). In addition, other enzymes of the cytochrome
P450 family (CYP3A5, CYP1A1, and CYP1A2) may meta-
bolize sunitinib, as these enzymes are known to be
involved in the metabolism of other TKIs (13).
Besides pharmacokinetic factors, pharmacodynamic fac-
tors may determine the efficacy of sunitinib. In RCC,
sunitinib is thought to exert its major therapeutic effect
by inhibition of the VEGFR on tumor-associated endothe-
lium, leading to reduced tumor angiogenesis (14). In
addition, inhibition of the PDGFR might increase the
antiangiogenic effects of sunitinib by targeting pericytes,
which are able to protect endothelial cells from apoptosis
(15). As the main targets for sunitinib are thought to be
located in the microenvironment of tumor cells, the effi-
cacy of sunitinib treatment may be related to the genetics of
the surrounding microenvironment (16). Particularly,
genetic variation in VEGFR-2 may affect sunitinib activity,
because VEGFR-2 is expressed in the normal endothelium
(17) and the tumor vasculature may develop from preex-
isting vessels of the host (18).
Single nucleotide polymorphisms (SNP) in genes
encoding for efflux transporters, metabolizing enzymes,
and drug targets may affect the efficacy of sunitinib in
mRCC, as SNPs in specific genes have previously been
associated with sunitinib-induced toxicities in patients
with mRCC and gastrointestinal stromal tumors (19, 20).
Therefore, SNPs may be useful markers for personalized
treatment planning and may be candidate markers for
selecting mRCC patients for sunitinib treatment. The
objective of the current study was to identify SNPs
involved in the pharmacokinetics and pharmacody-
namics of sunitinib that are associated with a prolonged
PFS and/or OS in mRCC patients.
Patients and Methods
Study population
In our previous study, 219 sunitinib-treated patients
with various malignancies were included to investigate
the association between SNPs and sunitinib-induced toxi-
cities (19). In the present study, a subset of patients with
histologically proven clear-cell RCC was selected for the
analyses. A total of 136 consecutive mRCC patients who
initiated sunitinib treatment between December 2005 and
May 2008 were included. Sunitinib was administered
orally at a dose of 50 mg daily, consisting of 4 weeks
of treatment followed by a 2-week rest-period in cycles
of 6 weeks. Dose reductions of sunitinib were allowed
Translational Relevance
Currently, sunitinib is the most widely prescribed
drug for the treatment of metastatic renal cell cancer.
Unfortunately, only a part of treated patients will ben-
efit from sunitinib therapy, despite the implementation
of clinical prognostic criteria in the choice of therapy. As
multiple systemic treatment modalities arise, a further
refinement is needed to identify renal cell cancer
patients who predispose to benefit from sunitinib treat-
ment and patients who do not. One of the possible
options to study the differential response to sunitinib
treatment is to identify genetic polymorphisms related
to the pharmacokinetics and pharmacodynamics of this
drug. In the future, genetic variants may be added to the
current prognostic criteria, enabling physicians to pre-
dict benefit from sunitinib in individual patients.
excretion
Figure 1. Schematic diagram of the pharmacokinetic and
pharmacodynamic pathways that may be involved in the efficacy of
sunitinib in mRCC. *, NR1I2 and NR1I3 regulate CYP3A4 expression.
Pharmacogenetics in Sunitinib-Treated mRCC Patients
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depending on the type and severity of adverse events
according to the current guidelines (21). The study was
approved by the medical ethics review board.
Study design
Demographic and clinical data of patients were
reported on case record forms designed for data collection
for this study. Patient characteristics considered relevant
for PFS and OS analysis were age, gender, Eastern Coop-
erative Oncology Group (ECOG) performance status,
prior systemic therapy, prior radiotherapy, the number
of metastatic sites, and the risk factors according to
Memorial Sloan-Kettering Cancer Center (MSKCC) prog-
nostic criteria, which is based on 5 risk factors including
low Karnofsky performance status (< 80%), high lactate
dehydrogenase (LDH; >1.5 times the upper limit of
normal), low hemoglobin level, high corrected serum
calcium (> 10 mg/dL), and time from initial diagnosis
to treatment < 1 year (22). Residual blood or serum
samples taken for routine patient care were stored at
20C at the local hospital laboratory. Of each patient
one whole blood or serum sample was collected from the
participating hospitals. All samples were anonymized by
a third party, according to the instructions stated in the
Codes for Proper Use and Proper Conduct in the Self-
Regulatory Codes of Conduct (www.federa.org).
Genetic polymorphisms
Nineteen polymorphisms in 7 genes involved in the
pharmacokinetics and 11 polymorphisms in 4 genes
involved in the pharmacodynamics of sunitinib were
selected (Supplementary Table S1). Selection criteria for
the polymorphisms were a minor allelic frequency > 0.2 in
Caucasians and an assumed clinical relevance based on
previously reported associations or the assumption that
nonsynonymous amino acid change leads to changed
protein functionality.
The 11 candidate genes were selected on their potential
relation with the pharmacokinetics and pharmacody-
namics of sunitinib (Fig. 1). First, the candidate genotypes
were selected by literature review. If there was no available
data in the literature review, we referred to the SNPs from
the dbSNP database (http://www.ncbi.nlm.nih.gov/sites/
entrez). ABCB1, ABCG2, NR1I2, NR1I3, CYP3A5, CYP1A1,
and CYP1A2 were selected for the pharmacokinetic path-
ways, whereas VEGFR-2, VEGFR-3, PDGFR-a, and FLT-3
were selected for the pharmacodynamic pathways. The
most common functional SNPs in human ABCB1 are
the synonymous 3435C > T and 1236C > T changes and
the nonsynonymous 2677G > T change. As functional
studies have shown that the haplotype of these three SNPs
is a silent mutation and alters the function of the efflux
transporter including its substrate specificity (23), the
haplotype of ABCB1, instead of the three individual SNPs,
was included in the analysis. Although VEGFR-1 is a target
of sunitinib, and CYP3A4 is an important enzyme for
metabolism of sunitinib (11), no polymorphisms of
VEGFR-1 and CYP3A4 were analyzed, as no functional
polymorphisms met the criteria for SNP selection.
Methods for genotyping assay validation and haplotype
estimation have been described previously (19). Briefly,
germline DNA was isolated from 1 mL of serum or EDTA-
blood with the Magnapure LC (Roche Diagnostics). Poly-
morphic sites in genomic DNAwere analyzed with TaqMan
assays (Applied Biosystems).
Statistical design and data analysis
For PFS and OS, data collection was closed on August 31,
2009. The primary outcome measures of this study, PFS,
was defined as the time between the first day of sunitinib
and the date of progressive disease (PD) according to
Response Evaluation Criteria in Solid Tumors (24), clear
clinical evidence of PD or death due to PD within 12 weeks
after the last response evaluation. If a patient had not
progressed, PFS was censored at the time of the last fol-
low-up. If the PD date was unknown or a patient died due
to PD later than 12 weeks after the last response evaluation,
PFS was censored at the last adequate tumor assessment.
OS was the secondary outcome and was defined as the time
between the first day of sunitinib treatment and the date of
death or the date at which patients were last known to be
alive.
All patient characteristics were tested univariately against
the primary outcome using Kaplan–Meier and Cox-regres-
sion analysis, depending on the tested variables. The poly-
morphisms and haplotypes were tested univariately against
PFS andOS using the Kaplan–Meiermethod. For this initial
analysis, the general model was used. Given the explorative
nature of this study, variables with a P  0.1 were selected
as candidate variables for multivariate Cox-regression ana-
lyses. Data were fitted to the most appropriate model
(multiplicative, dominant or recessive) and tested in the
multivariate Cox regression survival analysis with PFS and
OS as depending variables. Additional patient character-
istics were introduced in the multivariate analyses based on
univariately tested results if P < 0.1. Hazard ratios (HR)
were generated considering patients with the most com-
mon clinical factor or genotype as the reference group.
Missing data were kept as missing except for factors in the
MSKCC score and the ECOG performance status. Patients
with missing performance status (n ¼ 2), LDH (n ¼ 2),
hemoglobin (n ¼ 1), and baseline calcium values (n ¼ 2)
were assumed to be part of the worse prognosis scores.
Accordingly, MSKCC scores were increased with one risk
factor in 5 patients and with two risk factors in one patient.
As a result 3 patients were categorized into the intermediate
risk group, whereas 3 other patients were categorized into
the poor risk group. Patients with missing ECOG perfor-
mance statuses (n ¼ 2) were scored as ECOG ¼ 1. To test
these assumptions, the multivariate analyses were per-
formed with and without the replacement of the patients
with missing factors in the MSKCC score. Similar results
were generated, indicating that the replacement was legit-
imate. All statistical analyses were performed using SPSS
16.0 software. A 20% improvement (HR, 0 ¼ 0.44) in PFS
van der Veldt et al.
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at 1 year in patients with sunitinib was judged to be
clinically meaningful by the investigators designing the
study. Forty-six events with disease progression were esti-
mated to be needed to detect such an improvement using a
two-sided, unstratified log-rank test with an overall signif-
icance level of 0.05 and power of 0.80. All results from the
multivariate analyses with P < 0.05 were considered sig-
nificant. Because this is an explorative study, no correction
for multiple testing was made.
Results
Study population
The main patient characteristics are presented in Table 1.
Thirty-one (22.8%) patients had one metastatic site, 47
(34.6%) patients had two metastatic sites, and 58 (42.6%)
patients had at least 3 metastatic sites. According to the
MSKCC prognostic criteria most patients (59.6%) were
categorized into the intermediate risk group, whereas
24.3% and 16.2% of the patients were categorized into
the favorable and poor risk group, respectively.
At the time of the analysis, 47 (34.6%) patients were alive
and 92 (67.6%) patients had disease progression. Overall,
the median PFS time was 10.0 months (range, 7.6–12.4
months) and the median OS time was 16.3 months (range,
13.5–19.2 months). Of the clinical characteristics, the
MSKCC risk factors had the largest contribution to PFS
and OS (P ¼ 0.001 and P < 0.001, respectively; Tables 2
and 3). In addition, the number of metastatic sites, age, and
the ECOG performance status were prognostic for PFS (P¼
0.019, 0.047, and 0.049, respectively), whereas only the
ECOG performance status and the number of metastatic
sites were also prognostic for OS (P ¼ 0.004 and 0.058,
respectively).
Baseline characteristics entered into the multivariate Cox
models included the MSKCC risk factors, the number of
metastatic sites, and age for PFS analyses, and the MSKCC
risk factors and the number of metastatic sites for OS
analyses. The ECOG performance status was excluded from
the multivariate analyses due to colinearity with the
MSKCC prognostic criteria (22).
Pharmacogenetic factors for sunitinib and
progression-free survival
Among the 30 studied polymorphisms, only poly-
morphisms related to the pharmacokinetics of sunitinib
were predictive of PFS (Table 2). A prolonged PFS was
found in the univariate analysis of patients with presence of
the A-allele in CYP3A5 6986A/G (P ¼ 0.017), absence of a
CAT copy in the NR1I3 haplotype (P ¼ 0.021), presence of
the C-allele in NR1I2 8055C/T (P ¼ 0.025), presence of
the C-allele in NR1I2 -25385C/T (P ¼ 0.032), presence
of a TCG copy in the ABCB1 haplotype (P ¼ 0.072) and
presence of the A-allele in ABCG2 34G/A (P ¼ 0.077).
Together with the MSKCC risk factors, the numbers of
metastatic sites and age, these polymorphisms were entered
into the multivariate Cox model.
Table 1. Patient characteristics
Characteristic No. %
Median age, y 60
Range 25–84
Sex
Male 83 61.0
Female 53 39.0
Ethnicity
Caucasian 130 95.6
Black 3 2.2
Asian 1 0.7
Latin–American 1 0.7
Arab 1 0.7
ECOG performance status
0 66 48.5
1 54 39.7
2 10 7.4
3 4 2.9
Missing 2 1.5
Previous medical treatments
Yes 56 41.2
No 80 58.8
Previous treatment regimen
Cytokine-based therapy 45 33.1
Antiangiogenic therapy 4 2.9
Both 7 5.1
Previous nephrectomy
Yes 105 77.2
No 31 22.8
Previous radiation therapy
Yes 34 25.0
No 102 75.0
No. of metastatic sites
1 31 22.8
2 47 34.6
3 58 42.6
Sites of metastases
Lung 100 73.5
Liver 33 24.3
Bone 46 33.8
Lymph nodes 61 44.9
Brain 5 3.7
MSKCC risk factorsa
0 (favorable) 33 24.3
1–2 (intermediate) 81 59.6
3 (poor) 22 16.2
aRisk groups according to Memorial Sloan-Kettering Can-
cer Center (MSKCC) prognostic criteria [based on the 5 risk
factors: low Karnofsky performance status (<80%), high
LDH (>1.5 times the upper limit of normal), low serum
hemoglobin, high corrected serum calcium (>10 mg/dL),
and time from initial diagnosis to treatment <1 year] (22).
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Multivariate analysis confirmed the following factors as
significant (<0.05) predictors of improved PFS: the MSKCC
risk factors (HR: 1.988; 95% CI, 1.394–2.837), the number
of metastatic sites (HR: 1.400; 95% CI, 1.042–1.880), age
(HR: 1.031 per year increase; 95% CI, 1.003–1.060), pre-
sence of the A-allele in CYP3A5 6986A/G (HR: 0.266; 95%
CI, 0.079–0.892), absence of a CAT copy in the NR1I3
haplotype (HR: 1.758; 95% CI, 1.108–2.790), and the
presence of a TCG copy in the ABCB1 haplotype (HR:
0.522; 95% CI, 0.287–0.950).
Pharmacogenetic factors for sunitinib and overall
survival
In univariate analysis, polymorphisms related to the
pharmacokinetics and pharmacodynamics of sunitinib
were predictive of OS (Table 3). Of the pharmacokinetic
Table 2. Univariate and multivariate analyses of progression-free survival in mRCC patients treated with
sunitinib
Factors No. Univariate analysesa Multivariate analyses
Median PFS
(mo)
95% CI P HRb 95% CI P
Clinical factors
MSKCC risk factorsc 0.001 1.988 1.394–2.837 <0.001d
0 33 24.3 11.3–37.2
1–2 81 8.7 6.3–11.2
3 22 7.0 0.0–14.4
No. of metastatic sites 0.019 1.400 1.042–1.880 0.025d
1 31 19.4 7.8–31.0
2 47 11.0 5.1–16.8
3 58 8.1 7.6–8.6
Age (HR ¼ 1.024 per
year increase)
1.000–1.048 0.047 1.031 per
year increase
1.003–1.060 0.029
Genetic factors
pharmacokinetic pathway
CYP3A5 6986A/G 0.017
GG versus 117 9.3 6.9–11.8 1 0.032
AG þ AA 11 Not reached – 0.266 0.079–0.892
NR1I3 haplotypee 0.021 0.017
Other–other versus 75 13.3 7.9–18.8 1
CAT-other þ CAT-CAT 60 8.0 7.5–8.6 1.758 1.108–2.790
NR1I2 8055C/T 0.025 0.656
CC þ CT versus 119 10.8 8.0–13.6 1
TT 17 6.7 3.6–9.9 1.638 0.187–14.380
NR1I2 -25385C/T 0.032 0.795
CC þ CT versus 118 10.8 8.0–13.6 1
TT 18 6.7 2.8–10.7 0.755 0.091–6.273
ABCB1 haplotypef 0.072 0.033
Other–other versus 100 8.4 7.0–9.7 1
TCG–other 29 15.2 6.1–24.3 0.522 0.287–0.950
ABCG2 34G/A 0.077 0.497
GG versus 124 9.0 6.9–11.2 1
AG 12 19.4 0.0–40.8 0.713 0.269–1.891
aOnly factors with P < 0.1 level are presented; factors with P < 0.1 in the univariate analyses were selected for multivariate analyses.
bHR < 1.0 indicates that the factor associates with improved PFS, HR > 1.0 associates with worse PFS.
cRisk groups according to Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria [based on the 5 risk factors: low
Karnofsky performance status (<80%), high LDH (>1.5 times the upper limit of normal), low serum hemoglobin, high corrected serum
calcium (>10 mg/dL), and time from initial diagnosis to treatment <1 year] (22).
dMultiplicative model, HR per increase in MSKCC class or number of metastatic sites class.
Description haplotypes: e ¼ NR1I3 5719C/T, 7738A/C, and 7837T/G; f ¼ ABCB1 3435C/T, 1236C/T, and 2677G/T.
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polymorphisms, presence of the C-allele in NR1I2-
25385C/T (P ¼ 0.017), presence of a TCG copy in the
ABCB1 haplotype (P ¼ 0.097) and presence of the A-allele
in ABCG2 34G/A (P ¼ 0.072) were associated with a
prolonged OS. In addition, univariate analyses identified
two pharmacodynamic polymorphisms including two
GCGT copies in the PDGFR-a haplotype and presence of
the A-allele in VEGFR-2 1718T/A as factors for a prolonged
OS (P ¼ 0.002 and 0.022, respectively).
Multivariate analysis confirmed the MSKCC risk factors
(HR: 2.273; 95% CI, 1.595–3.238) and the presence of the
A-allele in VEGFR-2 1718T/A (HR: 2.907; 95% CI, 1.224–
6.903) as significant (< 0.05) predictors of a prolonged OS.
In multivariate analysis, there was a trend toward an
improved OS for patients with a TCG copy in the ABCB1
haplotype (HR: 0.593; 95%CI, 0.332–1.061; P¼ 0.078) or
presence of the A-allele in ABCG2 34G/A (HR: 0.416; 95%
CI, 0.162–1.070; P ¼ 0.069).
Favorable genetic profiles and outcome
Polymorphisms that were associated with an improved
PFS were combined in a predictive model. Patients were
categorized as carriers of the favorable genetic profiles
when they had at least an A-allele in CYP3A5, a TCG copy
in the ABCB1 haplotype or a missing CAT copy in the
NR1I3 haplotype. Carriers with a favorable genetic profile
Table 3. Univariate and multivariate analyses of overall survival in mRCC patients treated with sunitinib
Univariate analysesa Multivariate analyses
Factors No. Median OS
(mo)
95% CI P HRb 95% CI P
Clinical factors
MSKCC risk factorsd <0.001 <0.001d
0 33 Not reached - 2.273 1.595–3.238
1—2 81 14.8 11.8–17.7
3 22 10.9 7.2–14.7
No. of metastatic sites 0.058 0.097d
1 31 28.8 15.3–42.2 1.273 0.957–1.693
2 47 15.6 13.5–17.7
3 58 13.2 9.5–16.9
Genetic factors
pharmacokinetic pathway
NR1I2 -25385C/T 0.017 0.178
CC þ CT versus 118 17.1 12.9–21.2 1
TT 18 10.2 7.4–13.1 1.490 0.834–2.660
ABCB1 haplotypee 0.097 0.078
Other–other versus 100 15.4 12.4–18.3 1
TCG–other 29 23.9 9.0–38.7 0.593 0.332–1.061
ABCG2 34G/A 0.072 0.069
GG versus 124 15.4 12.5–18.3 1
AG 12 39.9 16.7–63.1 0.416 0.162–1.070
Genetic factors pharmacodynamic
pathway
PDGFR-a haplotypef 0.002 0.108
GCGT–GCGT vs. 78 24.2 17.2–31.2 1
GCG–other þ other–other 56 14.8 11.6–17.9 1.458 0.920–2.310
VEGFR-2 1718T/A 0.022 0.016
AA þ AT versus 125 16.3 12.4–20.2 1
TT 8 9.4 7.2–11.7 2.907 1.224–6.903
aOnly factors with P < 0.1 level are presented; factors with P < 0.1 in the univariate analyses were selected for multivariate analyses.
bHR < 1.0 indicates that the factor associates with improved OS, HR > 1.0 associates with worse OS.
cRisk groups according to Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria [based on the 5 risk factors: low
Karnofsky performance status (<80%), high LDH (>1.5 times the upper limit of normal), low serum hemoglobin, high corrected serum
calcium (>10 mg/dL), and time from initial diagnosis to treatment <1 year] (22).
dMultiplicative model, HR per increase in MSKCC class or number of disease sites class.
Description haplotypes: e ¼ ABCB1 3435C/T, 1236C/T and 2677G/T; f ¼ PDGFR-a 1580T/C -1171C/G -735G/A -573G/T.
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(n ¼ 95) had an improved PFS and OS as compared with
noncarriers (median PFS: 13.1 versus 7.5 months, P ¼
0.001 and median OS: 19.9 versus 12.3 months, P ¼
0.009). Multivariate analysis including the clinical factors
showed consistent predictive value of the model for PFS
and showed a trend for OS (HR: 0.541; 95% CI, 0.340–
0.860, P¼ 0.009 andHR: 0.667; 95%CI, 0.420–1.058, P¼
0.085, respectively; Fig. 2).
Discussion
InmRCC patients treated with sunitinib, theMSKCC risk
groups and the number of metastatic sites are clinical
factors that are usually associated with PFS and OS
(2,3,7). However, these clinical factors are prognostic cri-
teria that are associated with the extent of the disease and
do not necessarily predict antitumor efficacy of a specific
drug. As an increasing number of drugs is currently avail-
able for the treatment of mRCC (25), tools are needed to
identify patients who predispose to benefit from sunitinib
treatment and to select individual mRCC patients for
treatment with this drug. The efficacy of sunitinib may
be influenced by multiple genes encoding for enzymes,
efflux transporters and targets related to the pharmacoki-
netics and pharmacodynamics of sunitinib. Therefore, we
analyzed whether SNPs in the pharmacokinetic and phar-
macodynamic pathways of sunitinib were predictive of PFS
and OS in patients with clear-cell mRCC. Our study
showed that next to 3 clinical characteristics (MSKCC
prognostic criteria, number of metastatic sites, and age),
3 genetic variants in the CYP3A5,NR1I3, and ABCB1 genes
were predictive factors for PFS. In addition, a role of an A-
allele in VEGFR-2 1718T/A for a prolonged OS as a sec-
ondary outcome was found.
Clinical benefit from sunitinib treatment may depend on
systemic exposure to sunitinib. Sunitinib is metabolized
primarily to the active N-de-ethylatedmetabolite SU12662,
which reaches similar plasma concentrations and has equi-
potent biochemical activity as the parent compound (26).
Thereafter, SU12662 undergoes a second N-de-ethylation
step, which occurs at a slower rate, to the inactive metab-
olite SU14335. Recently, a meta-analysis of pharmacoki-
netic data in 443 patients treated with sunitinib, showed
that higher plasma levels of sunitinib and its active
metabolite SU12662 were associated with a prolonged
time–to–tumor progression and OS (27). Currently, it is
not clear which underlying factors account for the observed
interindividual differences in plasma levels of sunitinib
and its active metabolite SU12662. Interindividual differ-
ences in sunitinib exposure may be the result of variations
in sunitinib absorption, metabolism, distribution, and
excretion through metabolizing enzymes and transporter
proteins. Concerning the pharmacokinetics of sunitinib,
the present study identified variants in three genes
(CYP3A5, NR1I3, and ABCB1) as predictive factors for
PFS in mRCC patients treated with sunitinib. Although
these polymorphisms were not predictive of OS, there was a
trend toward a prolonged OS for patients with a TCG copy
in the ABCB1 haplotype. Additional treatment after dis-
continuation of sunitinib treatment may explain the dis-
crepancy between the results of the PFS and OS analyses,
as 26% of patients were subsequently treated with at least
one other agent, including sorafenib (22%), temsirolimus
(2%), and everolimus (4%).
P = 0.009
Figure 2. Favorable (—) and nonfavorable genetic profile (. . .) in mRCC patients treated with sunitinib for progression-free (A) and overall survival
(B) using multivariate Cox regression analysis. Patients were categorized as carriers of the favorable genetic profiles when they had at least an A-allele in
CYP3A5, a TCG copy in the ABCB1 haplotype or a missing CAT copy in the NR1I3 haplotype.
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CYP3A4 is the major key enzyme for the biotransforma-
tion of sunitinib (11). However, no polymorphisms of
CYP3A4 were analyzed in the present study, as there are
no functional polymorphisms in CYP3A4 that meet our
described criteria for SNP selection yet. The CYP3A5
enzyme is another important enzyme for the metabolism
of several TKIs including erlotinib, gefitinib, and imatinib
(13). Similarly, the CYP3A5 enzyme may metabolize suni-
tinib and was therefore included in the analysis, though the
sunitinib-metabolizing capacity of CYP3A5 has to be con-
firmed. In the current study, presence of the A-allele in
CYP3A5, an SNP which leads to the CYP3A5 expressor
phenotype (28, 29), was a predictive factor for a prolonged
PFS. As the CYP3A5 expressor phenotype may lead to
increased metabolism of sunitinib, these findings suggest
that the prolonged PFS in patients with presence of the A-
allele in CYP3A5 may be caused by increased levels of the
active metabolite SU12662, which has a longer half-life
than the parent compound (80–100 hours versus 40–60
hours; ref. 26). Furthermore, polymorphisms in other
genes (NR1I2 and NR1I3) that regulate the expression of
CYP3A4 (12) were identified as predictive factors for out-
come in sunitinib-treated mRCC patients.
The efflux transporters ABCB1 and ABCG2 play an
important role in drug absorption, excretion, cellular accu-
mulation, and resistance (10). Consequently, polymorph-
isms in ABCB1 and ABCG2may affect drug absorption and
excretion of sunitinib. In the present study, the found
associations between polymorphisms in the ABCB1 hap-
lotype (a TCG copy) and the ABCG2 gene (presence of the
A-allele), and improved outcome suggest that these poly-
morphisms may lead to reduced efflux transport of suni-
tinib into the gastrointestinal lumen and bile, resulting in
increased systemic exposure of sunitinib. In vitro studies
have reported conflicting data on the affinity of sunitinib
for ABCB1 and ABCG2 (8, 9). Hu and colleagues (8) found
a moderate affinity of sunitinib for ABCB1 and a negligible
transport of sunitinib in cells overexpressing ABCG2,
whereas another study reported higher sunitinib affinity
for ABCG2 compared with ABCB1 (9). Furthermore, suni-
tinib reversed ABCG2-mediated multidrug resistance by
inhibiting the drug efflux function of ABCG2 (30). This
inhibitory capacity of sunitinib on ABCG2 appeared to be
sensitive for the ABCG2 1291T > C genotype (31). In
addition, another SNP in ABCG2 (421C > A) was asso-
ciated with increased sunitinib exposure (32).
The ABC transporters may contribute to multidrug resis-
tance in tumors by actively extruding drugs from cancer
cells. In RCC, an increase in ABCB1 expression (33, 34) and
activity (35) has been reported, suggesting a contribution
of ABCB1 to the resistance of RCC to some anticancer
drugs. Although polymorphisms in ABCB1 and ABCG2
may be associated with the development of RCC (36,
37), it is currently not known whether polymorphisms
in ABCB1 and ABCG2 are associated with the expression
and function of these transporters at the somatic level in
renal cancer cells (38). Nevertheless, the role of efflux
transporters in tumor cells may be limited for acquired
resistance to sunitinib, which may develop after an initial
response to sunitinib, as acquired resistance to sunitinib
may be more related to physiological changes in the
microenvironment of tumors, allowing reestablishment
of angiogenesis during sunitinib treatment (16).
Clinical efficacy of treatment with TKIs may also be
related to specific mutations in drug targets, as was shown
for imatinib and gefitinib (39–40). Currently, it is not
known which targets in RCC predict response to sunitinib
or whether the somatic polymorphisms of targets in RCC
correlate with genetic polymorphisms obtained from
germline cells. Of the studied pharmacodynamic poly-
morphisms of sunitinib, only a polymorphism of VEGFR-
2 1718T/A was associated with a decreased OS in multi-
variate analysis, whereas the presence of two GCGT copies
in the PDGFR-a haplotype was associated with a pro-
longed OS in univariate analysis. However, no significant
association between these polymorphisms and PFS was
found. These findings may suggest that polymorphisms in
VEGFR-2 and PDGFR-amay be associated with the nature
of the disease and may therefore be prognostic instead of
predictive. However, prospective validation in an inde-
pendent mRCC cohort that is not treated with sunitinib is
necessary to determine whether the associated poly-
morphisms of the present study are predictive markers
of sunitinib activity or prognostic markers of mRCC
disease.
In our previous study, several polymorphisms in genes
involved in the pharmacokinetic and pharmacodynamic
pathways of sunitinib were associated with sunitinib-
induced toxicity (19). Polymorphisms of NR1I3 (absence
of a CAG copy in the haplotype), ABCB1 (presence of a TTT
copy), and VEGFR-2 (T allele in 1191 C/T) were signifi-
cantly related with an increased risk for leucocytopenia,
hand-foot syndrome, and any toxicity > grade 2, respec-
tively (19). In the present study however, other genotypes
or haplotypes in NR1I3, ABCB1, and VEGFR-2 were asso-
ciated with clinical outcome. It is currently not clear how
the different genotypes and haplotypes between these
studies are related, but it is conceivable that severity and
prevalence of some sunitinib-induced toxicities may basi-
cally depend on inhibition of a specific molecular pathway
rather than variation in exposure, whereas other sunitinib-
induced toxicities may mainly depend on exposure to the
drug. In addition, the discrepancy between these two
studies may be the result of different study populations,
as patients with different malignancies were included in
our previous study. Recently, Houk and colleagues (27)
have shown a relationship between sunitinib exposure and
the probability of grade  1 fatigue, the absolute neutro-
phil count, and the changes in diastolic blood pressure.
However, these sunitinib-induced toxicities cannot be
extrapolated to our previous toxicity study (19), as different
toxicities and grades of toxicity were analyzed in both
studies.
A potential limitation of the study is the retrospective
design. As a result, pharmacokinetic data were not available
to correlate polymorphisms ofCYP3A5,NR1I3, and ABCB1
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with plasma levels of sunitinib and its active metabolite
SU12662. If future studies reveal a relation between suni-
tinib exposure and presence of an A-allele in CYP3A5
6986A/G, absence of a CAT copy in the NR1I3 haplotype
or presence of a TCG copy in the ABCB1 haplotype, the
sunitinib starting dose may be adjusted to dose-escalation
of sunitinib > 50 mg/daily for patients without these
genotypes and haplotypes. The nonbeneficial genetic pro-
file may be used to select patients who may be eligible for
alternative dosing schedules with intensive monitoring of
plasma levels of sunitinib and its active metabolite
SU12662. Before this genetic profile can be implemented,
prospective validation in an independent patient popula-
tion is necessary.
In conclusion, pharmacokinetic but not pharmacody-
namic polymorphisms were independent predictive factors
for PFS in patients with clear-cell mRCC who were treated
with sunitinib. Patients with an A-allele in CYP3A5 6986A/
G, absence of a CAT copy in the NR1I3 haplotype, or
presence of a TCG copy in the ABCB1 haplotype had a
prolonged PFS. These polymorphisms may be valuable
factors to identify patients with reduced exposure to suni-
tinib in order to improve treatment strategies in these
patients. The findings of this study advocate more phar-
macokinetic studies in patients treated with sunitinib to
further elucidate the role of these genetic determinants in
sunitinib exposure and efficacy.
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Predictive factors for severe toxicity of sunitinib in unselected
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Sunitinib has been registered for the treatment of advanced renal cell cancer (RCC). As patient inclusion was highly selective in
previous studies, experience with sunitinib in general oncological practice remains to be reported. We determined the efficacy and
safety of sunitinib in patients with advanced RCC included in an expanded access programme. ECOG performance status 41,
histology other than clear cell and presence of brain metastases were no exclusion criteria. Eighty-two patients were treated: 23%
reached a partial response, 50% had stable disease, 20% progressed and six patients were not evaluable. Median progression-free
survival (PFS) was 9 months and median overall survival (OS) was 15 months. Importantly, 47 patients (57%) needed a dose
reduction, 35 (43%) because of treatment-related adverse events, 10 (12%) because of continuous dosing, and two because of both.
Stomatitis, fatigue, hand–foot syndrome and a combination of grade 1–2 adverse events were the most frequent reasons for dose
reduction. In 40 patients (49%), there was severe toxicity, defined as dose reduction or permanent discontinuation, which was highly
correlated with low body surface area, high age and female gender. On the basis of age and gender, a model was developed that
could predict the probability of severe toxicity.
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Advanced renal cell cancer (RCC) has been recognised as a
chemoresistant disease. The only treatment available has been
cytokine-based therapy. Increasing knowledge of the underlying
biology of RCC, and more specifically, the clear cell subtype, has
recently changed the treatment options. Clear cell carcinomas,
which account for 75% of all RCC subtypes, appear to contain an
inactivated von Hippel–Lindau (VHL) tumour suppressor gene in
at least 60% of these tumours (Brugarolas, 2007). von Hippel–
Lindau gene alterations lead to elevated protein levels of hypoxia-
induced factor-a, which upregulates vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF) genes
and proteins (Brugarolas, 2007). The overexpression of these
growth factors results in blood vessel formation which may
account for the high vascular density of these tumours. Conse-
quently, tumour angiogenesis has become an interesting
therapeutic target in patients with metastatic RCC (mRCC).
Antiangiogenic agents, such as bevacizumab (Escudier et al,
2007b), sorafenib (BAY 43–9006) (Escudier et al, 2007a) and
sunitinib (SU011248) (Motzer et al, 2007) have demonstrated
significant antitumour activity in advanced RCC preferentially of
the clear cell type excluding patients with poor prognosis. In a
phase III clinical trial in mRCC, bevacizumab, a neutralising
antibody against VEGF, in combination with interferon-a pro-
longed progression-free survival (PFS) with 4.8 months as
compared to interferon-a alone (Escudier et al, 2007b). Sunitinib
and sorafenib are oral tyrosine kinase inhibitors of the VEGF and
PDGF receptors. In comparison with placebo, sorafenib prolonged
PFS in cytokine-pretreated mRCC with almost 3 months (Escudier
et al, 2007a). Sunitinib demonstrated a significantly prolonged PFS
(11 vs 5 months) as well as a higher objective response rate than
treatment with interferon-a (31 vs 6%) (Motzer et al, 2007).
Temsirolimus, an inhibitor of mammalian target of rapamycin
(mTOR) kinase, has demonstrated to improve the overall survival
(OS) in RCC patients with unselected cancer histology and poor
prognosis in comparison with interferon-a (11 months vs 7 and 8
months for, respectively, single-agent temsirolimus vs single-agent
interferon-a and the combination) (Hudes et al, 2007).
In the pivotal trials on sunitinib, patients had to fulfil
prespecified criteria. Eastern Cooperative Oncology Group (ECOG)
performance status 41, brain metastases, uncontrolled hyperten-
sion or clinically significant cardiovascular events or disease
during the preceding 12 months were exclusion criteria (Motzer
et al, 2006a, b, 2007). In addition, only patients with clear cell
histology were allowed for entry in two out of the three previous
studies (Motzer et al, 2006b, 2007). Nowadays, sunitinib can be
prescribed widely to patients with advanced RCC, but the
experience with this drug in an unselected patient population that
does not meet the above-described criteria has yet to be revealed.
Here, we report on a first experience with sunitinib treatment in aRevised 7 May 2008; accepted 9 May 2008; published online 1 July 2008
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large advanced-stage RCC patient population reflecting general
oncological practice and show that clinical benefit is comparable to
that observed in the earlier phase II/III trials. An unexpectedly
high number of patients, however, required dose reductions to
maintain an acceptable quality of life.
PATIENTS AND METHODS
Patient population
From December 2005 to September 2006, patients with histologi-
cally confirmed advanced RCC were enrolled in a global expanded
access programme (EAP) for treatment with sunitinib. Results are
reported for patients treated in two centres in Amsterdam (VU
University medical center and the Netherlands Cancer Institute).
Until May 2006, patients were included only after cytokine-based
therapy had failed and, thereafter, the drug was also available first-
line. Inclusion criteria were as follows: age 18 years of age or older,
adequate organ function (total serum bilirubin p2 upper limit
of normal (ULN), serum transaminases o5ULN, serum
creatinine p2ULN, absolute neutrophil count X1 109 l1,
platelets X75 109 l1, haemoglobin X5.0mmol l1) and resolu-
tion of all toxic effects of prior systemic therapy, radiotherapy or
surgical procedure according to National Cancer Institute-
Common Toxicity Criteria (NCI-CTC) version 3.0 grade p1.
Before entry into the programme, each participant had to sign an
institutional review board-approved protocol-specific informed
consent in accordance with the national and institutional guide-
lines, which strictly adhere to the principles of the Declaration of
Helsinki and its subsequent amendments.
Exclusion criteria were as follows: pregnancy or breast feeding,
concurrent treatment in another therapeutic trial, previous treat-
ment with sunitinib, congestive heart failure, myocardial infarction
or coronary artery bypass graft in the previous 6 months, ongoing
severe or unstable angina, any unstable arrhythmia requiring
medication or another severe acute or chronic medical or
psychiatric condition or laboratory abnormality that would make
the patient inappropriate for entry in this EAP.
Treatment, efficacy and adverse events
Sunitinib was administered orally at a dose of 50mg daily,
consisting of 4 weeks of treatment followed by a 2-week rest period
in cycles of 6 weeks. A dose reduction of sunitinib (to 37.5 or
25mg) was allowed depending on the type and severity of adverse
events. If patients had symptoms of progressive disease (PD)
during the rest period, there was the possibility for continuous
dosing of sunitinib at 37.5mg per day.
Patients underwent physical examination on day 1 of every
cycle. Complete blood cell count and serum chemistry tests were
carried out on day 1 and 28 of every treatment cycle. Complete
blood cell count was also performed on day 14 of the first cycle.
Electrocardiography was performed at baseline and on day 28 of
the first treatment cycle. Haematological and non-haematological
toxic effects were graded according to NCI-CTC version 3.0.
Toxicity evaluation was conducted on day 1, 14 and 28 of the first
treatment cycle and on day 1 and 28 of each treatment cycle
thereafter. If grade 3 haematological toxicity was recorded, the
treatment was withheld until the recovery grade p2 or blood
counts had returned to baseline after which sunitinib was resumed
at the same dose level. In case of grade 4 haematological toxicity
and grade 3 or 4 non-haematological toxicity, treatment was
delayed until side effects had recovered to grade p2 or grade 1,
respectively, or had returned to baseline after which the dose was
reduced by one level at the discretion of the treating physician. In
the case of grade 4 non-haematological toxicity, treatment was
discontinued.
Computed tomography (CT) or magnetic resonance imaging
(MRI) was performed at baseline and every two to three cycles
of treatment to assess clinical response according to
Response Evaluation Criteria in Solid Tumours (RECIST)
(Therasse et al, 2000).
Data analysis
Specific case report forms were used for data entry. For response
evaluation and toxicity, the cutoff date for data analysis was
1 March, 2007. For survival analysis, data collection was closed on
1 September, 2007. Patients were classified according to two
prognostic classification systems for mRCC: (1) the Memorial
Sloan–Kettering Cancer Center (MSKCC) prognostic criteria
(based on five risk factors: low Karnofsky performance status
(o80%), high lactate dehydrogenase (LDH,41.5 times the ULN),
low serum haemoglobin, high-corrected serum calcium (410mg
per 100ml) and time from initial diagnosis to treatment of less
than 1 year) (Motzer et al, 2002) and (2) the prognostic criteria for
VEGF-targeted therapy according to Choueiri et al (2007) (based
on the following 5 risk factors: time from diagnosis to treatment
o2 years, baseline platelet count 4300 109 l1, baseline
neutrophil count 44.5 109 l1, baseline corrected calcium
o8.5mg per 100ml or 410mg per 100ml and initial ECOG
performance status 40).
Efficacy parameters were best response, time-to-treatment
failure (TTF), PFS and OS. The TTF was defined as the time
between the first day of treatment and the date of the first event
considered as failure of treatment. Such events could be disease
progression, early discontinuation (owing to unacceptable toxicity,
patient’s request and lost to follow-up) or death. The PFS was the
time between the first day of sunitinib and the date of PD on CT or
MRI, clear clinical evidence of PD or death owing to PD within 12
weeks after the last response evaluation. If a patient had not
progressed, PFS was censored at the time of the last follow-up. If
the PD date was unknown or a patient died owing to PD later than
12 weeks after the last response evaluation, PFS was censored at
the last adequate tumour assessment. Overall survival was the time
between the first day of treatment and the date of death or the date
at which patients were last known to be alive. Progression-free
survival and OS were calculated with the Kaplan–Meier method.
Severe toxicity was defined as dose reduction or permanent
discontinuation of sunitinib because of treatment-related adverse
events.
The following clinical characteristics were analysed for a
possible relation with severe toxicity: gender, age, body surface
area (BSA), ECOG performance status, tumour type, presence of
primary tumour, time of diagnosis to treatment, prior cytokine
based-therapy, previous radiation therapy, number of tumour
sites, liver metastases, MSKCC risk groups, Chouieri risk groups
and baseline biochemical parameters. Baseline biochemical
parameters (haemoglobin, LDH, albumin, creatinine, alkaline
phosphatase and corrected calcium) were all quantified as a factor
of the ULN. Statistical analysis was carried out using SPSS software
(SPSS for Windows 15.0, SPSS, Inc., Chicago, IL, USA). Univariate
logistic regression was performed to explore associations between
the separate clinical characteristics and severe toxicity. Thereafter,
the variables with a significance of Po0.05 were used for
multivariate logistic regression analysis.
RESULTS
Patients and treatment
Eighty-two patients with advanced RCC were registered in the
EAP. Patient characteristics are depicted in Table 1. Fourteen
patients had non-clear cell histology, 17 patients had a
Predictive factors for sunitinib toxicity in renal cell cancer
AAM van der Veldt et al
260
British Journal of Cancer (2008) 99(2), 259 – 265 & 2008 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
88
performance status of ECOG 41, 16 patients had a concurrent
primary tumour in situ and five patients had concurrent brain
metastases. All patients received sunitinib for a period of at least 1
week. At the time of the analysis, 18 patients were still on study
and 64 had discontinued sunitinib. Reasons for termination were
PD (n¼ 44), adverse events either related to treatment or disease
(n¼ 14), early death (n¼ 3), nephrectomy after downsizing of the
primary tumour (n¼ 2) and radiofrequency ablation of liver
metastases (n¼ 1).
Efficacy
With respect to best response, 19 (23%) patients achieved a partial
response (PR) (15 confirmed and four non-confirmed), 41 (50%)
patients had stable disease (SD) and 16 (20%) patients had PD. Six
patients could not be evaluated, five as a result of early termination
and one patient because of bone metastases only. Impressive
responses were observed in the 16 primary tumours (Van der
Veldt et al, 2008) and six of them achieved a PR. Ten out of 14
patients with non-clear cell histology and two out of five patients
with brain metastases had SD. No objective responses
were observed in these subgroups. Seven patients developed
symptomatic brain metastases as first or only sign of PD
(Helgason et al, 2008).
Excluding the three patients with nephrectomy and radio-
frequency ablation, the median TTF in 61 patients who discon-
tinued treatment with sunitinib, was 3.6 months (range: 0.3–18.4
months). The median PFS (n¼ 77) was 9.3 months (range:
0.5–18.3 months; Table 2). The patient with bone metastases only
was included in PFS and had clinical benefit lasting 48 months.
PFS was censored for the patient with radiofrequency ablation. The
median PFS in the 14 patients with non-clear cell histology was 3.2
months (range: 1.2–17.0 months). The median OS for the total
patient population was 15.0 months (range: 0.5–19.4 months;
Table 2).
Additional analyses were carried out with respect to individual
patient characteristics and the course of the disease. Both the
MSKCC criteria (Motzer et al, 2002) and the criteria according to
Choueiri et al (2007) correctly predicted the PFS (P¼ 0.001 and
P¼ 0.007, respectively) as well as the OS (Po0.001 and P¼ 0.002,
respectively; Table 2 and Figure 1). The predictive value of the
number of disease sites was rather low, but for OS, the number of
disease sites still had prognostic value (P¼ 0.039).
Safety and dose reductions
The most frequent non-haematological grade 1–2 adverse events
were stomatitis, nausea, diarrhoea, vomiting, fatigue, hand–foot
syndrome and taste alteration (Table 3). Grade 3 adverse events
most frequently occurring were hand–foot syndrome (11%),
stomatitis (9%), diarrhoea (7%), fatigue (6%) and hypertension
(6%). Detailed information on three patients with reversible
cognitive disorders grade 2–3 has been published elsewhere
(Van der Veldt et al, 2007). Thrombocytopenia, leucocytopenia
and neutropenia were the most frequently reported haematological
adverse events (Table 4). The frequency of grade 3 haematological
adverse events was also low, being lymphopenia (9%), thrombo-
cytopenia (7%), neutropenia (7%), leucocytopenia (5%) and
anaemia (1%). No grade 4 adverse events were observed.
In 40 (49%) patients, there was severe toxicity requiring dose
reduction in 37 patients (median time to dose reduction 1.4
months, range: 0.2–12.4 months) and permanent discontinuation
in three patients (for all three patients within 0.5 month; Table 5).
Dose reduction in at least 6 out of 37 patients was not sufficient to
alleviate symptoms, because of which sunitinib had to be
discontinued. Stomatitis grade 3 was the most frequently reported
reason for dose reduction, followed by fatigue, hand–foot
syndrome and the combination of several grade 1–2 adverse
events. In addition, 10 (12%) patients needed continuous dosing
because of PD or recurrence of disease-related symptoms during
the 2-week rest period (median time to continuous dosing
3.1 months, range: 1.1–11.8 months). Two patients had dose
Table 1 Patient characteristics
Total n¼ 82
Variable n (%)
Sex
Male 55 (67)
Female 27 (33)
Median age, years (range) 60 (25–84)
ECOG performance status
0 33 (40)
1 29 (35)
2 12 (15)
3 5 (6)
Unknown 3 (4)
Tumour type
Clear cell 68 (83)
Other 14 (17)
Previous nephrectomy 66 (80)
Prior treatment
None 26 (32)
Cytokine based-therapy 53 (65)
Antiangiogenic therapy 5 (6)
Previous radiation therapy 25 (30)
Number of disease sites
1 11 (13)
2 31 (38)
X3 40 (49)
Sites of disease
Lung 66 (80)
Lymph nodes 43 (52)
Bone 26 (32)
Liver 22 (27)
Local recurrence 10 (12)
Brain 5 (6)
MSKCC risk groupsa
0 (favourable) 20 (24)
1–2 (intermediate) 41 (50)
X3 (poor) 17 (21)
Unknown 4 (5)
Chouieri risk groupsb
1 (0 or 1 adverse prognostic factor) 16 (20)
2 (2 adverse prognostic factors) 18 (22)
3 (42 adverse prognostic factors) 48 (59)
ECOG¼ Eastern Cooperative Oncology Group; LDH¼ lactate dehydrogenase;
MSKCC¼Memorial Sloan–Kettering Cancer Center; VEGF¼ vascular endothelial
growth factor. aRisk groups according to MSKCC prognostic criteria (based on the
five risk factors: low Karnofsky performance status (o80%), high LDH (41.5 times
the upper limit of normal), low serum haemoglobin, high-corrected serum calcium
(410mg per 100ml) and time from initial diagnosis to treatment of less than 1 year;
Motzer et al, 2002). bPrognostic risk groups for VEGF-targeted therapy according to
Chouieri et al (2007) (based on the five risk factors: time from diagnosis to treatment
o2 years, baseline platelet count 4300 109 l1, baseline neutrophil count
44.5 109 l1, baseline corrected calcium o8.5mg per 100ml or 410mg per
100ml and initial ECOG performance status 40).
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reduction because of both toxicity and continuous dosing (time to
dose reduction 1.4 and 4.2 months).
Female gender, high age, low BSA and to a lesser extent also high
LDH were significantly related with severe toxicity (univariate
logistic regression; P¼ 0.006, P¼ 0.006, P¼ 0.005 and P¼ 0.035,
respectively). There was no significant relation between severe
toxicity and the separate prognostic risk groups according to the
MSKCC criteria (Motzer et al, 2002) as well as the criteria of
Choueiri et al (2007). In multivariate logistic regression of gender,
age, BSA and LDH, the latter two variables appeared to be of no
additional significance in the prediction of severe toxicity. In
multivariate logistic regression, gender and age had a significant
effect (P¼ 0.018 and P¼ 0.024, respectively) and the combination
of these two variables was highly predictive for severe toxicity
(P¼ 0.001). On the basis of gender and age, a model was developed
to predict the probability of severe toxicity in male patients and
female patients (Figure 2).
DISCUSSION
We here describe the efficacy and safety of sunitinib treatment in
an unselected mRCC patient population as can be found in general
oncological practice. In our mRCC patients, the SD rate (50%)
resembled that observed in the large phase III clinical trial in
which sunitinib was compared with interferon-a, but the PR rate
was slightly less (23 vs 31%; Motzer et al, 2007). The PR rate in
patients with clear cell histology (28%), however, was similar to
that in the phase III study in patients with clear cell mRCC only
(Motzer et al, 2007). The MSKCC risk groups (Motzer et al, 2002)
appropriately predicted PFS and OS in this patient population,
which indicates that the Motzer prognostic factors model is still
valid to predict survival in mRCC in the sunitinib era. The
prognostic criteria of Choueiri et al (2007) designed for patients
with clear cell histology receiving VEGF-targeted therapy, however,
did not discriminate a difference in OS between risk groups 1 and
2 in our patient population. An explanation may be that we have
treated a large number of cytokine-pretreated patients (65%) as
well as patients with non-clear cell histology (17%).
In the non-clear cell histology patient population, 10 out of 14
patients had SD, whereas no PR was observed. Recently, Choueiri
et al (2008) have reported their experience with sunitinib and
sorafenib in patients with non-clear cell histology. During either
sunitinib or sorafenib treatment, 5 out of 53 patients with non-
clear cell histology, either papillary or chromophobe tumours,
reached a PR, whereas 36 patients had SD of more than 3 months.
Table 2 Best tumour response, progression-free survival and overall survival
Best tumour response
PR SD PD NE Median PFSa Median OSa
Variable n (%) n (%) n (%) n (%) Months (range) Months (range)
All patients 19 (23) 41 (50) 16 (20) 6 (7) 9.3 (0.5–18.3) 15.0 (0.5–19.4)
Histology P¼ 0.528 P¼ 0.105
Clear cell histology 19 (23) 31 (38) 12 (15) 6 (7) 9.3 (0.5–18.3) 15.0 (0.5–19.4)
Non-clear cell histology 0 (0) 10 (12) 4 (5) 0 (0) 3.2 (1.2–17.0) 6.5 (1.4–18.4)
ECOG performance status P¼ 0.397 P¼ 0.049
ECOG p1 14 (17) 34 (41) 12 (15) 2 (2) 9.4 (1.2–17.0) NR (1.8–18.9)
ECOG 41 5 (6) 6 (7) 3 (4) 3 (4) 8.9 (0.5–18.3) 9.7 (0.5–19.4)
Unknown 0 (0) 1 (1) 1 (1) 1 (1) 1.2 (1.2–13.2) 2.2 (0.5–13.2)
MSKCC risk groupsb P¼ 0.001 Po0.001
0 (favourable) 6 (7) 11 (13) 2 (2) 1 (1) 11.6 (1.1–17.0) NR (2.0–18.9)
1–2 (intermediate) 9 (11) 23 (28) 7 (9) 2 (2) 9.6 (1.2–18.3) 15.4 (4.3–19.4)
X3 (poor) 2 (2) 6 (7) 7 (9) 2 (2) 2.6 (0.5–17.0) 3.6 (0.5–16.5)
Unknown 2 (2) 1 (1) 0 (0) 1 (1) 9.7 (9.3–13.2) 15.0 (0.5–15.0)
Choueiri risk groupsc P¼ 0.007 P¼ 0.002
1 (0 or 1 adverse prognostic factor) 3 (4) 8 (10) 4 (5) 1 (1) 12.2 (1.2–17.0) NR (3.6–18.9)
2 (2 adverse prognostic factors) 8 (10) 8 (10) 1 (1) 1 (1) 12.2 (2.1–18.3) NR (4.7–19.4)
3 (42 adverse prognostic factors) 8 (10) 25 (30) 11 (13) 4 (5) 7.0 (0.5–16.1) 10.8 (0.5–17.7)
Number of disease sites P¼ 0.096 P¼ 0.039
1 1 (1) 7 (9) 2 (2) 1 (1) NR (1.2–17.0) NR (3.6–17.2)
2 11 (9) 13 (16) 5 (6) 2 (2) 9.7 (0.9–18.3) NR (1.5–19.4)
X3 7 (9) 21 (26) 9 (11) 3 (4) 8.4 (0.5–16.1) 11.0 (0.5–18.4)
Miscellaneous
Concurrent primary tumour 6 (7) 6 (7) 4 (5) 0 (0) 9.3 (0.9–16.1) 15.0 (1.4–17.7)
Concurrent brain metastases 0 (0) 2 (2) 2 (2) 1 (1) 3.0 (2.6–12.2) 7.5 (3.6–18.4)
Previous cytokine-based therapy 14 (17) 27 (33) 8 (10) 4 (5) 10.6 (1.2–18.3) NR (0.5–19.4)
Previous antiangiogenic therapy 1 (1) 1 (1) 2 (2) 1 (1) 2.6 (1.2–18.3) 4.6 (3.6–19.4)
ECOG¼ Eastern Cooperative Oncology Group; LDH¼ lactate dehydrogenase; MSKCC¼Memorial Sloan–Kettering Cancer Center; NE¼ not evaluable; NR¼median not
reached; OS¼ overall survival; PD¼ progressive disease; PFS¼ progression-free survival; PR¼ partial response; SD¼ stable disease; VEGF¼ vascular endothelial growth factor.
aMedian PFS and OS were calculated with the Kaplan–Meier method. bRisk groups according to MSKCC prognostic criteria (based on the five risk factors: low Karnofsky
performance status (o80%), high LDH (41.5 times the upper limit of normal), low serum haemoglobin, high-corrected serum calcium (410mg per 100ml) and time from
initial diagnosis to treatment of less than 1 year; Motzer et al, 2002). cPrognostic risk groups for VEGF-targeted therapy according to Chouieri et al (2007) (based on the five risk
factors: time from diagnosis to treatmento2 years, baseline platelet count4300 109 l1, baseline neutrophil count 44.5 109 l1, baseline corrected calciumo8.5mg per
100ml or 410mg per 100ml and initial ECOG performance status 40).
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The present data and the study of Choueiri et al (2008) indicate
that patients with non-clear cell histology may benefit from
sunitinib. Furthermore, patients with poor performance status
(ECOG 41) and brain metastases also experienced benefit from
sunitinib treatment in 65 and 40% of cases, respectively.
Treatment-related adverse events were mostly grade 1 or 2 and
only few grade 3 toxicities were observed. The incidence rates of
the most common grade 3 adverse events requiring dose
discontinuation and/or reduction, such as hand–foot syndrome,
stomatitis, diarrhoea, fatigue and hypertension were grossly
similar to the rates reported in previous trials (Demetri et al,
2006; Motzer et al, 2006a, b, 2007). In this patient population, we
observed a relatively lower incidence of thrombocytopenia and
leucocytopenia than that reported in the largest trial on sunitinib
so far (Motzer et al, 2007). Although thyroid function was not
measured consistently, only five patients experienced hypo-
thyroidism grade 1–2 (data not shown).
More than half of our patients needed a dose reduction of
sunitinib and 35 out of 82 patients (43%) because of treatment-
related adverse events. In comparison, only for 32% of the patients
treated with sunitinib in the large randomised phase III trial of
sunitinib vs IFN-a a dose reduction was reported, which might
partially be explained by a higher number of patients with ECOG
X1 in our population. The remarkably high number of dose
reductions, however, was not only based on grade 3 toxicities, but
also on the accumulation of a series of grade 1 and 2 adverse
events. These toxicities were palliated in every possible way.
Some adverse events, however, interfered excessively with daily
life, such as stomatitis and taste alteration requiring changes in
food habits, hand–foot syndrome limiting walking and the urgent
pattern of diarrhoea with risk for soiling. In this respect, the NCI-
CTC grading system is inadequate to express the impact of
particular toxicities of sunitinib for the well-being of the patient.
Our findings are indicative that the sunitinib dosing schedule is
not optimal for unselected mRCC patients and that a number of
patients are initially overtreated resulting in unnecessary adverse
events. On the other hand, patients who do not experience any
toxicity may be undertreated. Therefore, dosing on the basis of
BSA might be meaningful, as BSA was highly correlated with
severe toxicity. In the previous phase I study in patients with solid
tumours, the simulated intrapatient variability in drug plasma
levels between BSA-normalised and fixed dosing was comparable
on days 1 and 28 for both sunitinib and its major plasma
metabolite SU012622 (Faivre et al, 2006). It was concluded that no
or minimal improvement in variability could be expected from
calculating the dose on the basis of BSA. With respect to our data,
it should be reconsidered to administer initial doses on the basis of
BSA and taper off to tolerable doses if required, or increase the
dose if no toxicity is observed. Alternatively, population-based
sunitinibþ SU012622 plasma levels could be of help to develop
better algorithms for optimal sunitinib dosing.
With the use of the fixed dosing regimen, we not only found a
highly significant correlation between severe sunitinib-related
toxicity and patient characteristics BSA, but also with female
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Figure 1 Kaplan–Meier curves for progression-free survival and overall survival of mRCC patients treated with sunitinib for risk groups 1 (y), 2 (—) and
3 (– – ) according to the MSKCC criteria (Motzer et al, 2002) (A and C) and the criteria according to Choueiri et al (2007) (B and D).
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gender and high age. We developed a model to predict the
probability of severe toxicity based on gender and age in which
BSA was not additive. Although the model requires external
validation, it might be helpful to closely monitor patients at risk to
develop invalidating adverse events on sunitinib given in the
currently proposed schedule. It can also be proposed to dose
patients on BSA and determine, whether female gender and high
age remain prognostic factors for severe toxicity. Any grade 3
toxicity was also significantly related to gender and BSA, but not to
age. The occurrence of any grade 3 adverse event was the reason
for dose reduction or discontinuation of sunitinib in 79% of these
patients.
Ten (12%) patients required continuous dosing at a lower dose
of 37.5mg daily owing to objective disease progression or
recurrence of disease-related symptoms in the 2-week period of
rest of the treatment cycle. Two phase II studies have demon-
strated that the safety of a continuous dosing schedule of 37.5mg
per day in patients with RCC and gastrointestinal stromal tumours
(GIST) was similar to that of the intermittent schedule (George
Table 3 Non-haematological adverse events
Non-haematological
adverse eventa
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%) All %
Stomatitis 34 (41) 17 (21) 7 (9) 71
Nausea 31 (38) 9 (11) 4 (5) 54
Diarrhoea 27 (33) 8 (10) 6 (7) 50
Hand-foot syndrome 16 (20) 9 (11) 9 (11) 41
Fatigue 12 (15) 14 (17) 5 (6) 38
Vomiting 22 (27) 5 (6) 0 (0) 33
Taste alteration 20 (24) 6 (7) 0 (0) 32
Hypertension 5 (6) 9 (11) 5 (6) 23
Anorexia 6 (7) 12 (15) 0 (0) 22
Headache 7 (9) 6 (7) 2 (2) 18
Yellow skin 12 (15) 0 (0) 0 (0) 15
Rash/desquamation 8 (10) 4 (5) 0 (0) 15
Fever 7 (9) 4 (5) 0 (0) 13
Heartburn 7 (9) 4 (5) 0 (0) 13
Pain extremity 7 (9) 2 (2) 0 (0) 13
Esophagitis 5 (6) 3 (4) 1 (1) 11
Gastric complaints 7 (9) 2 (2) 0 (0) 11
Myalgia 8 (10) 1 (1) 0 (0) 11
Periorbital oedema 9 (11) 0 (0) 0 (0) 11
Dizziness 7 (9) 1 (1) 0 (0) 10
Epistaxis 8 (10) 0 (0) 0 (0) 10
Oedema 3 (4) 2 (2) 1 (1) 7
Pain mouth 2 (2) 1 (1) 1 (1) 5
Muscle weakness 0 (0) 2 (2) 1 (1) 4
Cognitive disorder 0 (0) 2 (2) 1 (1) 4
Hyperthyroidism 0 (0) 0 (0) 1 (1) 1
Transient ischaemic attack 0 (0) 0 (0) 1 (1) 1
aAdverse events grade 1 and 2 occurring in at least 10% of patients and all grade 3
events.
Table 4 Haematological adverse events
Haematological
adverse event
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%) All %
Thrombocytopenia 27 (33) 7(9) 6 (7) 49
Leucocytopenia 17 (21) 16 (20) 4 (5) 45
Neutropenia 7 (9) 13 (16) 6 (7) 32
Lymphopenia 7 (9) 7 (9) 7 (9) 26
Anaemia 10 (12) 9 (11) 1 (1) 24
Table 5 Severe toxicity causing change of sunitinib dosing
Reasons for dose reduction n (¼ 37)
Non-haematological
Stomatitis grade 3 6
Fatigue grade 3 5
Hand-foot syndrome grade 2–3 5
Combination of several grade 1–2 toxicities 5
Diarrhoea grade 3 2
Cognitive disorder grade 2–3 2
Esophagitis grade 3 1
Headache grade 3 1
Hypertension grade 3 1
Pain mouth grade 3 1
Transient ischaemic attack grade 3 1
Haematological
Neutropenia grade 3 3
Thrombocytopenia grade 3 3
Leucocytopenia grade 3 1
Reasons for permanent discontinuation at once n (¼ 3)
Cognitive disorder grade 2 1
Hypertension grade 3 1
Stomatitis grade 2 1
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Figure 2 Probability of severe toxicity from sunitinib (50mg per day 4 weeks on and 2 weeks off) in patients with advanced RCC based on the following
model: Probability of severe toxicity in male patients¼ exp (3.986þ 0.059*age)/(exp (3.986þ 0.059*age)þ 1) Probability of severe toxicity in female
patients¼ exp (2.750þ 0.059*age)/(exp (2.750þ 0.059*age)þ 1) Grey lines represent confidence intervals.
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et al, 2007; Srinivas et al, 2007). In addition, preliminary results
suggest a comparable PFS and OS for the two dosing schedules
(Faivre et al, 2007), although the objective response rate appears to
be lower. In mRCC, the 4 weeks on and 2 weeks off schedule is the
most preferred as a direct relation between the exposure to
sunitinib (area under the plasma concentration-time curve), which
is the highest during the 4 weeks on 50mg per day, and a higher
probability of PR, longer time-to-tumour progression, longer OS
and greater decrease in tumour volume have been observed (Houk
et al, 2007).
In conclusion, sunitinib demonstrates clinical benefit in
unselected mRCC patients, including patients with non-clear cell
histology, brain metastases and an ECOG performance status 41.
The need for dose reduction owing to adverse events in this
unselected mRCC patient population is rather high. Gender, age
and BSA are highly predictive of severe toxicity. Attempts to
optimise the dosing schedule of sunitinib in unselected mRCC
patients are warranted.
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Reversible cognitive disorders
after sunitinib for advanced renal
cell cancer in patients with
preexisting arteriosclerotic
leukoencephalopathy
In 2006, the Food and Drug Administration has approved
sunitinib (sunitinib malate; SU011248; Sutent) for the
treatment of advanced renal cell cancer and imatinib-resistant
gastrointestinal stromal tumors (GIST). Sunitinib is a novel
oral tyrosine kinase inhibitor that targets multiple receptors,
e.g. the vascular endothelial growth factor receptors
(VEGFR-1 and VEGFR-2), platelet-derived growth factor
receptors a and b (PDGFRs) and c-Kit and Flt-3 [1, 2].
Blocking VEGF and PDGF receptors will inhibit tumor
angiogenesis.
In the past years, the standard treatment of metastatic
renal cell cancer (mRCC) has been on the basis of cytokines,
such as interferon-a (IFN-a), but only <20% of patients have
a response. A summarized analysis of two phase II studies
on second-line sunitinib in mRCC has revealed a partial
response in 42% of patients and stable disease for >3 months
in 24% of patients [3, 4].
A recently completed, large randomized phase III trial has
shown a signiﬁcant increase of the median progression-free
survival time in patients treated with sunitinib when compared
with that in patients on IFN-a (11 versus 5 months) [5].
In advanced GIST after failure on imatinib, sunitinib has
also demonstrated signiﬁcant clinical beneﬁt with
a progression-free survival time of 27 weeks as compared
with 6 weeks in patients on placebo [6].
Sunitinib is tolerated reasonably well. In general, side-effects
graded according to National Cancer Institute–Common
Toxicity Criteria do not exceed grade 2 and are reversible upon
dose reduction or discontinuation of the drug. The most
important side-effects are fatigue, diarrhea, nausea, stomatitis,
hypertension, hand–foot syndrome, leucocytopenia and
thrombocytopenia [3–6]. In the previous trials, patients
included had to fulﬁll prespeciﬁed criteria, but currently the
drug can be prescribed widely to patients in the general
oncology practice.
Here, we describe three elderly patients with mRCC who
developed cognitive and behavioral changes during
sunitinib treatment. In all three patients, brain metastases
were excluded. The neurological symptoms disappeared after
discontinuation of sunitinib.
An 84-year-old female patient was known since 2002 with
a local recurrence and liver metastases of renal cell cancer
after a nephrectomy in 1997. For aggravating trigeminal
neuralgia, she received gabapentin 300 mg three times per
day. For one episode of atrial ﬁbrillation in 2006, she
received metoprolol. Additional medication consisted of
risedronate for osteoporosis, diclofenac/misoprostol for
arthrosis and pantoprazole to prevent gastritis. In 2004, she
was on treatment of mRCC with IFN-a for 6 months
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without clinical beneﬁt. Because of progressive disease in
2006, the patient started sunitinib (50 mg daily oral dosing
for 4 weeks, followed by a 2-week rest period in a cycle of 6
weeks). On a regular visit on day 12, her blood pressure
had raised as compared with the baseline value (from 128/55
to 142/72 mmHg as measured by ambulatory 24-h blood
pressure monitoring). On day 14, the patient visited the
outpatient clinic because of periods of confusion and
disorientation. She also had word-ﬁnding difﬁculties and
a walking disorder. Furthermore, the pain of the trigeminal
neuralgia had increased. At that time, sunitinib was
temporarily interrupted. The next day the patient was
admitted to the hospital because of increased confusion. The
neurologist diagnosed cognitive disorders consisting of
disorientation for time, expressive aphasia, perseveration and
a gait disorder. A computed tomography (CT) scan of the
brain demonstrated preexisting leukoencephalopathy
consistent with subcortical arteriosclerotic encephalopathy
(SAE), but excluded brain metastases (Figure 1A). Of
interest, a magnetic resonance imaging (MRI) scan carried
out in 2004 for trigeminal neuralgia had already
demonstrated SAE of sufﬁcient severity to fulﬁll criteria for
vascular dementia according to the radiological criteria of
the National Institute of Neurological Disorders and Stroke
and Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (NINDS-AIREN)
(Figure 1B) [7]. Vascular dementia, however, had never been
a clinical diagnosis in this patient. Three days after
discontinuation of sunitinib, she completely recovered.
Recovery from excessive pain of the trigeminal neuralgia did
not occur until stereotactic radiotherapy. Sunitinib was not
restarted. Thus far, 7 months later, the neurological
symptoms did not recur.
A 74-year-old male patient was diagnosed in 2006 with
locoregional metastases, lung metastases and bone metastases
of renal cell cancer after a nephrectomy in 2000. The patient
was also known with coronary artery disease with pectoral
angina for which he received isosorbide mononitrate, calcium
carbasalate and nitroglycerine. Furthermore, he received
metoprolol for hypertension, pravastatin for
hypercholesterolemia, esomeprazole for heartburn and
salmeterol with ﬂuticasone for emphysema. He likely had
beginning dementia because of episodes of amnesia and
hallucinations, but brain imaging had never been carried out.
For progressive mRCC, the patient started in 2006 with
sunitinib (50 mg daily 4 weeks on, 2 weeks off). On
a regular visit on day 13, the blood pressure had raised as
compared with the baseline value (from 110/60 to 122/71
mmHg as measured by ambulatory 24-h blood pressure
monitoring). On day 18, the patient was admitted to the
hospital because of a change in behavior suspected for brain
metastases. Neurological examination showed a mask face,
severe apathy, moderate bradyphrenia, moderate hypokinesia
and moderate rigidity with cog wheeling. Retrospectively, the
patient’s family had noticed these changes since the start of
sunitinib treatment. CT and MRI scans excluded brain
metastases, but demonstrated SAE with ischemic defects
fulﬁlling the radiological criteria of NINDS-AIREN (Figure 2)
[7]. Sunitinib was discontinued and 3 days thereafter the
neurological symptoms disappeared. After a rest period of 2
weeks, sunitinib was restarted at a dose of 37.5 mg. Nine
days later the patient was admitted to the hospital again
because of recurrent bradyphrenia, hypokinesia and rigidity.
At this second admission, the symptoms were less severe and
the blood pressure had not changed. It was decided to
permanently discontinue sunitinib, after which the patient
recovered promptly within 4 days. Seven months later the
neurological symptoms have not recurred.
Since 2004, an 82-year-old male patient was known with
lung metastases of renal cell cancer. In 1992, the patient had
a durable complete remission of the lung metastases after
nephrectomy and one dose of interleukin-2. In 2002, he
received an endoprosthesis for an abdominal aortic
Figure 1. (A) Computed tomography scan of patient 1 at the time of
symptoms, demonstrating white matter hypodensity consistent with
subcortical arteriosclerotic leukoencephalopathy due to small vessel disease
(arrow). (B) Magnetic resonance imaging (MRI) scan of the same patient
in 2004 showing preexisting small vessel disease seen as white matter
hyperintensity on MRI (arrow).
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aneurysm. The patient did not have a history of cognitive
problems. His medication consisted of diclofenac and
paracetamol/codeine for pain in the chest and right hip,
lactulose for constipation, esomeprazole for heartburn and
temazepam to treat insomnia. In 2006, the patient started
with sunitinib (50 mg daily 4 weeks on, 2 weeks off) for
progressive mRCC. CT scan evaluation after two cycles
demonstrated stable disease. At the end of the fourth cycle,
the patient visited the outpatient clinic because he experienced
visual hallucinations and word-ﬁnding difﬁculties. Other
neurological symptoms were absent. The blood pressure had
raised as compared with the baseline value (110/59 versus
160/75 mmHg). A CT scan excluded brain metastases, but
visualized age-related SAE (Figure 3). The severity was not
sufﬁcient to fulﬁll the NINDS-AIREN criteria [7]. During
the rest period, the cognitive symptoms recovered promptly.
Because the neurological symptoms were possibly related
to sunitinib, the ﬁfth cycle was started at a reduced dose
of 37.5 mg. The complaints did not recur during the
following cycles.
We describe three elderly patients with mRCC and
preexisting cerebral vascular changes, who developed cognitive
disorders on treatment with sunitinib. Since all patients
recovered within 1 week, which is in line with the elimination
half-life of sunitinib of 41–86 h [8], a causal relationship with
the drug seems evident. Rechallenge with a reduced dose was
successful in the third patient. The recurrent symptoms upon
dose reduction in the second patient are also indicative for
a causal relation.
In our patients, we did not detect brain metastases, and
cerebrovascular accident or delirium caused by a metabolic
disorder or co-medication could be excluded.
Since sunitinib is metabolized in the liver by cytochrome
P450 isoenzyme 3A (CYP3A), attention should be paid to
a drug interaction caused by co-medication. Inhibitors (e.g.
clarithromycin or verapamil) and inducers (e.g. fenobarbital
or fenytoı¨ne) of CYP3A can affect the plasma concentration
of sunitinib and should be avoided. Our patients did not
use co-medication that requires CYP3A for metabolism.
Recovery from neurological symptoms also occurred in
the patient on continuous gabapentin for trigeminal
neuralgia.
Cognitive disorders during sunitinib treatment have not
been described before. There is a case report, however, on
a transient ischemic attack upon bevacizumab treatment [9].
Further, reversible neurological symptoms during treatment
with bevacizumab and sorafenib (BAY 43-9006) have been
reported [10–13]. In these cases, a reversible posterior
leukoencephalopathy syndrome (RPLS) was the underlying
Figure 3. Computed tomography scan of patient 3 showing age-related
subcortical arteriosclerotic leukoencephalopathy due to small vessel disease
seen as white matter hypodensity (arrow).
Figure 2. (A) Computed tomography scan of patient 2 with white
matter hypodensity consistent with subcortical arteriosclerotic
leukoencephalopathy due to small vessel disease (arrow). (B) Magnetic
resonance imaging (MRI) scan of the same patient demonstrating small
vessel disease seen as white matter hyperintensity on MRI (arrow).
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cause which was accompanied by an elevated blood pressure.
According to the product information, RPLS has also been
described during treatment with sunitinib (<1% of cases). In
our patients, however, there was absolutely no suspicion of
a transient ischemic attack or evidence of posterior
leukoencephalopathy on CT and MRI scans, while their
blood pressure was only mildly increased.
Sunitinib and other inhibitors of VEGF signaling, such as
soraﬁnib and bevacizumab, can induce hypertension to
a variable degree [3, 6, 14, 15]. VEGFR-2 plays a role in
the regulation of the vascular tone, since inhibition of the
VEGFR-2 signaling route may cause vasoconstriction [16].
The effect of VEGF(R) inhibitors on the cerebral vasculature is
unknown. Sunitinib and its metabolite are known to penetrate
the brain up to 30%–40% of plasma concentrations in animal
studies [17]. Since the neurological symptoms in our patients
were reversible, sunitinib might reduce the cerebral blood ﬂow
due to vasoconstrictive effects.
Vascular dementia is known to be associated with a reduced
cerebral blood ﬂow, especially in the frontal lobes [18]. It is
conceivable that sunitinib decreases the cerebral blood ﬂow by
vasoconstriction which might become symptomatic in elderly
patients with preexisting cerebral vascular disease, such as
microangiopathy. Ideally, future studies should investigate the
cerebral blood ﬂow before and during sunitinib treatment.
Positron emission tomography utilizing 15O-labeled H2
15O and
C15O is a valuable imaging modality to quantify regional blood
ﬂow and volume [19].
These three case reports strongly indicate a relationship
between cognitive disorders and sunitinib. All three patients
appeared to have preexisting arteriosclerotic
leukoencephalopathy which most likely has contributed to the
development of these side-effects. Treating physicians should
be aware of the occurrence of cognitive disorders in elderly
patients using this new antitumor agent. Fortunately, the
neurological symptoms seem to be reversible upon
discontinuation or a dose reduction of sunitinib. Additional
investigations of the effects of VEGF(R) inhibitors on the
cerebral vasculature are warranted.
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A B S T R A C T
Purpose
To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib
that predispose for development of toxicities: thrombocytopenia, leukopenia, mucosal inﬂamma-
tion, hand-foot syndrome, and any toxicity according to National Cancer Institute Common Toxicity
Criteria higher than grade 2.
Patients and Methods
A multicenter pharmacogenetic association study was performed in 219 patients treated with
single-agent sunitinib. A total of 31 single nucleotide polymorphisms in 12 candidate genes,
together with several nongenetic variants, were analyzed for a possible association with toxicity.
In addition, genetic haplotypes were developed and related to toxicity.
Results
The risk for leukopenia was increased when the G allele in CYP1A1 2455A/G (odds ratio [OR], 6.24;
P  .029) or the T allele in FLT3 738T/C (OR, 2.8; P  .008) were present or CAG in the NR1I3
(5719C/T, 7738A/C, 7837T/G) haplotype (OR, 1.74; P  .041) was absent. Any toxicity higher than
grade 2 prevalence was increased when the T allele of vascular endothelial growth factor receptor
2 1191C/T (OR, 2.39; P  .046) or a copy of TT in the ABCG2 (15622C/T, 1143C/T) haplotype
(OR, 2.63; P  .016) were present. The risk for mucosal inﬂammation was increased in the
presence of the G allele in CYP1A1 2455A/G (OR, 4.03; P  .021) and the prevalence of hand-foot
syndrome was increased when a copy of TTT in the ABCB1 (3435C/T, 1236C/T, 2677G/T)
haplotype (OR, 2.56; P  .035) was present.
Conclusion
This exploratory study suggests that polymorphisms in speciﬁc genes encoding for metabolizing
enzymes, efﬂux transporters, and drug targets are associated with sunitinib-related toxicities. A
better understanding of genetic and nongenetic determinants of sunitinib toxicity should help to
optimize drug treatment in individual patients.
J Clin Oncol 27:4406-4412. © 2009 by American Society of Clinical Oncology
INTRODUCTION
The oral, multitargeted tyrosine kinase inhibitor
sunitinib (sunitinib malate; Sutent; Pﬁzer Pharma-
ceuticals Group, New York, NY) is known to in-
hibit vascular endothelial growth factor receptors
(VEGFRs) 1, 2, and 3, platelet-derived growth
factor receptor (PDGFR)  and , KIT, Fms-like
tyrosine kinase 3 receptor (FLT3), and the receptor
encoded by the ret proto-oncogene (RET).1-4
Sunitinib is approved for ﬁrst-line treatment of
metastatic renal cell carcinoma (mRCC) and
imatinib-resistant metastatic gastrointestinal stro-
mal tumors (GIST).4-6 Targeted cancer therapies are
generally considered to be less toxic than conven-
tional chemotherapy since they speciﬁcally inhibit
tyrosine kinase receptors that are frequently overex-
pressed or mutated in various types of tumor cells.7
Tyrosine kinases, however, are also present in nor-
mal tissues and toxic effects are therefore difﬁcult to
eliminate. The 4weeks on 2weeks off dosing sched-
uleof sunitinibwas selected for theﬁrstphase I study
on request of the health authorities to allow patients
to recover frompotential bonemarrow and adrenal
toxicity observed in animal models, indicating that
toxicity was regarded as a serious problem.3,8 Al-
though the proportion of patients with grade 3 to 4
adverse events was relatively low in the recent phase
III studies, a dose interruption appeared to be nec-
essary in 38%of patients withmRCC and in 28%of
patients with GIST whereas a dose reduction was
required in 32% and 11%, respectively. Similar
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percentages were reported in other studies.2,4,9 Disease- and
sunitinib-related toxicities can be distinguished based on results of
a phase III trial in which the toxicity proﬁle of sunitinib-treated
patients has been compared with events in the placebo-treated
patients.2 Adverse events that preferentially occurred in the group
treated with sunitinib were diarrhea, hand-foot syndrome, mu-
cositis, vomiting, hypertension, leukopenia, neutropenia, and
thrombocytopenia.2-4,9-13 Less common, but speciﬁc toxicities re-
lated to sunitinib were cardiotoxicity and hypothyroidism.5,14,15
Sunitinib is used as palliative therapywithno standard therapeu-
tic options available after failure of the therapy. It is therefore relevant
for patients to adhere to sunitinib therapy while their quality of life is
not unnecessarily reduced by drug toxicity. To date, it is not com-
pletely clear which patient characteristics render an individual patient
at risk for sunitinib-induced toxicity. The aim of this study is to
identify genetic markers in sunitinib disposition, metabolism, and
mechanism of action that predispose for development of common
sunitinib related toxicities: thrombocytopenia, leukopenia, mucosal
inﬂammation, hand-foot syndrome, and any higher than grade 2
National Cancer Institute Common Toxicity Criteria for Adverse
Events (CTCAE) toxicity.
PATIENTS AND METHODS
A total of 219 patients from ﬁve Dutch medical centers were analyzed in this
study. The study was approved by the medical ethics review board. Patients
were treated at the Erasmus University Medical Center (n 74), the Nether-
lands Cancer Institute (n 51), Leiden University Medical Center (n 37),
Vrije Universiteit University Medical Center (n  36), and the University
Medical Center Groningen (n 21). The collection of DNA and patient data
was performed between June 2004 and May 2008. A total number of 159
mRCC, 50 GIST, and 10 patients with other tumors were included in this
study.Of these, 77patientswithmRCCand26patientswithGISTwere treated
according to an expanded access program of sunitinib. Eligible patients were
those treated with single-agent sunitinib for at least one treatment cycle (4
consecutive weeks of 50 mg per day followed by a 2-week period of rest).
Study Design
Sunitinib toxicity was evaluated during the ﬁrst treatment cycle by CT-
CAE version 3.0.16 Toxicity scores were assessed by analysis of adverse events,
physical examination, and laboratory assessments carried out at baseline (be-
fore starting sunitinib), after 4 weeks of sunitinib therapy, and after 6 weeks
(just before starting the second cycle). Demographic and clinical data of
patientswere reportedoncase record formsdesigned fordata collection in this
study. Patient characteristics considered relevant for experiencing toxicity
were: age, sex, ethnicity, body-surface area (BSA), EasternCooperativeOncol-
ogy Group (ECOG) performance status, tumor type, renal, liver, and bone
marrow function (serum creatinine, total bilirubin, albumin, ALT, AST, he-
moglobin, leukocytes, and thrombocytes). Residual blood or serum samples
taken for routine patient care were stored at 20°C at the local hospital
laboratory. Of each patient one whole blood or serum sample was collected
from the participating centers. All samples were anonymized by a third party,
according to the instructions stated in the Codes for Proper Use and Proper
Conduct in the Self-Regulatory Codes of Conduct (www.federa.org).
Deﬁnition of Toxicity
All adverse events were graded by independent physicians of the partic-
ipating medical centers. Four- and 6-week reported toxicities were compared
to baseline conditions. The primary outcome measures of this study were
thrombocytopenia, leukopenia,mucosal inﬂammation, hand-foot syndrome,
and any toxicity higher than grade 2. Toxicities were selected based on objec-
tivity, clinical relevance, and manageability of the symptoms. Thrombocyto-
penia and leukopenia were scored from blood cell counts and are thus
objective end points. In case of any toxicity higher than grade 2, a dose
interruption and, dependingon the kindof toxicity, a resumed treatmentwith
25% dose reduction is advised in the drug label of sunitinib. Moreover, mu-
cosal inﬂammation and hand-foot syndrome are frequently reported and
poorlymanageable and therefore dose reduction is relatively soon considered.
In addition, dose reduction of at least 25% according to the drug label (data
complete for 187 patients), which is applied because of safety or tolerability
issues, after cycles 1 to 3 was related to the toxicity outcomes.
Genetic Polymorphisms
Nineteenpolymorphisms in sevengenes involved in thepharmacokinet-
ics and 12 polymorphisms in ﬁve genes involved in the pharmacodynamics of
sunitinibwere selected. Selectioncriteria for thepolymorphismswereanallelic
frequencyhigher than0.2 inwhites andanassumedclinical relevancebasedon
previously reported associations or the assumption that nonsynonymous
amino acid change leads to changed protein functionality. The selected poly-
morphisms are listed in Table 1.Methods for genotyping assay validation and
haplotype estimation are included in the Appendix (online only).
Statistical Design and Data Analysis
For theanalysis of toxicity,weuseddichotomousendpoints expressedas
increased toxicity (yesorno)or any toxicityhigher thangrade2 (yesorno).All
demographic andclinical variableswere testedunivariately against the selected
primary outcomes using t test, the Mann-Whitney U test or the 2 test,
depending on the tested variables. A 2 test was also used to detect linkage
Table 1. Polymorphisms Genotyped in the Pharmacokinetic and
Pharmacodynamic Pathway of Sunitinib
Gene Polymorphism rs Number
Pharmacokinetic pathway
NR1I2 25385C/T rs3814055
24113G/A rs2276706
7635A/G rs6785049
8055C/T rs2276707
10620C/T rs1054190
10799G/A rs1054191
NR1I3 5719C/T rs2307424
7738A/C rs2307418
7837T/G rs4073054
CYP3A5 6986A/G rs776746
CYP1A1 2455A/G rs1048943
CYP1A2 163A/C rs762551
ABCG2 421C/A rs2231142
34G/A rs2231137
15622C/T 
1143C/T rs2622604
ABCB1 3435C/T rs1045642
1236C/T rs1128503
2677G/T rs2032582
Pharmacodynamic pathway
PDGFR 1580T/C rs35597368
1171C/G rs1800810
735G/A rs1800813
573G/T rs1800812
VEGFR2 ( KDR) 604T/C rs2071559
92G/A rs1531289
54T/C rs7692791
1191C/T rs2305948
1718T/A rs1870377
VEGFR3 ( FLT4) 1501A/G rs307826
RET 2251G/A rs1799939
FLT3 738T/C rs1933437
No rs number assigned yet.
Pharmacogenetics of Sunitinib Toxicity
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disequilibrium (LD). The polymorphismswere initially testedwith 2 df . If the
initial 2df tests resulted inP  .1, the polymorphismswere ﬁtted and themost
appropriate model (multiplicative, dominant, or recessive) was selected. The
number of copies of each haplotypewas used as parameter in the analysis. The
polymorphisms and haplotypes were tested univariately against the selected
primary outcomes using a 2 test. Candidate variables with P  .1 were
selected for themultiple logistic regression analysis with toxicity as depending
variable. All multivariate logistic regression analyses were corrected for age,
sex, and ECOG performance status. Additional patient characteristics were
introduced in the multivariate analyses based on univariate tested results if
P  .1. Missing data were kept as missing data except for BSA and ECOG
performance status.MissingBSAvalues (n15)were replaced for themedian
BSA (1.93 m2) and missing ECOG performance status (n 7) were replaced
for the median ECOG performance status (1). To test this action, the multi-
variate analyses were performed with and without the replacement of the
patientswithmissingBSAandECOGperformance status. Similar resultswere
generated, indicating that the replacement was legitimate. All statistical analy-
ses were performed using SPSS version 16.0 software (SPSS, Chicago, IL).
With the sample size of our study, an increase in toxicity of 17% could be
measured between two groups with a power of 80% and a CI of 99%. All
results from the multivariate analyses with P less than .05 were considered
signiﬁcant. Since this was an exploratory study, no correction for multiple
testing was done.
RESULTS
Patients
Nineteen of 219 patients had to be excluded from analysis for
several reasons including progressive disease (PD) during the ﬁrst
treatment cycle resulting in early death (n  4), discontinuation of
sunitinib in the ﬁrst treatment cycle due to adverse events (hyperten-
sion grade 3, headache grade 3, and rash grade 3, respectively; n 3),
and no acceptable genotyping success rate due to poor DNA quality
(n 12). For toxicity analyses, a total of 200 patients were assess-
able (Table 2). For the end point any toxicity higher than grade 2,
the three patients who stopped therapy due to adverse events were
included (n 203).
Toxicities
The hematologic toxicities scored in this analysis were thrombo-
cytopenia (40%any grade) and leukopenia (59%, any grade).Nonhe-
matologic toxicities were primarily any toxicity higher than 2 (22%),
mucosal inﬂammation (44%), and hand-foot syndrome (19%; Table
3). Dose reduction after cycles 1 to 3 was related to mucosal inﬂam-
mation (P .002) and any toxicity higher than grade 2 (P .001).
Pharmacogenetic Risk Factors for
Sunitinib-Induced Toxicity
The results of the multivariate logistic regression analysis for the
selected end points thrombocytopenia, leukopenia, mucosal inﬂam-
mation, hand-foot syndrome, and any toxicity higher than grade 2 are
summarized in Table 4. For thrombocytopenia, an increase in age
(P .030) and ECOG performance status (P .050) were indepen-
dently signiﬁcant in the multivariate logistic model. The factors asso-
ciated with development of leukopenia were: CYP1A1 2455A/G; the
presence of the G allele in an additive model was related to a 6.2-fold
increase in the risk for leukopenia during the ﬁrst treatment cycle
(P .029); the presence of the FLT3 738C allele (dominant model)
was related to a 2.8-fold reduction in the risk for leukopenia
(P .008); the absence of the NR1I3 CAG haplotype was related to a
Table 2. Patient Demographics and Clinical Characteristics (N  203)
Characteristic No. %
Median age, years 60
Range 20-84
Sex
Male 129 63.5
Female 74 36.5
Median body surface area, m2 1.93
Range 1.47-2.51
ECOG performance status
0 81 39.9
1 90 44.3
2 17 8.4
3 8 3.9
Missing 7 3.4
Ethnicity
White 190 93.6
Black 6 3.0
Asian 2 1.0
Latin American 2 1.0
Middle Eastern 3 1.5
Tumor type
Renal cell carcinoma 152 74.9
Gastrointestinal stromal tumor 46 22.7
Other 5 2.5
Previous medical treatments
Yes 116 57.1
No 87 42.9
First treatment regimen (n  116)
Interferon alfa 46 39.7
Imatinib 46 39.7
Sorafenib 5 4.3
Other 19 16.4
Dose reduction after sunitinib cycles 1 to 3
Yes, renal cell carcinoma 58 28.6
GIST 14 6.9
Other tumor 1 0.5
No, renal cell carcinoma 94 46.3
GIST 32 15.8
Other tumor 4 2.0
Baseline chemistry and hematology
Median creatinine, M 96.0
Range 40-176
Median total bilirubin, M 7
Range 3-32
Median albumin, g/L 40
Range 23-52
Median ALT, units/L 18
Range 3-210
Median AST, units/L 24
Range 9-190
Median hemoglobin, mM 7.6
Range 5.2-10.4
Median leukocytes, 109/L 7.5
Range 3.6-56.5
Median thrombocytes, 109/L 284.0
Range 92-864
Abbreviations: ECOG, Eastern Cooperative Oncology Group; GIST, gastroin-
testinal stromal tumor; CR, complete response; PR, partial response; SD
stable disease; PD, progressive disease.
First treatment regimen applies only to those 116 patients who underwent
previous medical treatments.
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1.7-fold increased risk for leukopenia (P  .041); and one grade
increase in ECOG performance status, implicating a worse clinical
condition, was related to a 1.8-fold reduction in the risk of leukopenia
(P .016).Thepresenceof theVEGFR21191Tallele (additivemodel)
was related to an increased risk of 2.4-fold for the development of any
toxicity higher than grade 2 (P .046), while the risk for this toxicity
was 2.6-fold higher when 1 or 2 copies of TT in theABCG2 haplotype
were present (P  .016). For mucosal inﬂammation, only CYP1A1
2455A/G was independently related; the G allele (additive model)
resulted ina4.0-foldhigher risk formucosal inﬂammation(P .021).
The occurrence of hand-foot syndrome was related to the ABCB1
haplotype; the absence of copies of the TTT haplotype was protective
and was related to a 2.6-fold lower risk to experience hand-foot
syndrome as compared to patients with copies of the TTT haplo-
type (P .035). The explained variance (R2) of the patient character-
istics, without taking the polymorphisms into account, in the
multivariate analyseswasbetween the 2%to10%of the total variance.
After adding the selected polymorphisms the explained variance in-
creased to 10% to 23% of the total variance.
DISCUSSION
To the best of our knowledge, this is the ﬁrst study exploring the
relationship between drug-induced toxicity and genetic polymor-
phisms in genes encoding for enzymes, efﬂux transporters, and
targets involved in the pharmacokinetics and pharmacodynamics
of sunitinib.
Sunitinib is metabolized by cytochrome P450 3A4 (CYP3A4)
and CYP3A5. In addition, afﬁnity of sunitinib for the ATP-binding
cassette transporters ABCG2 and ABCB1 has also recently been re-
ported.17 The transcriptionofCYP3A4 is regulatedbymembers of the
NR1I nuclear receptor subfamily.18 Metabolism through CYP1A1
and CYP1A2 is hypothesized since these enzymes appear to be in-
volved in the metabolism of multiple tyrosine kinase inhibitors (eg,
imatinib, erlotinib).19,20 Both genes encoding the sunitinib targets, as
well as genes encoding the enzymes (except forCYP3A4, inwhich not
functional polymorphismshavebeen identiﬁed) andefﬂux transport-
ers involved in sunitinib’s disposition and metabolism are highly
polymorphic andmaybe related to thedifferential toxicity response in
patients treated with sunitinib.
Although the nature and incidence of adverse events related to
sunitinib are currently well recognized and described, data regarding
determinants of toxicity are still scarce.2,4,5,14,21,22 So far, only one
study has described factors (low BSA, high age, female sex) that are
associated with the development of severe toxicities, deﬁned as dose
reduction or permanent discontinuation of sunitinib therapy.9 That
study, however, was limited to patient characteristics and no genetic
determinants were investigated. In our study, these patient character-
istics, and another (performance status), were included as covariates
in the data analysis. We should emphasize, however, that the deﬁni-
tion of the end point severe toxicity is different in both studies as well
as the observed study period (whole sunitinib treatment period v ﬁrst
treatment cycle in our study).
To our knowledge, we report for the ﬁrst time herein that the
ABCB1 TTT haplotype was related to hand-foot syndrome. The TTT
haplotype as well as the T genotype in 3435C/T and the T polymor-
phism in 1236C/T separately have been associated with higher expo-
sures to drugs transported byABCB1due to a decreased expression of
the ABCB1 transporter.23-28 Also, for the other ABC transporter in-
vestigated, ABCG2, the TT haplotype was related to the development
of increased toxicity (eg, any toxicity grade 2). This haplotype has
been associated with increased erlotinib exposure, a tyrosine kinase
inhibitor that uses metabolic and predisposition pathways similar to
those of sunitinib.29 Thus, our results concerningABCB1 andABCG2
are in line with previously reported functional consequences of the
studied genetic variants andmight lead to an increased systemic expo-
sure to sunitinib resulting in dose-limiting toxicities. Certainly, to
conﬁrm our ﬁndings, further studies that relate pharmacogenetics to
pharmacokinetics and pharmacodynamics are required.
Thus far, the extrahepatic CYP1A1 enzyme has not been de-
scribed as being involved in the metabolism of sunitinib. For other
receptor tyrosine kinase inhibitors, such as erlotinib, imatinib, and
geﬁtinib afﬁnity for CYP1A1 has been demonstrated in in vitro stud-
ies.19,20 Therefore, we also included genetic variants ofCYP1A1 in this
study. The polymorphism studied in CYP1A1 resulting in an amino
acid change of isoleucine 462 valine was found to be related to the
occurrence of mucosal inﬂammation and leukopenia. This suggests
that CYP1A1 may also play a role in the metabolism of sunitinib
in vivo.
In addition, we investigated genetic polymorphisms in the
NR1I3 gene, encoding the constitutive androstane receptor. This
nuclear receptor plays an important role in the regulation of mul-
tiple drug detoxiﬁcation genes, such as CYP3A4. The functionality
of polymorphisms in NR1I3 is not yet fully elucidated, however we
found a relationship between the absence of the CAG haplotype in
Table 3. Distribution of Increased Toxicity Grades
Toxicity by Grade No. %
Thrombocytopenia (n  198)
No 118 59.0
Yes
1 58 29.0
2 14 7.0
3 7 3.5
4 1 0.5
Leukopenia (n  198)
No 81 40.5
Yes
1 91 45.5
2 22 11.0
3 4 2.0
Any toxicity  2 (n  203)
0, 1, 2 158 77.8
3, 4 45 22.2
Mucosal inﬂammation (n  199)
No 112 56.0
Yes
1 57 28.5
2 25 12.5
3 5 2.5
Hand-foot syndrome (n  199)
No 162 81.0
Yes
1 27 13.5
2 8 4.0
3 2 1.0
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Table 4. Factors Relevant for Sunitinib-Induced Toxicity, Deﬁned as Thrombocytopenia, Leukopenia, Any Toxicity  Grade 2,
Mucosal Inﬂammation, or Hand-Foot Syndrome
Factor
Data Corrected for Patient Characteristics Uncorrected Data
Genotype OR 95% CI P OR 95% CI P
Thrombocytopenia (n  177)
Age 1.04 1.00 to 1.07 .030
Sex 1.93 0.97 to 3.85 .063
ECOG 0.60 0.37 to 1.00 .050
NR1I2 24,113G/A GG versus 1 1
AG  AA 0.60 0.28 to 1.28 .187 0.51 0.25 to 1.05 .067
CYP1A2 163A/C AA versus 1 1
AC  CC 0.67 0.34 to 1.32 .251 0.65 0.34 to 1.23 .186
ABCG2 421C/A CC versus 1 1
CA  AA 2.09 0.88 to 4.96 .096 1.93 0.85 to 4.42 .118
ABCG2 haplotype  TT-TT  TT-other versus 1 1
Other-other 1.93 0.96 to 3.86 .065 1.77 0.91 to 3.46 .093
PDGFR haplotype 	 TGAT-TGAT  TGAT-other versus 1 1
Other-other 0.44 0.17 to 1.18 .103 0.36 0.14 to 0.92 .033
Leukopenia (n  188)
Age 1.01 0.98 to 1.04 .423
Sex 0.81 0.41 to 1.60 .536
ECOG 0.57 0.36 to 0.90 .016
VEGFR2 92G/A GG 3 GA 3 AA 0.74 0.44 to 1.23 .241 0.74 0.45 to 1.22 .235
VEGFR2 1718T/A TT 3 AT 3 AA 1.49 0.84 to 2.66 .172 1.47 0.83 to 2.60 .188
CYP1A1 2455A/G AA 3 AG 3 GG 6.24 1.20 to 32.42 .029 4.87 1.06 to 22.29 .042
FLT3 738T/C TT versus 1 1
CT  CC 0.36 0.17 to 0.77 .008 0.41 0.20 to 0.85 .016
NR1I3 haplotype  CAG-CAG 3 CAG-other 3 other-other 1.74 1.02 to 2.96 .041 1.81 1.07 to 3.04 .026
NR1I3 haplotype  TCT-TCT 3 TCT-other 3 other-other 0.54 0.27 to 1.06 .074 0.55 0.28 to 1.06 .075
Any toxicity  grade 2 (n  183)
Age 1.03 0.99 to 1.07 .140
Sex 1.71 0.69 to 4.26 .248
ECOG 1.31 0.79 to 2.19 .299
BSA 0.22 0.02 to 2.49 .220
VEGFR2 1191C/T CC 3 TC 3 TT 2.39 1.02 to 5.60 .046 2.31 1.07 to 4.99 .033
ABCG2 haplotype  TT-TT  TT-other versus 1 1
Other-other 0.38 0.17 to 0.83 .016 0.40 0.19 to 0.84 .016
Mucosal inﬂammation (n  193)
Age 1.00 0.97 to 1.03 .956
Sex 1.54 0.82 to 2.88 .177
ECOG 1.31 0.86 to 1.99 .212
NR1I2 24113G/A GG versus 1 1
AG  AA 0.58 0.30 to 1.13 .110 0.55 0.29 to 1.04 .064
CYP1A1 2455A/G AA 3 AG 3 GG 4.03 1.24 to 13.09 .021 4.15 1.29 to 13.36 .017
ABCG2 34G/A GG 3 AG 2.45 0.74 to 8.17 .144 2.41 0.75 to 7.76 .140
NR1I3 haplotype  TCT-TCT 3 TCT-other 3 other-other 0.78 0.42 to 1.44 .420 0.77 0.42 to 1.42 .404
Hand-foot syndrome (n  182)
Age 0.99 0.96 to 1.02 .563
Sex 1.22 0.56 to 2.68 .612
ECOG 0.76 0.43 to 1.33 .336
ABCB1 haplotype 	 TTT-TTT  TTT-other versus 1 1
Other-other 0.39 0.16 to 0.94 .035 0.39 0.16 to 0.92 .032
ABCB1 haplotype 	 CTT-CTT 3 CTT-other 3 other-other 0.38 0.11 to 1.32 .126 0.36 0.10 to 1.27 .114
NOTE. Multiplicative model is indicated with (3) between the genotypes. Dominant and recessive models are indicated with (versus) between the two groups of
genotypes. P value  .05 is regarded as signiﬁcant and indicated with bold font. Table 1 provides a description of polymorphisms and rs numbers.
Abbreviations: OR, odds ratio; ECOG, Eastern Cooperative Oncology Group; description haplotypes:   ABCG2 15622C/T and 1143C/T; 	  PDGFR 573G/T,
1171C/G, 735G/A and 1580T/C;   NR1I3 5719C/T, 7738A/C and 7837T/G; 	  ABCB1 3435C/T, 1236C/T and 2677G/T.
All toxicity outcomes in the corrected analysis are corrected for age, gender, and ECOG performance status. Additional correction with body surface area was done
for any toxicity  grade 2. Under the uncorrected data, only the genotypes are included in the multivariate analysis.
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this gene and an increased risk for leukopenia.30 Obviously, it
would be interesting to relate this polymorphism with sunitinib
exposure levels in future studies.
The functionality of VEGFR2 1191CT and TT genotypes was
found to be predictive for the development of coronary heart disease
due to a lower binding efﬁciency of VEGF to the polymorphic
VEGFR-2.31 In our study, these genotypes were related to the devel-
opment of any toxicity higher than 2, which predominantly included
fatigue, thrombocytopenia, and hypertension. The polymorphic re-
ceptor might therefore be involved in sunitinib-induced cardiac tox-
icity and the development of hypertension.
The importance of the FLT3 receptor has been described in
relation to the development of several subtypes of leukemia such as
acute myeloid leukemia, acute lymphocytic leukemia, and chronic
myeloid leukemia, in which FLT3 is frequently overexpressed and/or
mutated.32,33 However, the association between FLT3 738T/C poly-
morphismanda reduction in the riskof leukopeniahasnotpreviously
been described. Since sunitinib-induced leukopenia could be regu-
lated strongly by this polymorphic receptor the clinical relevance
should be further investigated.
In our study, a large number of candidate polymorphic loci were
evaluated and multiple analyses of each genetic polymorphism were
performed. This introduces the potential problem of multiple testing
which increases the risk to ﬁnd false-positive relations. However, our
studywasdesigned toexploreassociations that shouldbeconﬁrmed in
an independent group of patients. The presented odds ratios and CIs
facilitate comparisons of replicate studies with our data.
TheECOGperformance statuswasnot consistently related to the
occurrence of toxicities in our study. The quantiﬁed performance
status is multifactorial and is dependent on subjective interpretation
of the physician. Moreover, in our study patients with poor perfor-
mance status had relatively high baseline thrombocyte and leukocyte
counts resulting ina smallnumberof reported leukopeniaand throm-
bocytopenia in this group in the ﬁrst treatment cycle.
Toxicities in the ﬁrst treatment cycle of sunitinib were used as
outcome measure. The rationale was that signs of clinical deteriora-
tion from disease progression in later cycles could be misinterpreted
and would interfere with the drug-induced toxicity outcome. We
hypothesized that patients that suffer from relatively mild (grade 1 or
2) toxicities in the ﬁrst treatment cycle were at risk for developing
more severe toxicity during further treatment cycles because the 2
weeks of restwould not be sufﬁcient for patients to recover to baseline
conditions. This cumulative effect is underscored by measured blood
cell counts and the observed dose reduction after cycles 1 to 3. Indeed,
we found for leukocyte count, and to a lesser extent also for thrombo-
cyte count, that 91% and 73%, respectively, of the patients had not
returned to baseline values (deﬁned as 90% of baseline counts) at
cycle 2 day 1 (data not shown). In addition, we found that mucosal
inﬂammation and any toxicity higher than grade 2 were strongly
related to a dose reduction after cycles 1 to 3, indicating that these
toxicities are regarded as clinically relevant to the treating physicians.
Together, the genetic, clinical, anddemographic determinants in
this exploratory study explain between 10% and 23% of the total
variance in toxicity response. Although it indicates that the major
part of the variability is left unexplained, it also shows that phar-
macogeneticsmaymakeagreater contribution toexplainingvariabil-
ity in sunitinib toxicity as compared to the nongenetic determinants
inour study. Fromthis study,we cannot concludewhether the genetic
variants are prognostic or predictive markers, due to the absence of a
placebo-treated control group of patients. However in the future,
pharmacogeneticsmayhelp to select patientswhichneed apriori dose
reduction to prevent toxicities.
In conclusion, this study suggests a relationship between poly-
morphisms in the genes CYP1A1, ABCB1, ABCG2, NR1I3, VEGFR2,
andFLT3 and thedevelopmentof sunitinib toxicity.Thenext stepwill
be to validate our data with the aim to better understand the determi-
nants of sunitinib toxicity.
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CORRECTIONS
Author Corrections
The September 10, 2009, article by van Erp et al, entitled
“Pharmacogenetic Pathway Analysis for Determination of
Sunitinib-Induced Toxicity” (J Clin Oncol 27:4406-4412,
2009), contained an error.
In Table 4, under Hand-foot syndrome, the ABCB1 CCT
haplotype was given, whereas it should have been the TCG
haplotype, as follows:
“TCG-TCG3 TCG-other3 other-other”
The authors apologize to the readers for the mistake.
DOI: 10.1200/JCO.2010.30.2380
■ ■ ■
The November 10, 2009, article by Kornblith et al, entitled
“Quality of Life of Patients With Endometrial Cancer Undergoing
Laparoscopic International Federation of Gynecology andObstetrics
Staging Compared With Laparotomy: A Gynecologic Oncology
GroupStudy” (JClinOncol27:5337-5342,2009), containedanerror.
In theResults section, under “QoLof PatientsWith Endome-
trial Cancer Assigned to Laparoscopy Versus Laparotomy,” the
number of patients in the last sentence of the third paragraph was
given as 273, whereas it should have been 237, as follows:
“Of 237 patients reporting the time to return to work, the
median time to return to work was 42 days for the laparoscopy
group compared with 45 days in the laparotomy group, a small
but signiﬁcant difference (Wilcoxon rank sum test, P .04).”
The authors apologize to the readers for the mistake.
DOI: 10.1200/JCO.2010.30.2398
■ ■ ■
The March 20, 2010, article by Goldzweig et al, entitled
“Meeting Expectations of Patients With Cancer: Relationship
Between Patient Satisfaction, Depression, and Coping” (J Clin
Oncol 28:1560-1565, 2010), contained an error in the spelling
of the second author’s name. It was originally given as Amichai
Meirowitz and should have been Amichay Meirovitz. The au-
thors apologize to the readers for the mistake.
DOI: 10.1200/JCO.2010.30.2414
■ ■ ■
Journal Corrections
The October 1, 2007, article by Hsu et al, entitled “Phar-
macogenomic Strategies Provide a Rational Approach to the
Treatment of Cisplatin-Resistant PatientsWith AdvancedCan-
cer” (J Clin Oncol 25:4350-4357, 2007), contained errors.
In Figure 1B, the labels for resistant and sensitive cell lines
were inadvertently transposed.
InthelegendofFigure2A,thereferenceto“bottom,lung”aswell
as the correspondingP value (P .03) should have beenomitted.
Journal of Clinical Oncology apologizes to the authors and
readers for the mistakes.
DOI: 10.1200/JCO.2010.30.2323
■ ■ ■
The February 1, 2010, Diagnosis in Oncology article by
Zareifar et al, entitled “T-Cell Lymphoblastic Lymphoma of the
Sternum” (J Clin Oncol 28:e51-e53, 2010), contained an error
in the spelling of the third author’s name. It was originally given
as Mehran Karim and should have been Mehran Karimi. Jour-
nal of Clinical Oncology apologizes to the authors and readers
for the mistake.
DOI: 10.1200/JCO.2010.30.2364
■ ■ ■
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Choi response criteria for early prediction of clinical outcome in
patients with metastatic renal cell cancer treated with sunitinib
AAM van der Veldt1, MR Meijerink2, AJM van den Eertwegh1, JBAG Haanen3 and E Boven*,1
1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; 2Department of Radiology, VU University Medical
Center, Amsterdam, The Netherlands; 3Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital,
Amsterdam, The Netherlands
BACKGROUND: Because sunitinib can induce extensive necrosis in metastatic renal cell cancer (mRCC), we examined whether criteria
defined by Choi might be valuable to predict early sunitinib efficacy.
METHODS: Computed tomography was used for measurement of tumour lesions in mm and lesion attenuation in Hounsfield units
(HUs). According to Choi criteria partial response (PR) was defined as X10% decrease in size or X15% decrease in attenuation.
RESULTS: A total of 55 mRCC patients treated with sunitinib were included. At first evaluation, according to the Response Evaluation
Criteria in Solid Tumours (RECIST) 7 patients had PR, 38 stable disease (SD), and 10 progressive disease (PD), whereas according to
Choi criteria 36 patients had PR, 6 SD and 13 PD. Median tumour attenuation decreased from 66 to 47 HUs (Pp0.001). In patients
with PR, Choi criteria had a significantly better predictive value for progression-free survival and overall survival (both Pso0.001) than
RECIST (P¼ 0.685 and 0.191 respectively). The predictive value for RECIST increased (P¼ 0.001 and o0.001 respectively), when
best response during treatment was taken into account.
CONCLUSION: Choi criteria could be helpful to define early mRCC patients who benefit from sunitinib, but the use of these criteria will
not change the management of these patients.
British Journal of Cancer (2010) 102, 803–809. doi:10.1038/sj.bjc.6605567 www.bjcancer.com
Published online 9 February 2010
& 2010 Cancer Research UK
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The Response Evaluation Criteria in Solid Tumours (RECIST) is
the most widely used measurement system in clinical trials and is
based on the sum of the longest diameters of the appointed target
lesions in the transversal plane (Therasse et al, 2000). Clinically
meaningful responses, however, may be underestimated by
RECIST, as new targeted therapies can cause tumour necrosis
without a marked decrease in tumour size (Faivre et al, 2007). The
receptor tyrosine kinase inhibitors (TKIs) imatinib, sunitinib,
sorafenib, and axitinib are known to cause early and extensive
necrosis (Vanel et al, 2005; Faivre et al, 2007; Flaherty, 2007; Rixe
et al, 2007; Van der Veldt et al, 2008b). Treatment-induced
necrosis, however, is not a part of RECIST and may even mimic
progressive disease (PD).
In hepatocellular carcinoma (HCC), RECIST may be inappro-
priate as primary end point to evaluate sunitinib treatment (Faivre
et al, 2007). Therefore, Faivre et al (2007) have used volumetric
measurements for sunitinib-induced necrosis in HCC expressed
as minor (o50%) and major (¼ 50%) post-treatment tumour
necrosis. As RECIST also underestimates imatinib-induced
responses in gastrointestinal stromal cell tumours (GISTs), Choi
et al (2007) have developed new response criteria to evaluate
imatinib treatment in patients with GIST. These criteria include
changes in tumour attenuation on computed tomography (CT),
which reflect tumour density (Benjamin et al, 2007; Choi et al,
2007). Choi et al (2007) have defined a partial response (PR) as a
X10% decrease in one-dimensional tumour size or a X15%
decrease in tumour attenuation on CT scan, whereas PD was
defined as X10% increase in size without meeting PR criteria by
change in attenuation (Table 1). The Choi criteria correlated better
with disease-specific survival in imatinib-treated GIST patients
than RECIST.
Several studies have indicated that sunitinib can induce necrosis
in metastatic renal cell cancer (mRCC; Motzer et al, 2006; Baccala
et al, 2007; Van der Veldt et al, 2008b). During sunitinib treatment,
responding RCC lesions can be observed with dramatic decrease in
attenuation, but little change in size. Although sunitinib has shown
PR in 31% of patients in the first-line setting (Motzer et al, 2007), it
remains unclear if RECIST optimally predicts treatment outcome
and if new response criteria are required. Because the beneficial
effect of anti-angiogenic agents in mRCC may also be stabilisation
rather than substantial tumour regression in a large number of
patients, the one-dimensional RECIST for PR, a X30% decrease
in the sum of the longest diameter of target lesions, may be
inaccurate in the TKI era (Van Cruijsen et al, 2008). Because
Choi criteria (Choi et al, 2007) may also be of value to evaluate
tumour responses in tumours other than GIST, such as RCC
and HCC, treated with targeted agents, we here compared the
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usefulness of Choi criteria with RECIST in sunitinib-treated
mRCC patients.
PATIENTS AND METHODS
Patients and treatment
Medical records of patients were reviewed who were treated with
sunitinib for advanced RCC in two centres in the Netherlands (VU
University Medical Center and The Netherlands Cancer Institute)
from December 2005 to October 2007. Most patients had been
included in an expanded access programme (EAP) (Van der Veldt
et al, 2008a) until September 2006 after which sunitinib was
registered and available on doctor’s prescription. In the EAP, each
participant signed a protocol-specific informed consent approved
by the institutional review board in accordance with national and
institutional guidelines. For further analysis of CT scans according
to Choi criteria, adequate safeguards to protect patient privacy
were maintained.
Sunitinib was administered orally at a dose of 50mg daily,
consisting of 4 weeks of treatment followed by a 2-week rest period in
cycles of 6 weeks. A dose reduction of sunitinib (to 37.5 or 25mg) was
allowed depending on the type and severity of adverse events. If
patients had symptoms of PD during the rest period, there was the
possibility for continuous dosing of sunitinib at 37.5mg per day.
For evaluation of sunitinib efficacy, CT scans were performed at
baseline and during treatment to assess clinical response according to
RECIST version 1.0 (Therasse et al, 2000). For RECIST, best response
was also determined on subsequent CT scans during treatment.
Progression-free survival (PFS) was the time between the first day of
sunitinib treatment and the date of PD on the CT scan according to
RECIST, clear clinical evidence of PD, or death due to PD within 12
weeks after the last response evaluation. If a patient had not
progressed, PFS was censored at the time of the last follow-up. If the
PD date was unknown or a patient died due to PD later than 12 weeks
after the last response evaluation, PFS was censored at the last
adequate tumour assessment. Overall survival (OS) was the time
between the first day of treatment and the date of death or the date at
which a patient was last known to be alive. For PFS and OS analyses,
data collection was closed on 1 September 2009.
Image analysis
Patients were eligible for inclusion in the analysis, if they had CT
scans at baseline and at first evaluation according to the same scan
protocol in the same hospital and at least one tumour lesion at
baseline 415mm. Patients with bone metastasis (n¼ 2) or
primary tumour (n¼ 1) as only evaluable lesion were excluded.
Primary tumours were also excluded, as the overall response may
be underestimated due to their enormous size (Van der Veldt et al,
2008b; Bex et al, 2009). Furthermore, brain (Helgason et al, 2008)
and bone metastases at baseline were excluded.
Routine helical CT scans of the thorax and abdomen were
obtained with a scanning delay of 30 and 70 s after start of
intravenous (i.v.) injection of a low-osmolar non-ionic contrast
agent (Omnipaque 300 (nycomed Amersham plc, Buckinghamshire,
England) or Ultravist 300 (Bayer Shenng Pharma, Berlin, Germany)).
For abdominal scans, Choi criteria were applied in the portal
venous phase of contrast. All series were reconstructed in 5mm
contiguous axial slices. Scans were shown at standard soft tissue
kernel and window (window centre, 20 Hounsfield units (HUs);
window width, 360 HU) to avoid pixel averages from surrounding
lung parenchyma. Image viewing and manipulation were con-
trolled with Centricity RA 600 version 6.1 software (GE Healthcare
Inc., Wauwatosa, WI, USA), which allows the radiologist to draw
perimeters around the regions of interest. The software then
automatically calculates the area enclosed by the perimeter and the
mean attenuation of this area in HU. A specialised radiologist
(MRM, 7 years of experience in radiology) masked to clinical
history and patients’ outcome and experienced in using the image
viewing and manipulation software examined the CT scan images
in the presence of a junior researcher (AAM vdV). To draw
comparable perimeters over the tumours, we analysed CT scans at
baseline and evaluation from one patient in the same session.
Between the two observers, agreement on identification and
delineation of the lesions was obtained in all cases. In addition,
to evaluate the intra-observer variability for the determination of
tumour attenuation, reproducibility of placing regions of interest
over tumours was tested on 2 different days (43 months between
the measurements). As to the intra-observer variability for tumour
attenuation measurements, Spearman’s correlation coefficients
were rX0.957 (P40.001) for the HU value of individual lesions as
well as the mean HU value in the individual patients.
For each patient, a maximum of 10 delineated tumour target
lesions were identified (not more than 5 per organ). For RECIST
measurements, the longest diameter of the tumour lesions was
X10mm, whereas for Choi criteria the diameter was X15mm
(Table 1; Choi et al, 2007). The attenuation on CT (density) of lesions
X15mm was determined in HUs by drawing a region of interest
around the margin of the entire tumour. Then, the tumour
attenuation assessments of all lesions were combined and a mean
attenuation on CT was computed for each patient. Thereafter, the
percentage of change in attenuation from the pretreatment scan to
the first evaluation during sunitinib was calculated for each patient.
Statistics
Statistical analysis was performed using SPSS software (SPSS for
Windows 15.0, SPSS Inc., Chicago, IL, USA). For testing possible
correlations, the Spearman’s correlation test was performed. The
Wilcoxon’s signed-ranks test was used to compare the changes in size
and attenuation at baseline and at first evaluation. A two-tailed
probability value of Po0.05 was considered significant. For the
analyses according to RECIST and Choi criteria, patients were
categorised into response (CRþPR) vs no response (SDþPD). For
RECIST, patients were also classified as having clinical benefit
(CRþ PR and SDX12 weeks) vs no clinical benefit (SDo12 weeks
and PD). PFS and OS were calculated with the Kaplan–Meier method.
Log-rank test was used to test the differences between survival curves.
RESULTS
Patients
A total of 55 mRCC patients treated with sunitinib were included
in this study, of which 45 patients were participants in an EAP
Table 1 Choi response criteria (Choi et al, 2007)
Response Definition
CR Disappearance of all lesions
No new lesions
PR A decrease in size X10% or a decrease in tumour attenuation
(HU) X15% on CT
No new lesions
No obvious progression of non-measurable disease
SD Does not meet criteria for CR, PR, or PD
No symptomatic deterioration attributed to tumour
progression
PD An increase in tumour sizeX10% and does not meet criteria of
PR by tumour attenuation on CT
New lesions
Abbreviations: CR¼ complete response; PR¼ partial response; SD¼ stable disease;
PD¼ progressive disease; HU¼Hounsfield unit.
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of sunitinib. One patient was excluded due to evident differences in
phases of i.v. contrast between the two subsequent CT scans.
Table 2 presents the patients’ characteristics. The median age
was 59 years (range: 20–81 years). Of 55, 48 patients had clear
cell histology. Of 55 patients, 40 patients were cytokine-pretreated
of whom 4 patients were also pretreated with other anti-angiogenic
agents. The median time from the baseline CT scan and
the initiation of sunitinib treatment was 0.5 months (range:
0–1.5 months). The median time from the start of sunitinib to the
CT scan for first evaluation was 1.9 months (range: 1.1–3.4
months).
Response according to RECIST
For RECIST measurements, 225 tumour lesions were eligible. At
first evaluation these lesions showed a median change in tumour
size of 10% (range: 100 to þ 189%). Seven (13%) patients
reached PR, 38 (69%) patients stable disease (SD), and 10 (18%)
patients PD, resulting in 7 responders and 48 non-responders. Five
out of ten patients with PD were categorised as PD based on the
occurrence of new lesions, including two patients with sympto-
matic brain metastases. Ten (18%) patients had SD at first
evaluation, but reached a PR at later time points (median time to
PR: 3.9 months; range: 2.4–9.7 months), resulting in an overall PR
rate of 31%. A total of 24 patients had SDX12 weeks as best
response.
Table 3 Tumour lesions for the efficacy analysis in patients with mRCC
treated with sunitinib
N
Eligible lesions for analysis
RECIST 225
Choi criteria 173
Exclusion according to both RECIST and Choi criteria 26
Bone metastasis 11
Primary tumour 10
Brain metastasis 5
Exclusion according to Choi criteria only 52
10mmp tumour lesion at baseline o15mm 38
Air-containing cavity at evaluation 8
Beam-hardening artefact obscuring helical CT density
(e.g. metal-containing parts)
6
Abbreviations: RECIST¼Response Evaluation Criteria in Solid Tumours;
CT¼ computed tomography.
Table 2 Patient characteristics
Total N¼ 55
Variable N (%)
Sex
Male 34 (62)
Female 21 (38)
Median age, years (range) 59 (20–81)
ECOG performance status
0 24 (43)
1 22 (40)
2 5 (9)
3 2 (4)
Unknown 2 (4)
Tumour type
Clear cell 48 (87)
Other 7 (13)
Previous nephrectomy 45 (82)
Prior treatment
None 15 (27)
Cytokine based-therapy 40 (73)
Anti-angiogenic therapy 4 (7)
No. of disease sites
1 7(13)
2 20 (36)
X3 28 (51)
Sites of disease
Lung 49 (89)
Lymph nodes 32 (58)
Bone 13 (24)
Liver 11 (20)
Local recurrence 7 (13)
Brain 4 (7)
MSKCC risk groupsa
0 (favourable) 11 (20)
1–2 (intermediate) 36 (65)
X3 (poor) 7 (13)
Unknown 1 (2)
Abbreviations: ECOG¼ Eastern Cooperative Oncology Group; MSKCC¼Memorial
Sloan-Kettering Cancer Center. aRisk groups according to MSKCC prognostic criteria
(based on the 5 risk factors: low Karnofsky performance status (o80%), high LDH
(41.5 times the upper limit of normal), low serum haemoglobin, high corrected
serum calcium (410mg per 100ml), and time from initial diagnosis to treatment of
less than 1 year) (Motzer et al, 2002).
Figure 1 An example of a renal cell cancer patient with lung metastases at baseline (A) and pulmonary cavitations at first evaluation during sunitinib
(B, arrow). For the purpose of illustration the lung window setting is shown.
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Response according to Choi criteria
For Choi criteria, less tumour lesions were eligible than for RECIST
(Table 3; Figure 1), namely 173. Lesions most frequently excluded
from the analysis had a tumour size o15mm before treatment
(n¼ 38). In 24 lesions the change in tumour attenuation could not
be determined due to a tumour size o15mm at evaluation. At
baseline, the median tumour size was 26mm (range: 15–140mm)
for all lesions, with a median attenuation of 66 HUs (range: 6–135
HUs). During sunitinib at first evaluation, the median size
and attenuation had decreased to, respectively, 24mm (range:
0–186mm; Wilcoxon’s signed-ranks test, Pp0.001) and 47 HUs
(range: 4–112 HUs; Pp0.001). A significant decrease in attenua-
tion was measured at all tumour sites (Table 4; Figure 2).
Preliminary analysis did not show a significant difference in the
change in attenuation between the seven patients with non-clear
cell histology and the 48 patients with clear cell histology. Overall,
a weak correlation was calculated between the percentage of
change in tumour size and the percentage of change in attenuation
(Spearman’s r¼ 0.187, P¼ 0.022).
At first evaluation according to Choi criteria, 36 (65%) patients
reached PR, 6 (11%) had SD, and 13 (24%) had PD, resulting in 36
responders and 19 non-responders. Of 38, 29 patients who were
categorised as SD according to RECIST had PR according to Choi
criteria. Patients were categorised as PR according to Choi based
on decrease in tumour size X10% (n¼ 12), decrease in tumour
attenuation X15% (n¼ 9) or both (n¼ 15). All six patients with
SD according to Choi criteria had a PFSX12 weeks. Of note, 3 out
of 38 patients defined as SD by RECIST had PD according to Choi
Table 4 Change in tumour size and density for tumour lesions included in the Choi criteria for evaluation of sunitinib treatment in patients with mRCC
Number of eligible
lesionsa
Median pretreatment
values (range)
Median values at first
evaluation (range) Median change (range)
Tumour site N (size/attenuation)
Size
(mm)
Attenuation
(HUs)
Size
(mm)
Attenuation
(HUs)
Size
(%)
Attenuation
(%)
Lung 55/41 25 (15–91) 59 (15–98) 19 (5–110)** 38 (4–81)** 24 (71 to +21) 31 (92 to +146)
Lymph node 63/56 25 (15–123) 68 (6–118) 25 (9–101) 55 (17–105)** 5 (57 to +59) 14 (69 to +183)
Liver 16/16 31 (19–83) 83 (40–96) 32 (16–67) 51 (22–66)** 3 (25 to +45) 38 (76 to 5)
Abdominal otherb 26/24 41 (15–140) 65 (33–135) 41 (0–186) 61 (20–112)* 4 (100 to +65) 13 (78 to +47)
Thoracic otherc 13/12 27 (17–44) 67 (18–116) 20 (13–55) 53 (21–87) 23 (39 to +189) 19 (73 to +28)
Total number of lesions 173/149 26 (15–140) 66 (6–135) 24 (0–186)** 47 (4–112)** 11 (100 to +189) 24 (92 to +183)
Abbreviation: HU¼Hounsfield unit. *Pp0.05, **Pp0.001 compared to baseline value by the Wilcoxon’s signed-ranks test. aTumour lesionsX15mm at baseline buto15mm
at evaluation were included for the analyses regarding the change in tumour size, but were excluded for the analyses regarding the change in tumour attenuation. bAbdominal
sites, including local recurrence, adrenal gland, spleen, and peritoneum. cThoracic sites including pleura, breast, and subcutis.
Figure 2 An example of a renal cell cancer patient on sunitinib treatment in which the lung lesion (arrow) showed a decrease in attenuation at first
evaluation. (A) At baseline, the tumour attenuation was 107 Hounsfield units (HUs) and the longest diameter 48mm. (B) At first evaluation, the tumour
attenuation was 65 HUs (39%) and the longest diameter was 39mm (19%).
Table 5 PFS and OS of mRCC according to RECIST and Choi criteria
Median PFSa Median OS
Months (range) Months (range)
Response
Choi criteria Log rank¼ 16.1,
Po0.001
Log rank¼ 20.0,
Po0.001
Respondersb (n¼ 36) 14.5 25.4
Non-respondersc (n¼ 19) 3.2 10.4
RECIST at first evaluation Log rank¼ 0.2,
P¼ 0.685
Log rank¼ 1.7,
P¼ 0.191
Respondersb (n¼ 7) 18.3 27.4
Non-respondersc (n¼ 48) 9.0 13.2
RECIST at best response Log rank¼ 11.2,
P¼ 0.001
Log rank¼ 13.2,
Po0.001
Respondersb (n¼ 17) 19.3 31.3
Non-respondersc (n¼ 38) 7.0 15.3
Clinical benefit
RECIST Log rank¼ 63.2,
Po0.001
Log rank¼ 18.8,
Po0.001
Clinical benefitd (n¼ 41)a 12.2 22.3
No clinical benefite
(n¼ 13)
2.6 7.2
Abbreviations: RECIST¼Response Evaluation Criteria in Solid Tumours; PFS¼ pro-
gression-free survival; OS¼ overall survival. aFor one patient with stable disease, date
of progressive disease was not available. bPartial response. cStable disease+pro-
gressive disease. dPartial response+stable disease X12 weeks. eProgressive
disease+stable disease o12 weeks.
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criteria. These three patients had a PFS412 weeks among whom
was one patient that reached a PFS410 months.
Survival analysis
At first evaluation in patients with PR, Choi criteria had a
significantly better predictive value for PFS and OS (Po0.001 for
both) than RECIST (P¼ 0.685 and 0.191 respectively) (Table 5;
Figure 3). When best response during treatment was analysed
according to RECIST, the predictive value of RECIST increased for
both PFS and OS (P¼ 0.001 and o0.001 respectively). For clinical
benefit (PR and SDX12 weeks), the predictive value of RECIST for
PFS and OS was also significant (Po0.001 for both). When the two
Choi criteria were analysed separately, in which patients with new
lesions were categorised as PD, only a 15% decrease in attenuation
was predictive for PFS (P¼ 0.018; log rank¼ 5.6) and OS
(P¼ 0.005; log rank¼ 7.8).
DISCUSSION
In this study, we evaluated whether the new Choi criteria,
which include changes in tumour attenuation, are of additional
value to predict outcome in mRCC patients treated with sunitinib.
The response rate of 31% as measured by RECIST was comparable
with that reported previously (Motzer et al, 2007), indicating
that the present study is representative for sunitinib treatment in
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Figure 3 Kaplan–Meier curves for progression-free survival and overall survival of patients with metastatic renal cell cancer treated with sunitinib:
responders (—) and non-responders (- - -) at first evaluation according to Choi criteria (A, B) and the Response Evaluation Criteria in Solid Tumours
(RECIST) (C, D) as well as clinical benefit (partial responseþ stable disease X12 weeks) (—) and no clinical benefit (progressive diseaseþ stable disease
o12 weeks) (- - -) at first evaluation by RECIST (E, F).
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mRCC patients. At first evaluation, Choi criteria of PR were
able to define a large population with a long PFS and OS, whereas
RECIST PR only identified seven patients with favourable clinical
outcome. When patients with PR and SDX12 weeks during
treatment were taken into account, the predictive value of RECIST
substantially increased. The latter could have been expected, as
patients with SD at first evaluation are likely to continue sunitinib
treatment and a substantial number will eventually reach a PR or
SDX12 weeks.
During sunitinib treatment, we observed tumour necrosis as
illustrated by a reduction in tumour attenuation with a median
decrease of 24% at first evaluation. The TKI sorafenib can also
induce extensive necrosis (Flaherty, 2007). In comparison with
placebo, sorafenib prolonged PFS in cytokine-pretreated mRCC with
almost 3 months (Escudier et al, 2007), although the complete
response (CR) and PR rates by RECIST were only o1 and 10%
respectively (Escudier et al, 2007). These data suggest that
non-responders by RECIST may have benefited from sorafenib.
Therefore, Choi criteria may also be valuable to early identify
mRCC patients who will have a favourable outcome from
sorafenib treatment. Response evaluation by Choi criteria should
ideally be planned on a fixed day during treatment, i.e. day 28 of
sunitinib administration in the 4 weeks on 2 weeks off schedule
in mRCC. The variability in timing of the first on-treatment CT scan
in this study, however, could not be avoided because of its
retrospective design.
Although Choi criteria could easily be applied on routine
standardised contrast-enhanced CT scans, there were several
limitations in the use of these criteria for evaluation of sunitinib-
induced responses in mRCC. First, a large number of lesions
(22%), especially lung metastases, which could be measured by
RECIST, had to be excluded due to a size o15mm at baseline. As
mRCC patients can have rather small metastases, the reliability of
Choi criteria may decrease when smaller lesions (o15mm)
significantly decrease in size or attenuation, but are ineligible for
assessment. Second, the reliability of Choi criteria may also
decrease when fewer lesions are included for analysis. For example,
a 15% decrease in attenuation in five lesions would be more
reasonable than measured in one single lesion. Third, the
attenuation of heterogeneous lesions may be assessed inaccurately,
as the mean value is calculated in one region of interest in one
slice. Fourth, measurements of relatively hypodense lesions at
baseline may be less reliable, because a 15% decrease in
attenuation is less accurate than measurements in lesions with
higher pretreatment attenuation values. For that reason, use of
absolute change may be more precise than the percent change in
attenuation. Fifth, attenuation measurements are not possible in
lesions with sunitinib-induced cavitations, which was the case in
eight lung lesions (Figure 1). Sixth, although the intra-observer
variability appeared to be rather low, the above-described
limitations of Choi criteria imply a risk of high inter-observer
variability and may even lead to a change in response in an
individual patient. Therefore, mutual agreement on the delineation
method should be achieved between the observers. Last, although
i.v. contrast was administered according to the same scanning
protocol and patients with clear differences in i.v. contrast were
excluded, slightly different phases of scanning at subsequent time
points may lead to incorrect changes in lesion attenuation. In that
respect, it should also be mentioned that sunitinib-induced
changes in cardiac output (Chu et al, 2007) might possibly
influence the distribution of i.v. contrast. In mRCC patients,
administration of i.v. contrast may be harmful in the presence of
an impaired renal function.
The ultimate goal in the palliative treatment of mRCC with
sunitinib is prevention of disease progression combined
with acceptable quality of life. Sunitinib, however, is associated
with a wide range of mild toxicities that can be cumbersome,
and alternative treatments for mRCC, such as sorafenib and
temsirolimus, are readily available. Therefore, surrogate markers
for poor PFS and OS are warranted in patients with SD at first
evaluation. Unfortunately, Choi criteria were not able to identify
patients with clear-cut progression, because three patients defined
as PD had a PFS412 weeks. Compared with RECIST, Choi criteria
may be less optimal for identifying PD, probably due to theX10%
increase vs the X20% increase used by RECIST.
In conclusion, Choi criteria can be easily applied on contrast-
enhanced CT scans of mRCC patients treated with sunitinib, but its
reliability is limited, especially in patients with most lesions
o15mm, a small number of lesions, heterogeneous lesions or
hypodense lesions at baseline. Although Choi criteria had a
significantly better predictive value for PFS and OS than RECIST at
first evaluation in patients with PR, its predictive value for
outcome was similar to that of RECIST at later time points.
Because Choi criteria were not able to early identify patients with
PD, these criteria will not change the management of sunitinib-
treated mRCC patients.
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Sunitinib-Induced Hemoglobin
Changes Are Related to the
Dosing Schedule
TO THE EDITOR: We read with interest the correspondence by
Alexandrescu et al1 reporting the occurrence of erythrocytosis in ﬁve
of 21 patients treated with sorafenib or sunitinib. We also observed
erythrocytosis during sunitinib treatment, although we detected that
hemoglobin and erythrocyte changes occurred in a cyclic pattern. In
an expanded access program, 82 patients with metastatic renal cell
cancer were treated with sunitinib 50 mg daily, 4 weeks on, 2 weeks
off.2 We measured hemoglobin levels on days 1 and 28 of each cycle
and on day 14 of the ﬁrst cycle. In 90% of patients, we observed a
transient increase in hemoglobin during the ﬁrst cycle. The median
hemoglobin level of 7.5 mmol/L (range, 5.2 to 10.4 mmol/L) at base-
line increased to 8.4 mmol/L (range, 6.0 to 10.9 mmol/L; Wilcoxon
signed-rank test, P .001) on day 14 and 8.0 mmol/L (range, 5.7 to
10.7 mmol/L; P .001) on day 28 of the ﬁrst cycle. After the 2-week
rest period, the median hemoglobin level returned to baseline of 7.8
mmol/L (range, 5.2 to 10.0mmol/L;P .127). This transient increase
in hemoglobin occurred in all subsequent cycles (Fig 1). In 69% of
patients, themaximum level was reached during the ﬁrst cycle (range,
cycle 1 to cycle 10) with a median increase of 1.2 mmol/L. In 46
patients in theexpandedaccessprogram,hemoglobin-associatedvari-
ables, including hematocrit, erythrocytes, mean corpuscular volume,
mean cellular hemoglobin, and mean corpuscular hemoglobin con-
centration, aswell as vascular endothelial growth factor (VEGF), were
available (Table 1). The incidence of erythrocytosis (erythrocytes
above the upper limit of normal) was 26% during the ﬁrst cycle,
whereas a signiﬁcant increase in erythrocyte numbers occurred in
81% of these patients.
The cyclic kinetics in hemoglobin values and erythrocyte
numbers indicate that sunitinib scheduling is the cause of these
changes. Thus far, its mechanism is not known. Tam et al3 have
described that neutralization of VEGF inmouse and primatemod-
els can result in an increase in the secretion of erythropoietin from
the liver, leading to erythropoiesis and erythrocytosis. Another
study in mice has demonstrated that sunitinib can increase eryth-
ropoietin levels.4 Therefore, we measured erythropoietin at base-
line and on day 14 of the ﬁrst cycle in 20 unselected patients and
indeed found an increase from a median of 12 U/L (range, 1.2 to
119.9) to 26 U/L (range, 12.9 to 54.2; P  .002). Although the
difference in erythropoietin levels is signiﬁcant, an erythropoietin-
induced increase in erythrocytes is not expected to diminish rap-
idly within the 2 weeks of rest.
We propose anothermechanism for the transient hemoglobin
changes during sunitinib treatment. Like other inhibitors of VEGF
signaling, sunitinib is known to raise blood pressure.5 In 39 of our
patients, blood pressure was consistently monitored with a Di-
namap Dash 4000 (GE Medical Systems, Milwaukee, WI). In these
patients, we detected a signiﬁcant increase in blood pressure on day
14 and 28 of the ﬁrst cycle, whichwas reversible after the rest period
(Table 1). On day 28, changes inmean arterial blood pressure were
signiﬁcantly correlated with changes in hemoglobin levels (n 25;
Spearman’s 
  0.552; P  .004). Sunitinib-induced increase in
blood pressure is thought to be caused by increased peripheral
resistance.6,7 VEGF receptor 2 (VEGFR-2) plays a role in the regu-
lation of the vascular tone, given that inhibition of the VEGFR-2
signaling route may decrease the production of the potent vasodi-
lator nitric oxide (NO), leading to vasoconstriction.8,9 In rats,
Filep10 has previously described that inhibition of NO synthase
increased blood pressure and hematocrit, lowered plasma volume,
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Fig 1. Median hemoglobin levels during the ﬁrst 10 cycles of sunitinib
treatment. C, cycle; D, day.
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and induced albumin escape, primarily in the lung, heart, liver,
kidney, and GI tract. In 67 of 82 patients, baseline albumin levels
were available; albumin decreased during sunitinb treatment from
a median of 41 g/L to a median of 38 g/L on day 28 (n  67; P 
.001) and increased after the rest period from 38 to 40 g/L (n 67;
P .002). Loss of circulating plasma volume is a likely cause for the
relative increase in hemoglobin, hematocrit, and erythrocytes
by sunitinib.
In summary, we describe a zig-zag pattern in hemoglobin levels
and erythrocyte numbers during sunitinib treatment in metastatic
renal cell cancer patients. On the basis of previous studies and our
ﬁndings, we hypothesize that the cyclic kinetics of hemoglobin and
erythrocytes is the result of a temporary loss of intravascular ﬂuid
caused by inhibition of VEGFR-2 and subsequent reduction of NO,
rather than an increase in erythropoiesis.
Astrid A.M. van der Veldt, Epie Boven, Laura Vroling,
Henk J. Broxterman, and Alfons J.M. van den Eertwegh
Department of Medical Oncology, VU University Medical Center, Amsterdam,
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IN REPLY: The correspondence item of van der Veldt et al
presents much interest regarding the cellular regulation mecha-
nisms of erythropoietic homeostasis. The unique 4-weeks-on,
2-weeks-off administration schedule of sunitinib allows a direct
observation of the biologic effects of this drug on the tumor and
various organ systems. This schedule was recommended by the
regulatory authorities to allow recovery from bonemarrow toxicities.
The reported cyclic variations in hemoglobin (HgB) that parallel
the administration of sunitinib reinforce our previous observations.1
It is the merit of van der Veldt et al to have conducted a large enough
analysis to show statistical signiﬁcance for the increase inHgB. I agree
with the fact that cyclic administration of sunitinib is the cause of the
observed phenomenon. In fact, other biologic processes pertaining to
different organ systems share similar effects. Cyclic elevations in
Table 1. Changes in Hemoglobin-Associated Variables, VEGF, and Blood Pressure During the First Cycle of Sunitinib Treatment
Variable
C1D1 C1D14 C1D28 C2D1
No. Range Median No. Range Median No. Range Median No. Range Median
Hemoglobin, mmol/L 46 5.4-10.6 7.5 46 6.2-10.6 8.2 31 5.3-10.4 8.0† 39 5.2-9.4 7.0†
Hematocrit 45 0.27-0.48 0.36 45 0.32-0.51 0.39 30 0.25-0.50 0.39† 36 0.25-0.46 0.33‡
Erythrocytes 1012/L 42 3.1-8.5 4.4 42 3.7-6.7 4.7 30 2.9-5.6 4.6† 33 2.8-5.6 4.0‡
MCV, fL 41 68-94 85 42 68-93 84† 30 74-93 85 33 69-97 87
MCH, attomol/cell 41 1,198-2,023 1,762 42 1,260-1,936 1,787 30 1,465-1,955 1,815 33 1,266-2,023 1,843
MCHC, mmol/L 41 17.7-23.2 20.8 42 18.1-22.4 20.8 30 18.7-22.5 20.8 33 18.3-22.2 20.9
VEGF, pg/mL 30 21-650 70 32 57-1,722 258 22 45-1,499 210* 21 34-300 70
Blood pressure, mmHg
Systolic 39 93-170 120 38 105-189 139 25 108-178 137‡ 32 86-149 119
Diastolic 39 47-90 71 38 56-114 80 25 69-105 83‡ 32 48-99 70
MAP 39 69-117 90 38 73-138 101 25 83-129 100* 32 67-113 85
Abbreviations: VEGF, vascular endothelial growth factor; MCV, mean corpuscular volume; MCH, mean cellular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration; MAP, mean arterial pressure, calculated as Pdiastolic  1/3(Psystolic – Pdiastolic).
P  .001, compared with baseline value by the Wilcoxon signed-rank test.
†P  .05, compared with baseline value by the Wilcoxon signed-rank test.
‡P  .01, compared with baseline value by the Wilcoxon signed-rank test.
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Abstract Mature circulating endothelial cell (CEC) as
well as endothelial progenitor populations may reﬂect the
activity of anti-angiogenic agents on tumor neovasculature
or even constitute a target for anti-angiogenic therapy. We
investigated the behavior of CECs in parallel with hema-
topoietic progenitor cells (HPCs) in the blood of renal cell
cancer patients during sunitinib treatment. We analyzed the
kinetics of a speciﬁc population of small VEGFR2-
expressing CECs (CD45neg/CD34bright), HPCs (CD45dim/
CD34bright), and monocytes in the blood of 24 renal cell
cancer (RCC) patients receiving 50 mg/day of the multi-
targeted VEGF inhibitor sunitinib, on a 4-week-on/2-week-
off schedule. Blood was taken before treatment (C1D1), on
C1D14, C1D28, and on C2D1 before the start of cycle 2.
Also plasma VEGF and erythropoietin (EPO) were deter-
mined. Remarkably, while CD34bright HPCs and monocytes
decreased during treatment, CD34bright CECs increased
from 69 cells/ml (C1D1) to 180 cells/ml (C1D14;
P = 0.001) and remained high on C1D28. All cell popu-
lations recovered to near pre-treatment levels on C2D1.
Plasma VEGF and EPO levels were increased on C1D14
and partly normalized to pre-treatment levels on C2D1. In
conclusion, opposite kinetics of two circulating CD34bright
cell populations, HPCs and small CECs, were observed in
sunitinib-treated RCC patients. The increase in CECs is
likely caused by sunitinib targeting of immature tumor
vessels.
Keywords Circulating endothelial (progenitor) cells 
Renal cell cancer patients  Sunitinib  VEGF 
Erythropoietin
Introduction
Anti-angiogenic compounds have shown efﬁcacy in the
clinic during recent years. In particular, the anti-vascular
endothelial growth factor (VEGF) antibody bevacizumab
[1] and the receptor tyrosine kinase inhibitors (TKIs) of the
VEGF receptor family [2], sunitinib [3, 4] and sorafenib
[5], have proven activity in a number of tumor types [6].
Sunitinib is an oral TKI of the VEGF receptors, platelet-
derived growth factor (PDGF) receptors, Flt-3 and c-Kit,
and has been approved for treatment of advanced renal cell
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cancer (RCC) and imatinib-resistant gastrointestinal stro-
mal tumors (GISTs). In a phase III trial in RCC patients,
sunitinib has proven to be effective, albeit that a subset of
RCC patients did not beneﬁt from it [4]. Therefore, there is
still a need for better understanding which conditions,
factors, and cells facilitate or limit the beneﬁcial effects of
sunitinib on tumors.
In addition to immunohistochemical staining of tumor
biopsies and imaging techniques that quantify tumor
growth and perfusion [7], measurement of plasma circu-
lating proteins, such as VEGF [8] or soluble VEGFRs [9],
may reﬂect responsiveness to treatment. However, VEGF
or sVEGFR2 plasma levels have not been shown to be
predictive of response to sunitinib in GIST patients [10].
Alternatively, changes in the levels of circulating cells,
such as newly recruited progenitor cells and monocytes or
detached endothelial cells may be induced by anti-angio-
genic treatment [7, 11].
Circulating endothelial progenitor (CEPs) cells have
been suggested as potential pharmacodynamic or predic-
tive biomarker in tumor patients [11]. CEPs were ﬁrst
described by Asahara et al. [12], who introduced the con-
cept of circulating, bone marrow-derived endothelial
progenitor cells, contributing to adult vasculogenesis.
Later, Lyden et al. [13] have demonstrated that both
VEGFR2pos-circulating endothelial cells as well as
VEGFR1pos-myeloid, monocytic cells contributed to tumor
vascularization. Recently, the source of highly proliferative
endothelial outgrowth cells (EOCs) has been identiﬁed in
CD34pos/CD45neg/CD133neg circulating cell populations
[14, 15]. Besides CEPs, circulating endothelial cells
(CECs) as thought to be shed from mature blood vessels
may reﬂect the efﬁcacy of anti-vascular treatment, as
suggested in a number of studies [10, 16–18]. At present,
no studies have reported on changes in frequencies of
CECs or CEPs in combination with hematopoietic pro-
genitor cells (HPCs) during sunitinib treatment of RCC
patients.
Previously, we have identiﬁed a rare population of small
CD45neg/CD34bright/CD133neg/VEGFR2pos cells in the
peripheral blood (PB) of healthy volunteers, with increased
numbers in cancer patients [19]. On the basis of endothelial
marker expression these cells were indicated as ‘‘small-size
EC-like cells’’ or CECs [20], because they are relatively
small (\10 lm) when compared with mature CECs
[21–23]. Also, their marker proﬁle is the same as that of the
source of highly proliferative late outgrowth endothelial
cells present in umbilical cord blood or PB [15] and is
clearly distinct from CD45dim/CD34bright/CD133? hema-
topoietic progenitors. Here, we demonstrate that these
CECs increase during sunitinib treatment of RCC patients
in parallel to plasma VEGF and erythropoietin (EPO)
levels, while HPCs and monocytes show the opposite
changes, i.e., a decrease. In addition, a preliminary evalu-
ation of the relation of CECs with clinical response is
discussed.
Patients and methods
Patients and study design
From January 2006 to March 2007, 24 patients treated with
sunitinib for advanced RCC in an expanded access pro-
gram were included.
Sunitinib was administered orally, as monotherapy, at
the currently recommended dose of 50 mg daily in cycles
of 6 weeks, consisting of 4 weeks on treatment followed
by 2 weeks of rest (4/2 schedule). Before study entry, each
participant signed an institutional review board-approved
protocol-speciﬁc informed consent in accordance with
national and institutional guidelines, which strictly adhere
to the principles of the Declaration of Helsinki and its
subsequent amendments. During cycle 1, PB was taken on
four occasions: C1D1 before receiving the ﬁrst dose of
sunitinib, C1D14, C1D28, and C2D1 (=C1D42) before
administration of sunitinib of cycle 2. Computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) was
performed before treatment and after every two to three
cycles to assess clinical response according to response
evaluation criteria in solid tumors (RECIST) [24]. RECIST
is based on the sum of the largest diameters of appointed
target tumor lesions at baseline and compared with the sum
calculated in follow-up scans. Progression was deﬁned
based on 20% increase in the sum of the target lesions or
clear clinical evidence of progressive disease (PD), and a
20% decrease in the sum of the target lesions was con-
sidered as partial response (PR). Responses not ﬁtting these
criteria were considered as stable disease (SD). Tumor
response, PFS, and overall survival (OS) were used as
parameters of treatment outcome. The PFS was the time
between the ﬁrst day of sunitinib and the date of PD on CT
or MRI or clear clinical evidence of PD. OS was the time
between the ﬁrst day of treatment and the date of death or
the date on which patients were last known to be alive.
Data collection was closed on January 1st, 2008.
HPCs, CECs, and plasma monitoring
At the time of blood sampling, the ﬁrst 2 ml of blood was
discarded and blood for ﬂow cytometric enumerations was
processed within 2–4 h. At each time-point, 7 ml of EDTA
blood and 7 ml of citrate blood in a CPT tube (Becton
Dickinson) were collected for measurement of circulating
cell populations. One milliliter of full blood was used for
the measurement of CECs and HPCs, based on CD45 and
70 Angiogenesis (2009) 12:69–79
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CD34 marker expression and expressed as number per
milliliter, as published in detail [19]. Analysis of the sub-
sets of cells was performed with the antibodies CD45-
FITC, CD34-APC, and IgG isotypes as has been described
in detail [19]. For additional measurements of cell popu-
lations in patients, VEGFR2-APC and -PE antibodies were
used. The viability marker 7-AAD was used to gate viable
cells and annexin-V staining was used to determine early
stages of apoptosis. To assure the gating of nucleated small
CD34bright cells only, in a number of patients, we added
extra analysis tubes using the dye styril-751 (LDS-751).
Furthermore, we added tubes with 7-AAD plus 0.1%
saponin to permeabilize the cells and allow access of the
dye to nuclei of viable cells as described before [19, 25].
Flow cytometry was performed on a FACSCalibur (BD
Biosciences) and data were analyzed using CellQuest Pro
software. Subfractions of white blood cells (WBC) were
calculated as number per milliliter of blood by using
standard total WBC count on Sysmex [19]. The remaining
EDTA blood was used for the preparation of plasma and
stored at -80C. Plasma VEGF levels and EPO were
measured in duplicate with enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, Minneapolis). Albumin
was determined using conventional methods in the
department of clinical chemistry.
Human umbilical cord blood was obtained from full-
term deliveries and was processed for ﬂow cytometry,
according to the patients PB samples and used as a refer-
ence to identify the CD45neg/CD34bright/CD133neg CEC
population [15].
Statistics
Frequencies of circulating cell populations (numbers/ml),
plasma levels of VEGF (pg/ml), and EPO (mIU/ml) were
enumerated and expressed as median (range). Wilcoxon
Signed Ranks test (SPSS for Windows 14.0, SPSS, Inc.,
Chicago, IL) was used to compare the biomarkers at
pre-treatment and during treatment on C1D14, C1D28,
and C2D1. Clinical beneﬁt (CB) was deﬁned as SD
plus PR. PFS and OS were calculated with the Kaplan–
Meier method and tested with the log rank test. Values
of P B 0.05 (two-sided) were considered statistically
signiﬁcant.
Results
Patient characteristics and response to treatment
Twenty-four RCC patients treated with sunitinib were
enrolled in the study. One patient died on C1D14, due to
early progression and was excluded from the analysis. The
remaining patients (17 males and 6 females) had a median
age of 63 years (range 40–84) at the start of treatment. For
further patients characteristics, see Tables 1 and 2.
Two out of twenty-three patients could not be evaluated
for treatment response because of early discontinuation due
to sunitinib-related side-effects. Of the 21 evaluable
Table 1 Patient characteristics and best response to sunitinib
treatment
Characteristic No. %
Total 23 100
Sex
Male 17 74
Female 6 26
Median age, years (range) 63 (40–84)
Histology
Clear cell 19 83
Papillary 3 13
Other 1 4
Prior treatment
Prior nephrectomy 17 74
Prior cytokine-based therapy 15 65
Site of metastatic disease
Lung 20 87
Liver 9 39
Bone 4 17
No. of disease sites
1 3 13
2 5 22
C3 15 65
MSKCC risk groups [53]
Favorable risk 3 13
Intermediate risk 15 65
Poor risk 5 22
Best response to sunitinib treatmenta
Partial response 4 17 (19)
Stable disease 11 48 (52)
Progressive disease 6 26 (29)
No evaluationb 2 7 (–)
Progression-free survivalc 8.0 (1.1–19.3) –
Survivald 12.7 (1.4–23.2) –
MSKCC, Memorial Sloan-Kettering Cancer Center
a CT or MRI was performed before treatment and after every two to
three cycles to assess clinical response according to response evalu-
ation criteria in solid tumors (RECIST) [24]
b Two out of 23 patients could not be evaluated for treatment
response because of early discontinuation due to sunitinib related
side-effects
c The PFS was the time between the ﬁrst day of sunitinib and the date
of progressive disease (PD) on CT or MRI or clear clinical evidence
of PD
d Survival was the time between the ﬁrst day of treatment and the
date of death or the date on which patients were last known to be alive
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patients, 4 patients (19%) achieved a PR as best response,
11 patients (52%) had SD, and 6 patients (29%) had PD.
The median PFS of these 23 patients was 8.0 months
(range 1.1–19.3) and the median OS was 12.7 months
(range 1.4–23.2).
Blood cell counts during the ﬁrst cycle of sunitinib
The median WBC count of the patients showed a decrease
from 7.9 9 106 to 6.9 9 106 cells/ml on C1D14 (n = 23;
P = 0.002) and a further decrease on C1D28 (from median
pre-treatment 7.9 9 106 to 4.4 9 106 cells/ml, n = 15;
P = 0.001), which partly reverted after 2 weeks of rest
(from median pre-treatment 7.7 9 106 to 4.8 9 106,
n = 15; P = 0.001). A similar pattern was seen for
thrombocytes, neutrophils, and monocytes. The reduction
of circulating monocytes and their partial recovery pro-
ceeded faster than the total WBC change, whereas the
neutrophil decrease showed a more delayed effect. Eryth-
rocytes and hemoglobin showed the reverse, i.e., a
signiﬁcant increase after 14 and 28 days, while the number
of lymphocytes and basophils did not change during sun-
itinib treatment (Fig. 1).
Marker proﬁle of two CD34bright populations: CECs
and HPCs
Two populations of CD34bright circulating cells were
evaluated, CECs and HPCs. The deﬁnitions of CECs and
HPCs, according to CD45 and CD34 expression are visu-
alized for a representative RCC patient (Fig. 2a) and for
comparison from cord blood (Fig. 2b). CECs are CD45neg
and CD133neg; HPCs are CD45dim and are largely
CD133pos (Fig. 2a, b). Moreover, CECs have a slightly
higher CD34 brightness than the majority of HPCs [19].
CECs are small in size being comparable with HPCs. CECs
are viable cells, because they all exclude 7-AAD. We also
checked in separate analysis tubes that both the CD34bright
CD45neg and CD34bright CD45dim population had a similar
positive 7-AAD/saponin staining as well as LDS-751
staining, conﬁrming that both populations are nucleated
cells. Other markers for which CECs are positive are
Table 2 Patients characteristics and best response to sunitinib
Patient no. Age (years) Sex RCC type Prior treatment Responsea PFS (months) Survival (months)
1 68 F Clear cell Second-line PR 18.4 23.2
2 48 M Clear cell Second-line PD 3.0 8.2
3 40 M Papillary ca Second-line SD 10.1 11.0
4 76 M Clear cell Second-line SD 7.0 12.3
5 57 M Clear cell Second-line SD 10.6 22.2
6 62 F Clear cell Second-line PR 5.8 20.7
7 66 M Papillary ca Second-line PD 1.2 1.4
8 60 M Clear cell Second-line PR 19.4 19.3
9 81 M Clear cell Second-line SD 11.0 11.2
10 45 M Papillary ca Second-line PD 2.6 4.6
11 70 M Clear cell First-line SD 8.4 9.1
12 59 M Clear cell First-line SD 9.3 15.5
13 59 M Clear cell First-line PD 2.6 10.9
14 73 F Clear cell First-line SD 3.6 4.6
15 74 M Clear cell First-line SD 2.0 14.9
16 59 M Clear cell Second-line PR 8.9 12.7
17 57 F Clear cell First-line – – 9.7
18 69 F Clear cell First-line SD 16.5 16.5
19 84 F Clear cell Second-line – – 16.6
20 60 M Clear cell Second-line SD 8.0 15.3
21 57 M Clear cell Second-line PD 2.3 13.8
22 48 M Chromophobe ca First-line PD 1.1 2.0
23 64 M Clear cell Second-line SD 5.1 9.0
RCC, renal cell cancer; F, female; M, male; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival
a According to response evaluation criteria in solid tumors
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CD31, CD105, CD146, and VEGFR2, as previously
reported [19]. To conﬁrm the VEGFR2 expression on
CECs, we have measured VEGFR2 in parallel, in addi-
tional cancer patients. VEGFR2 positivity in CECs was
high (median 65%), in contrast to the CD45dim/CD34bright
HPCs (\1%). In addition, the EPO receptor was evaluated
on CECs of ﬁve sunitinib-treated patients and was found
present in 83.3% of the CECs (median range 66.7–93.3%).
Plasma membrane VE-cadherin was undetectable in CECs
in ﬁve treated patients (data not shown).
Kinetics of CECs and HPCs during the ﬁrst cycle
of sunitinib
A distinct difference in the kinetics of CECs (CD45neg/
CD34bright/7-AADneg) and HPCs (CD45dim/CD34bright/
Fig. 1 Blood cell count and
hemoglobin during treatment
with sunitinib. Median (range)
values are shown. Timepoints of
measurement: C1D1, cycle
1 day 1 (n = 23); C1D14, cycle
1 day 14 (n = 23); C1D28,
cycle 1 day 28 (n = 15); C2D1,
cycle 2 day 1 before start of the
second cycle (n = 15).
Wilcoxon Signed rank test,
* P\ 0.01, ** P\ 0.05
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7-AADneg) was observed during the ﬁrst cycle of sunitinib
(Fig. 3a). The median number of viable CECs before
treatment (C1D1) was 69 cells/ml (range 8–472), much
lower than the number of HPCs (1,350 cells/ml, range
305–5,351). The median of CECs increased from 69 on
C1D1 to 180 cells/ml on C1D14 (n = 23; P = 0.001) and
from pre-treatment 76 to 229 cells/ml (n = 14; P = 0.013)
on C1D28, while the HPCs displayed an opposite kinetic
pattern and decreased from 1,350 to 372 cells/ml on C1D14
(n = 23; P\ 0.001) and from pre-treatment 1,567 to 409
cells/ml on C1D28 (n = 14; P = 0.001). Both cell popu-
lations returned to values close to the pre-treatment levels
after the 2-week period of rest (C2D1; Fig. 3a). In a group
of non-small cell lung cancer patients not treated with a
VEGFR inhibitor, but treated with the EGF receptor
inhibitor erlotinib, the CECs did not change signiﬁcantly
over a 3-week period (data not shown).
When the kinetic changes in circulating cells were
expressed as percentage of pre-treatment values within
individual patients, 102% increase in CECs numbers was
observed after 2 weeks of treatment, whereas the HPCs
showed a 65% decrease (Fig. 3b). A similar change was
found on C1D28 (n = 14).
Plasma VEGF and EPO levels during the ﬁrst cycle
of sunitinib
Plasma levels of VEGF before treatment of sunitinib varied
more than tenfold among individual patients and had a
median value of 82 pg/ml (range 29–348, n = 19). These
median levels increased from 82 to 185 pg/ml on C1D14
(n = 19; P = 0.001), from median pre-treatment 79 to
198 pg/ml on C1D28 (n = 12; P = 0.028) and returned to
near pre-treatment levels on C2D1 (from 79 to 75 pg/ml;
n = 12, P = 0.875; Fig. 3b). In a subgroup of patients, we
assessed EPO levels and the median plasma EPO level on
C1D1 was 12 mIU/ml, which increased with 63% after
14 days (median, n = 20, Fig. 3c). In six patients, EPO was
measured during the complete cycle (Fig. 3d) showing
increases of 60 and 216% at days C1D14 and C1D28,
respectively, which remained above baseline level at C2D1.
Albumin concentrations determined in a larger group of
Fig. 2 Detection of hematopoietic progenitor cells (HPCs) and
circulating endothelial cells (CECs) using four-color ﬂow cytometry.
The mononuclear(MNC)-fraction of a renal cell cancer (RCC) patient
on C1D1 and C1D14 (a) and human umbilical cord blood (b). In the
upper panel CD45, CD34 expression, size and granularity is shown
for HPCs and CECs. HPCs measured as CD45dim/CD34bright and
CECs measured as CD45neg/CD34bright (see box). Second and third
panel is showing CD133 expression for both HPCs and CECs when
compared with the isotype control
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RCC patients treated with sunitinib were unaltered at C1D28
(n = 67) in comparison with the initial values at C1D0,
n = 81 (median of 38 lmol/l range 17–50 lmol/l and
median of 41 lmol/l range 22–52 lmol/l, respectively).
Biomarkers and treatment outcome
Clinical beneﬁt was observed in 15 out of 21 RCC patients.
Seventeen of all patients had clear cell RCC, of which 14
showed CB. PD was observed in 6 patients; 3 clear cell
RCC patients, 2 papillary carcinoma, and 1 chromophobe
carcinoma indicating that the patients with a clear cell
carcinoma had a good response to sunitinib. In the CB
group, the change in CECs after 14 days was increased in
14 out of 15 patients and in the PD group 4 out of 6 patients
showed an increase, while 2 had a decrease. An increased
number of CECs (n = 18) after 14 days of sunitinib
treatment, was associated with a longer PFS when com-
pared with patients (n = 3) with a decreased number of
CECs (log rank test; P = 0.034).
Discussion
We have investigated the changes in the frequency of cir-
culating cells with speciﬁc emphasis on a population of
small CD45neg/CD34bright CECs, previously shown to be
CD31pos/CD105pos/CD146pos/VEGFR2pos/CD133neg [19],
Fig. 3 Circulating endothelial
cells (CECs), total
hematopoietic progenitor cells
(HPCs), erythropoietin (EPO)
levels, and changes of VEGF
levels in comparison with
changes of blood cells during
treatment with sunitinib. a
Frequencies of CECs/ml and
viable HPCs/ml are shown
before (C1D1, n = 23), and on
C1D14 (n = 23), C1D28
(n = 14), and C2D1 (n = 14)
after start of sunitinib treatment.
b Percentage change in
circulating cells and plasma
VEGF levels on different time-
points during sunitinib
treatment are given. c and
d Plasma EPO levels are shown.
In (a), (c), and (d) individual
data and the median values are
shown, while in Fig. 3b pre-
treatment levels (C1D1) were
used as starting-point and
percentage of change on C1D14
(and other timepoints) was
calculated for each individual
patient. Wilcoxon Signed rank
test, * P\ 0.01, ** P\ 0.05,
ns not signiﬁcant
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in advanced RCC patients during the ﬁrst cycle of sunitinib
treatment. CECs increased in parallel to plasma VEGF and
EPO levels during the 4-week on and decreased during the
2-week off sunitinib period, while monocytes and HPCs
displayed an opposite pattern of change.
Blood cell-based biomarker analysis related to sunitinib
activity and clinical outcome has been studied only in
GIST patients with the main conclusion that a smaller
decrease in monocyte levels was seen in patients with
clinical beneﬁt compared to those with PD [10]. We
observed a decrease in circulating monocyte number after
sunitinib treatment in RCC patients in agreement with the
GIST study; a correlation with response was not seen in our
population, possibly related to the limited number of
patients with PD.
The number of HPCs decreased already maximally at
C1D14 in our patient group, in parallel to the monocytes,
while the overall WBC count dropped more slowly, due to
a more delayed change in circulating neutrophils (Fig. 1).
The decrease in HPCs might be partly related to bone
marrow suppression associated with the Flt3-inhibitory
action of sunitinib, since Flt3-signaling is required for HPC
proliferation [26, 27].
Despite intense interest in developing biomarker tests
for response prediction [7, 28, 29], levels of CECs during
sunitinib treatment of RCC patients have not yet been
reported. Therefore, the most interesting and novel ﬁnding
of our study was the increase in CD45neg/CD34bright CECs
during sunitinib treatment. The CEC population in PB is a
rare cell population [20], which is increased two to three-
fold in cancer patients [19]. In the present patient group,
the median pre-treatment (C1D1) frequency of the CECs
was 69 cells/ml (n = 23), which is well-comparable to the
median of 81 cells/ml (range 32–132) in a mixed group of
cancer patients [19]. The number of CECs approximately
doubled in the RCC patient group by sunitinib treatment.
Since we found a similar twofold increase in CEC levels
(without decrease in HPC numbers) in a group of bev-
acizumab plus erlotinib, but not erlotinib-single agent
treated NSCLC patients (L. Vroling et al., unpublished)
[30], this increase is more likely related to inhibition of
VEGFR signaling by sunitinib, rather than to inhibition of
other targets or off-target effects of sunitinib. Being a most
likely speciﬁc target-related effect of sunitinib, this
increase in CECs remains an interesting cell population to
be further investigated.
An important question regards the precise nature and
function of the CEC population that is elevated after sun-
itinib treatment, in particular in the light of the current
controversies on the identiﬁcation and role in tumor angi-
ogenesis of CECs or CEPs [11, 14, 25, 31]. A plausible
explanation for the increased number of CECs is that they
reﬂect endothelial cells, which became detached or shed
from sunitinib-targeted immature (tumor) blood vessels.
Although we have deﬁned this population by the marker
combination of CD45neg and CD34bright, which are both
essential for discriminating these cells from the HPCs and
all other MNCs, in theory, it may still be heterogeneous
with regard to other EC markers. Importantly, we have
assessed that this population has the highest VEGFR2
positivity (median 65%) of all by us deﬁned cell popula-
tions in the PB, further supporting their endothelial nature.
CECs are commonly characterized and deﬁned by a het-
erogeneous, but rather large size and granularity, exceeding
that of most mononuclear cell populations, typically
[20 lm [22, 32, 33] and a high CD146 expression
allowing selective extraction with immunobeads [34]. The
median diameter of CD146? PBMCs has been estimated
6.8 lm versus that of CD146? CECs as 21.5 lm [22]. Our
CECs are in the FSC/SSC range of the HPCs, which are
\10 lm. This ﬁts with the idea that these small CECs
originate from a rather immature vasculature and/or are
mobilized bone marrow or vascular wall resident EPCs. In
support of this explanation, several data suggest that sun-
itinib might selectively prune immature nascent tumor
neovessels not yet adequately stabilized by pericyte cov-
erage [35, 36], while relatively saving mature vessels
leading to vessel normalization [37].
A characteristic of endothelial cells in vitro is that they
rapidly become apoptotic after detachment from their
matrix [38]. However, in studies that measure CEC fre-
quencies in PB, cell viability was either not assessed or the
viability marker dye 7-AAD has been used to exclude dead
cells, as in most ﬂow cytometric approaches. While our
CEC values are intact, CECs by the deﬁnition of exclusion
of 7-AAD, more sensitive markers, such as annexin-V
staining or the dye SYTO-16, can detect early stages of
apoptosis in cells that still exclude 7-AAD [39]. We are not
aware of studies reporting apoptotic CECs using annexin-V
labeling, probably because this technique is not readily
incorporated in most CEC protocols and also the use of
frozen-thawed samples as used by some [10] precludes the
reliable assessment of apoptotic cells [39]. Therefore, we
have assessed the percentage of apoptotic CECs with
annexin-V (with ammonium chloride) protocol in several
RCC patients, separately from the main study protocol and
found that the number of early apoptotic CECs was con-
siderable (range 50–80% of CECs).
It should be noted that the endothelial cell marker VE-
cadherin was virtually absent in most of our CEC sub-
populations, while others reported it to be present on
mature CECs circulating in PB [40]. The lack of overt
surface VE-cadherin expression may reﬂect the immature
nature of these small CECs, or might also be explained by
internalization during or after loss of endothelial junctions
and detachment of the cells [41, 42].
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An alternative possibility may be that our CD45neg/
CD34bright CECs have endothelial progenitor (CEP) char-
acteristics, such as those recently ascribed to CD45neg/
CD34bright/CD133neg cells [14, 15, 43, 44]. A disturbed
homing of VEGFR positive CEPs into the tumor vasculature
caused by sunitinib might also contribute to the increase in
CD45neg/CD34bright CEC population. It is important to note
that the presence of a fraction of early apoptotic cells in the
population of CECs does not exclude a priory the presence of
endothelial progenitor cells, capable of highly proliferative
outgrowth, since the CD34bright/CD45neg/CD133neg cell
population from cord blood, which is the source of late
EOCs, also contained up to 60% apoptotic cells (F. Tim-
mermans, personal communication). This lends support to
the idea that the EPCs or EOC precursors circulating in
human PB might be in majority rather resident cells from
peripheral sites than from the bone marrow [45] and might
exist in multiple states of differentiation [46].
In addition to the increase in CECs, the soluble growth
factor VEGF increased during sunitinib exposure and partly
normalized 2 weeks after cessation of drug intake. This
ﬁnding is in accordance with previous ﬁndings on VEGF
receptor inhibition studies in mice and man [10, 47, 48]. The
mechanism for the VEGF increase is not known, but
according to the study of Ebos et al. [49], may reﬂect a direct
or indirect physiological response to receptor inhibition by
sunitinib. Indeed, we found also a prominent increase in EPO
during the ﬁrst cycle of sunitinib, consistent with the ﬁndings
of Ebos et al. [49] in sunitinib-treated mice. Functional
consequences of increased plasma EPO levels in sunitinib-
treated patients remain to be deﬁned.
The rapid return of VEGF and CECs to the pre-treat-
ment levels during the 2-weeks rest period is remarkable.
Studies by McDonald et al. [50] have pointed to the rapid
repopulation of vascular casts after cessation of anti-
angiogenic treatment of tumor-bearing animals. The
occurrence of a similar rapid resumption of vessel repair in
the RCC patients might contribute to the rapid normali-
zation of VEGF during the drug-free period.
The primary goal of this study was to investigate the
presence and pattern of change of CD34bright/CD45neg
CECs, separated from CD34bright/CD45pos HPCs in a
cohort of sunitinib-treated RCC patients. The question,
whether the observed changes in CECs or other circulating
subsets of cells are just a pharmacodynamic marker of
sunitinib activity or might have a predictive value, needs to
be addressed in a larger cohort of patients [51, 52].
In conclusion, this study shows that CD34bright CECs
and CD34bright HPCs counts change in opposite directions
by sunitinib; monocytes and HPC decrease and CECs
increase. CD34bright/CD133neg CECs might be detached
ECs and reﬂect sunitinib anti-vascular effects or might
include CEPs, which are potential targets.
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Sunitinib-induced changes in circulating endothelial cell-related
proteins in patients with metastatic renal cell cancer
Astrid A.M. van der Veldt1*, Laura Vroling1*, Richard R. de Haas1, Pieter Koolwijk2, Alfons J.M. van den Eertwegh1,
John B.A.G. Haanen3, Victor W.M. van Hinsbergh2, Henk J. Broxterman1 and Epie Boven1
1 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
2 Department of Physiology, VU University Medical Center, Amsterdam, The Netherlands
3 Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors are effective agents in the treatment of
metastatic renal cell cancer (mRCC). We here investigated whether inhibition of VEGFR signalin by sunitinib causes changes in
plasma proteins associated with tumor endothelium. Forty-three patients with mRCC received sunitinib 50 mg/day in a
4-weeks on 2-weeks off schedule. Sequential plasma samples were obtained before treatment (C1D1), on C1D14, on C1D28,
and on C2D1 before start of cycle 2. Plasma levels were assessed for VEGF, soluble vascular cell adhesion molecule-1
(sVCAM-1), soluble intercellular cell adhesion molecule-1 (sICAM-1), von Willebrand factor (vWF), circulating angiopoietin-2
(Ang-2) and soluble Tie-2 (sTie-2). Total tumor burden was calculated at baseline and at first evaluation. Progression-free
survival (PFS) and overall survival (OS) were determined. Tumor burden was positively associated with baseline circulating
Ang-2 [Spearman’s rho (q) 5 0.378, p 5 0.028] and vWF (q 5 0.417, p 5 0.008). During sunitinib treatment, circulating
Ang-2 and sTie-2 significantly decreased (p < 0.001 for both), plasma levels of sVCAM-1 and VEGF significantly increased
(p 5 0.022 and p < 0.001), whereas those of sICAM-1 and vWF remained stable. These protein changes had recovered on
C2D1. The reduction in circulating Ang-2 levels on C1D28 was positively correlated with the percentage decrease in tumor
burden (q 5 0.605; p 5 0.002). Baseline protein levels and subsequent changes were not associated with PFS or OS. In
conclusion, sunitinib-induced changes in Ang-2, sTie-2, sVCAM-1 and VEGF are related to the administration schedule, while
reduction in Ang-2 is also associated with decrease in tumor burden.
The development of antiangiogenic agents has signiﬁcantly
improved the perspectives of patients with metastatic renal
cell cancer (mRCC), known as a disease resistant against
standard chemotherapy.1 Currently, sunitinib is most widely
prescribed for ﬁrst-line treatment of mRCC.2 Sunitinib is an
oral tyrosine kinase inhibitor (TKI) which targets several
receptors including vascular endothelial growth factor recep-
tor (VEGFR)-1, -2 and -3, platelet-derived growth factor
receptors-a and -b, c-KIT and FLT3.3 Among these recep-
tors, VEGFR on tumor associated-endothelium is considered
to be a relevant target for sunitinib in RCC.4 In the majority
of RCC tumors, high levels of VEGF are being produced as a
result from a defective function of the von Hippel-Lindau tu-
mor suppressor gene.5
VEGF is a potent angiogenic factor which plays a key role
in tumor vascularization6 and is involved in proliferation,
migration and tube formation of endothelial cells as well as
endothelial cell survival.7 In response to VEGF, the endothe-
lium is activated and several proteins are expressed by endo-
thelial cells including vascular cell adhesion molecule-1
(VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1),
von Willebrand factor (vWF), angiopoietin-2 (Ang-2) and
Tie-2 (Tie-2).8–11 VCAM-1 and ICAM-1 are adhesion mole-
cules and their soluble ectodomains (sVCAM-1 and sICAM-
1) can be proteolytically released from the endothelial cell
surface into the circulation.12–14 Next to upregulation of
VCAM-1 and ICAM-1, VEGF is also known to activate exo-
cytosis of intracellular secretory granules in endothelial cells,
the so-called Weibel–Palade bodies, thereby releasing vasoac-
tive substances, including von Willebrand factor (vWF) and
Ang-2.8,9 The glycoprotein vWF is produced uniquely by en-
dothelial cells upon endothelial cell activation and is essential
for platelet adhesion to the subendothelial matrix after vascu-
lar injury. Ang-2 acts as a natural antagonist of its receptor
Tie-2.15 Endothelial shedding of soluble Tie-2 (sTie-2) is
stimulated by VEGF as well.10
Inhibition of VEGF(R) signaling may affect endothelial
cell activation and function, consequently leading to an
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altered release of endothelial cell-related proteins. Measure-
ment of these proteins in blood might be useful to monitor
the effect of anti-VEGF therapy in cancer patients. Because
sunitinib inhibits VEGFR signaling, we selected plasma
VEGF, sVCAM-1, sICAM-1, vWF, circulating Ang-2 and
sTie-2 in patients with mRCC to determine their value as
potential biomarkers. We not only assessed the effect of suni-
tinib on these circulating proteins but also explored whether
alterations in plasma protein levels were associated with the
change in tumor burden as well as treatment outcome.
Patients and Methods
Patients, treatment and evaluation
A total of 43 consecutive mRCC patients treated with suniti-
nib in two Dutch medical centers were included in this study.
Each patient signed a protocol-speciﬁc informed consent.
Collection of data was part of three protocols,16–19 which
were approved by the medical ethics review boards of the
institutes.
Sunitinib was administered orally at a dose of 50-mg
daily, consisting of 4 weeks on treatment followed by a 2-
weeks rest period in cycles of 6 weeks. Dose reductions of
sunitinib were allowed depending on the type and severity of
adverse events.
Computed tomography (CT) or magnetic resonance imag-
ing (MRI) was performed at baseline and every two to three
cycles of treatment to assess clinical response according to
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0 (RECIST).20 At baseline and at ﬁrst evaluation,
total tumor burden was calculated, which was deﬁned as the
sum of the longest diameters of all lesions, including primary
tumors.21,22
PFS was deﬁned as the time between the ﬁrst day of suniti-
nib and the date of progressive disease (PD) according to
RECIST version 1.0,20 or clear clinical evidence of PD. Overall
survival (OS) was the time between the ﬁrst day of sunitinib
treatment and the date of death or the date at which patients
were last known to be alive.
Blood samples analyses
Sequential plasma samples were obtained before treatment
with sunitinib deﬁned as cycle 1 day 1 (C1D1), on cycle
1 day 14 (C1D14), on cycle 1 day 28 (C1D28), and after
2 weeks of rest on cycle 2 day 1 (C2D1). At the time of
blood sampling, the ﬁrst 2-mL blood was discarded before
collection of 7 mL of EDTA blood. Within 30 min after col-
lection, samples were centrifuged at 3,000 rpm for 10 min at
4C. Plasma was removed and stored immediately at 80C
until analysis.
Concentrations of VEGF, sVCAM-1 and sICAM-1 were
assessed with Quantikine enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems). A commercially available ELISA
for vWF antigen was obtained from American Diagnostica
(Greenwich, CT). Plasma concentrations of circulating Ang-2
were measured with the human Ang-2 DuoSet ELISA Develop-
ment kit (R&D Systems, Minneapolis, MN). According to the
ELISA kits the range of protein levels in normal volunteers was
below 115 pg/mL for VEGF, in the range of 349–991 ng/mL
for sVCAM-1, 100–307 ng/mL for sICAM, 630–1,950 mU/mL
for vWF23 and 27–287 pg/mL for circulating Ang-2.24
Samples from the same patient were pipetted into the
same 96-wells plate. Samples were run in duplicate and the
mean value was recorded. In 20 patients, sTie-2 levels (Quan-
tikine ELISA kit; R&D Systems) were measured on C1D1
and on C1D14. These patients were selected on the basis of
the highest percentage change in plasma levels of circulating
Ang-2 on C1D14 when compared to that on C1D1. Accord-
ing to the ELISA kit, the range of sTie-2 was in the range of
17–36 ng/mL in normal volunteers.
Of all 43 patients, blood samples were available on C1D1
and on C1D14, while on C1D28 and on C2D1 blood samples
were available in 33 and 35 patients, respectively. Reasons for
missing blood samples were a temporary or permanent
discontinuation due to sunitinib-related adverse events or
evident progression of disease. In 5 of 43 patients, the
amount of plasma sample was limited and only VEGF and
vWF levels could be measured.
Statistics
Statistical analysis was performed using SPSS software (SPSS
for Windows 16.0, SPSS, Chicago, IL). Data were expressed
as median with range. The Mann–Whitney U test and the
Kruskal–Wallis test were used to examine the associations
between plasma protein levels and patient characteristics.
Changes in variables were expressed as the percentage change
from baseline values. The Wilcoxon Signed Ranks test was
used to compare plasma levels on C1D14, C1D28 and C2D1
with those at baseline. Correlations between continuous data
sets were analyzed using Spearman’s correlation test. In addi-
tion, Fisher’s exact test was performed to determine associa-
tions between categorical variables. A two-tailed probability
value of p < 0.05 was considered signiﬁcant.
For PFS and OS, data collection was closed on August 1,
2010. PFS and OS were calculated using the Kaplan–Meier
method. All patient characteristics were tested univariately
against PFS and OS using Kaplan–Meier and Cox-regression
analysis, depending on the tested variables. The plasma pro-
tein levels at baseline and their changes on day 14 were
dichotomized by median splitting followed by univariate test-
ing against PFS and OS using Kaplan–Meier analysis. Log-
rank test was used to test the differences between survival
curves. Candidate variables with p value  0.05 were selected
for the multiple Cox-regression survival analysis with PFS
and OS as depending variables. Additional patient character-
istics were introduced in the multivariate analyses based on
univariately tested results if p value  0.05. All results from
the multivariate analyses with p values < 0.05 were consid-
ered signiﬁcant. The analyses were preplanned before the
study started. Since this was an explorative study, no correc-
tion for multiple testing was done.
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Results
Patient characteristics and treatment
Table 1 summarizes the baseline characteristics of the 43
patients. Thirty-eight (88%) patients had clear cell histology
and 12 patients (28%) had a primary tumor in situ. Six
(14%) patients had one metastatic site, 10 (23%) patients had
two metastatic sites and 27 (63%) patients had at least three
metastatic sites. According to the Memorial Sloan-Kettering
Cancer Center (MSKCC) prognostic criteria25 most patients
were categorized into the intermediate and poor risk group
(each 44% of patients), whereas 12% of the patients was cate-
gorized into the favorable risk group.
According to RECIST, seven patients achieved a partial
response (PR), 21 patients had stable disease (SD), 13 patients
had PD and two patients could not be evaluated as a result of
early termination due to sunitinib-related adverse events. At
the time of the analysis, only three (7%) patients were still
alive. Overall, the median PFS time was 7.0 months (range,
0.5–47.1 months) and the median OS time was 12.3 months
(range, 0.5–41.1 months). In comparison with a previously
published compassionate use cohort of sunitinib-treated
mRCC patients,26 the median PFS and OS in this study were
relatively short, which can be explained by a higher number of
patients in the MSKCC poor risk group as well as a lower num-
ber of patients in the favorable risk group.
When all measurable lesions were taken into account
(n ¼ 40), the median tumor burden was 138 mm (range, 37–
321 mm). Total tumor burden could not be measured
adequately in three out of 43 patients, as the disease was
mainly localized in the bone. In addition, six patients could
not be evaluated for the effect of sunitinib on total tumor
burden due to early termination (n ¼ 2), PD with massive
increase in the number of metastases precluding adequate
measurements (n ¼ 2), and missing CT scan at ﬁrst evalua-
tion due to contraindications for administration of intrave-
nous contrast (n ¼ 2). In the remaining 34 patients, sunitinib
decreased the median tumor burden from 136 mm (range,
37–321 mm) to 128 mm (range, 29–262 mm; p ¼ 0.192)
with a median decrease of 9% (range, 48 to þ74%).
Of the clinical characteristics, the nonclear cell subtype
and a higher number of metastatic sites were prognostic fac-
tors for a poor PFS (log rank ¼ 8.328 and 11.115; p ¼ 0.004
and 0.004, respectively) and poor OS (log rank ¼ 14.160 and
7.351; p < 0.001 and p ¼ 0.025, respectively). In addition, a
higher number of MSKCC risk factors was prognostic for a
poor OS (log rank ¼ 7.840; p ¼ 0.020).
Plasma protein concentrations at baseline
A considerable number of mRCC patients had higher plasma
levels of VEGF, sVCAM-1, sICAM-1, vWF and Ang-2 than
those in healthy volunteers reported for the respective assays
(see Patients and Methods section). The median level of VEGF
was 97 pg/mL (range, 21–650 pg/mL). The median levels of
the soluble adhesion molecules sVCAM-1 and sICAM-1 were
762 ng/mL (range, 325–3,458 ng/mL) and 295 ng/mL
(range, 114–850 ng/mL), respectively. The median levels of
vWF and circulating Ang-2 were 2,281 mU/mL (range, 204–
4,049 mU/mL) and 1,336 pg/mL (range, 353–3,503 pg/mL),
respectively. Additional measurements of the soluble receptor
of Ang-2, sTie-2, were performed in 20 patients with relatively
high levels of Ang-2. The sTie-2 level at baseline (median, 48
ng/mL; range, 25–114 ng/mL) was elevated as compared to
that in healthy volunteers.
Table 1. Patient characteristics
Characteristic N %
Median age (years) 60
Range 20–84
Sex
Male 27 63
Female 16 37
ECOG performance status1
0 18 42
1 15 35
2 6 14
3 4 9
Histological subtypes
Clear cell 38 88
Nonclear cell 5 12
Previous treatment regimen
None 22 51
Cytokine-based therapy 18 42
Cytokine-based therapy and
antiangiogenic therapy
3 7
Previous nephrectomy
No 12 28
Yes 31 72
Previous radiation therapy
No 28 65
Yes 15 35
No. of metastatic sites
1 6 14
2 10 23
3 27 63
MSKCC risk factors2
0 (favorable) 5 12
1–2 (intermediate) 19 44
3 (poor) 19 44
1ECOG, Eastern Cooperative Oncology Group. 2Risk groups according to
Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria
[based on the ﬁve risk factors: low Karnofsky performance status
(<80%), high LDH (>1.5 times the upper limit of normal), low serum
hemoglobin, high corrected serum calcium (>10 mg/dL), and time
from initial diagnosis to treatment of less than 1 year].25
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Baseline plasma protein concentrations and patient
characteristics
Baseline plasma protein levels were assessed for a possible rela-
tionship with patient characteristics (Table 2). In this analysis,
sTie-2 was not taken into account because of limited sampling.
Patients with a primary tumor in situ had higher circulating
Ang-2 levels than patients with a previous nephrectomy
[median of 2,217 pg/mL (range, 1,157–3,503 pg/mL) vs.
median of 1,318 pg/mL (range, 353–3,466 pg/mL); p ¼ 0.007].
In addition, signiﬁcantly higher circulating Ang-2 levels were
measured in patients who were categorized into higher
MSKCC risk groups (p ¼ 0.020). Furthermore, patients with a
primary tumor in situ had higher vWF levels and patients with
more metastatic sites had higher VEGF levels, but these ﬁnd-
ings were not signiﬁcant (p ¼ 0.072 and 0.052, respectively).
Higher baseline levels of sICAM-1 and vWF were also
measured in patients who belonged to higher MSKCC risk
groups, but differences with levels in patients in lower risk
groups were not signiﬁcant (p ¼ 0.071 and 0.073, respectively).
The levels of sVCAM-1 were not associated with patient
characteristics.
In the assessment of a possible relationship between
plasma proteins and the extent of disease, we hypothesized
that total tumor burden may be a better reﬂection of disease
extent than the MSKCC criteria. Indeed, larger tumor burden
was associated with higher levels of circulating Ang-2 (Spear-
man’s q ¼ 0.378, p ¼ 0.028, n ¼ 34) and vWF (Spearman’s
q ¼ 0.417, p ¼ 0.008, n ¼ 39). There were no associations
between tumor burden and plasma levels of VEGF, sVCAM-
1 and sICAM-1. In further analysis, we determined whether
there was a relationship between circulating Ang-2 levels and
other proteins. It appeared that circulating Ang-2 levels were
positively associated with most proteins, being levels of
VEGF (Spearman’s q ¼ 0.436, p ¼ 0.007; n ¼ 37), sICAM-1
(Spearman’s q ¼ 0.371, p ¼ 0.024; n ¼ 37), and vWF (Spear-
man’s q ¼ 0.392, p ¼ 0.018; n ¼ 36). In the separate analysis
in 20 patients with relatively high levels of circulating Ang-2,
these were also positively associated with sTie-2 levels
(Spearman’s q ¼ 0.402, p ¼ 0.079, n ¼ 20).
Effect of sunitinib on circulating plasma proteins
Figure 1 shows the alterations in plasma levels of the circu-
lating proteins during sunitinib treatment in mRCC patients.
The circulating levels of sICAM-1 and vWF did not signiﬁ-
cantly change during treatment with sunitinib.
Sunitinib induced a signiﬁcant rise in plasma levels of
VEGF and sVCAM-1. The median VEGF levels increased
from 97 pg/mL (range, 21–650 pg/mL) at baseline to 312 pg/
mL (range, 57–1,722 pg/mL) on C1D14 (p < 0.001) and to
235 pg/mL (range, 53–1,499 pg/mL) on C1D28 (p < 0.001).
Table 2. Baseline plasma proteins vs. baseline characteristics
Characteristic
No. of
cases
Circulating plasma proteins at baseline1
VEGF (pg/mL) sVCAM-1 (ng/mL) sICAM-1 (ng/mL) vWF (mU/mL) Ang-2 (pg/mL)
Sex2
Male 27 102 (21–650) 782 (325–3,458) 356 (114–850) 2,233 (204–4,049) 1,246 (618–3,503)
Female 16 91 (29–331) 707 (416–1,503) 288 (179–527) 2,354 (1,019–3,756) 1,445 (353–3,466)
Histological subtypes2
Clear cell 38 97 (21–363) 762 (344–3,458) 295 (179–850) 2,233 (204–3,702) 1,318 (353–3,466)
Nonclear cell 5 118 (37–191) 734 (325–1,238) 346 (114–530) 2,701 (1,898–4,049) 2,217 (1,157–3,503)
Previous nephrectomy2
Yes 31 97 (29–650) 762 (344–1,365) 295 (179–850) 2,139 (204–4,049) 1,171 (353–3,135)**
No 12 98 (21–363) 714 (325–3,458) 304 (114–626) 2,749 (716–3,756) 1,781 (1,115–3,503)**
No. of metastatic sites3
1 6 44 (21–99) 718 (532–1,299) 242 (187–376) 1,656 (204–2,859) 1,134 (773–3,819)
2 10 118 (75–313) 782 (501–1,365) 298 (209–527) 2,261 (1,019–3,728) 1,604 (708–3,075)
3 27 91 (37–650) 781 (325–3,458) 334 (114–850) 2,341 (1,146–4,049) 1,369 (353–3,503)
MSKCC risk factors3,4
0 (favorable) 5 91 (29–118) 707 (636–822) 291 (187–356) 1,311 (204–2,859) 708 (353–1,372)*
1–2 (intermediate) 19 102 (21–331) 693 (344–1,503) 286 (179–441) 2,182 (716–3,756) 1,323 (430–3,466)*
3 (poor) 19 115 (29–650) 932 (325–3,458) 400 (114–850) 2,582 (1,583–4,049) 1,669 (739–3,503)*
*p  0.05, **p  0.01.
1Data are reported as median (range). 2Mann-Whitney U test was used to examine associations between plasma proteins and patient
characteristics. 3Kruskal–Wallis was used to examine associations between plasma proteins and patient characteristics. 4Risk groups according to
Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria [based on the ﬁve risk factors: low–Karnofsky performance status (<80%), high
LDH (>1.5 times the upper limit of normal), low serum hemoglobin, high corrected serum calcium (>10 mg/dL), and time from initial diagnosis to
treatment of less than 1 year].25
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The median sVCAM-1 levels increased from 762 ng/mL
(range, 325–3,458 ng/mL) at baseline to 931 ng/mL (range,
335–3,095 ng/mL) on C1D14 (p ¼ 0.022) and to 994 ng/mL
(range, 507–2,336 ng/mL) on C1D28 (p ¼ 0.002). After the
2-weeks rest period (C2D1), both VEGF levels and sVCAM-1
levels grossly returned to baseline values, being 114 pg/mL
(range, 34–412 pg/mL; p ¼ 0.964) and 870 ng/mL (range,
417–1,988 ng/mL; p ¼ 0.196), respectively.
Sunitinib induced a signiﬁcant decline in levels of circulat-
ing Ang-2 and sTie-2. Two weeks after the start of treatment,
the median level of circulating Ang-2 had signiﬁcantly
decreased from 1,336 pg/mL (range, 353–3,503 pg/mL) to
958 pg/mL (0–3,534 pg/mL; p < 0.001) and that of sTie-2
from 48 ng/mL (range, 25–114 ng/mL) to 37 ng/mL (range,
21–66 ng/mL; p < 0.001). On C1D28, the change in Ang-2
persisted (median, 884 pg/mL; range, 206–2,746 pg/mL;
p < 0.001), but on C2D1 the levels of circulating Ang-2 had
recovered and had grossly returned to baseline values (median,
1,232 pg/mL; range, 229–3,771 pg/mL; p ¼ 0.178).
We next explored whether the signiﬁcant changes in the
concentration of one protein in the 4 weeks of sunitinib
treatment were associated with that of another among
patients. On C1D14, the percentage change in levels of
circulating Ang-2 was negatively associated with the percent-
age change in the levels of VEGF (Spearman’s q ¼ 0.457,
p ¼ 0.005, n ¼ 36). Although changes in sTie-2 were also
negatively associated with changes in VEGF (Spearman’s
q ¼ 0.456, p ¼ 0.043, n ¼ 20), there was no association
between the percentage change in the levels of circulating
Ang-2 and that of the other proteins, in particular not
Figure 1. Plasma levels of circulating markers at baseline (C1D1), deﬁned as cycle 1 day 1 (C1D1), on C1D14, C1D28, and on C2D1 in
patients with mRCC treated with sunitinib 50 mg/day for 4 weeks in a 6-week cycle. Horizontal bars represent median values. *p  0.05,
compared to baseline value. **p  0.01, compared to baseline value. ***p  0.001, compared to baseline value.
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between circulating Ang-2 and sTie-2 (C1D14, Spearman’s
q ¼ 0.080, p ¼ 0.738, n ¼ 20).
Associations between changes in plasma proteins and
tumor burden
We assessed the effect of sunitinib on total tumor burden at
ﬁrst evaluation in relation to changes in plasma proteins.
There were no associations between changes in tumor burden
and the increase in plasma levels of VEGF or sVCAM-1. Of
interest, the percentage decrease in circulating Ang-2 on
C1D28 was positively associated with the percentage decrease
in tumor burden (Spearman’s q ¼ 0.605, p ¼ 0.002; n ¼ 24;
Fig. 2). When the outlyer with 92% increase in circulating
Ang-2 was excluded, the association was still positive
(Spearman’s q ¼ 0.551, p ¼ 0.006; n ¼ 23). In addition,
there was a trend on C1D14 (Spearman’s q ¼ 0.330,
p ¼ 0.087, n ¼ 28) and on C2D1 (Spearman’s q ¼ 0.367,
p ¼ 0.060, n ¼ 27). In patients with a > 30% decrease in
total tumor burden (n ¼ 6) the circulating Ang-2 levels on
C2D1 had not recovered to baseline values. On C2D1, the
median absolute decrease in circulating Ang-2 in these
patients was 363 pg/mL (range, 668 to 903 pg/mL), while
that in patients without clinically relevant tumor reduction
(n ¼ 21) was þ7 pg/mL (range, 1,293 to 414 pg/mL;
Mann–Whitney U test, p ¼ 0.064). In addition, patients with
PR as best response according to RECIST had a signiﬁcantly
larger decrease in circulating Ang-2 on C1D28 than that in
the other patients (Mann–Whitney U test, p ¼ 0.041).
Remarkably, one patient showed an absolute decrease of
circulating Ang-2 of 1,295 pg/mL on C1D28, but an absolute
increase of 903 pg/mL on C2D1. Clinically, this patient expe-
rienced a rapid tumor rebound during the rest period of the
ﬁrst treatment cycle. Consequently, in the subsequent cycles
the sunitinib dose was changed to 37.5 mg per day in a con-
tinuous schedule and the patient showed a 33% reduction in
total tumor burden at ﬁrst evaluation. For the purpose of
illustration, Figure 3 shows examples of CT images in a
responding and a nonresponding patient.
Plasma proteins and clinical outcome
The associations between circulating protein levels and clini-
cal outcome were explored. Baseline protein levels or suniti-
nib-induced changes in protein levels were not associated
with PFS. In univariate analysis, only pretreatment sVCAM-1
plasma levels above the median value (762 ng/mL) were asso-
ciated with poor OS (log rank ¼ 5.219; p ¼ 0.022). Baseline
characteristics entered into the multivariate Cox model for
OS analysis included histological subtype, the number of
metastatic sites, and MSKCC risk factors. In multivariate
analyses, pretreatment plasma levels of sVCAM-1 were no
longer predictive of OS (hazard ratio: 1.835; 95% CI, 0.825–
4.079; p ¼ 0.136).
Discussion
In this study, we explored the effect of sunitinib on levels of
circulating proteins involved in VEGF-regulated endothelial
cell activation and function including VEGF, sVCAM-1,
sICAM-1, vWF, Ang-2 and sTie2. At baseline, mRCC
patients showed elevated plasma levels of all proteins as com-
pared with those reported in healthy volunteers. Most of
these protein levels were related to factors associated with the
extent of the disease. At baseline, total tumor burden was
positively associated with vWF and circulating Ang-2. In
addition, levels of circulating Ang-2 were positively associated
with VEGF, sICAM-1, vWF and sTie-2. Treatment with suni-
tinib induced an increase in VEGF and sVCAM-1, a decrease
in circulating Ang-2 and sTie-2, while levels of sICAM-1 and
vWF were not affected. After the 2-weeks rest period,
changes in circulating proteins had grossly recovered. The
change in circulating Ang-2 levels was positively associated
with the percentage change in total tumor burden. Sunitinib-
induced changes in plasma protein levels were not signiﬁ-
cantly associated with PFS or OS.
At baseline, plasma levels of all selected proteins were
increased in patients with mRCC as compared with those in
healthy volunteers. Elevated plasma levels of VEGF, sVCAM-
1, sICAM-1 and sTie2 were grossly comparable with those
Figure 2. Association between percentage change in total tumor burden at ﬁrst evaluation and percentage change in circulating Ang-2
levels on C1D28 (a) and C2D1 (b) in patients with mRCC treated with sunitinib 50 mg/day for 4 weeks in a 6-weeks cycle.
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reported in other mRCC cohorts.13,27–29 The high-plasma
level of circulating Ang-2, however, is a new ﬁnding in
mRCC. In RCC tumor tissue, expression of Ang-2 has been
described predominantly on tumor-associated endothe-
lium,30,31 but Ang-2 expression has been observed in RCC
tumor cells as well.30 Currently, growing evidence indicates
that Ang-2 plays an important role in tumor angiogenesis.32
Ang-2 can collaborate with VEGF to induce angiogenesis in
Figure 3. Examples of CT images in two patients with mRCC treated with sunitinib. (a–d) A responding patient with a primary tumor
in situ (a, arrow), multiple lung and subcutaneous metastases (c, arrows) at baseline and at ﬁrst evaluation during sunitinib (b, d).
The patient showed a 71% decrease in circulating Ang-2 on C1D28 and a 33% decrease in total tumor burden at ﬁrst evaluation. (e,
f) A nonresponding patient with lung metastases at baseline (e, arrow) and at ﬁrst evaluation during sunitinib (f ). The patient showed a
92% increase in circulating Ang-2 on C1D28 and a 49% increase in total tumor burden at ﬁrst evaluation.
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a synergistic manner33 and can facilitate the angiogenic pro-
cess regulated by tumor-derived VEGF between existing host
vessels that co-opt with tumor cells.32 In our study, circulat-
ing Ang-2 was the strongest factor associated with the extent
of disease, which was characterized by a concurrent primary
tumor in situ, a higher risk group according to MSKCC and
a larger total tumor burden. Nevertheless, levels of circulating
Ang-2 or any other proteins were not independently associ-
ated with outcome in sunitinib-treated mRCC patients. In
contrast to these ﬁndings, other studies have shown a corre-
lation between high levels of circulating Ang-2 and a poorer
prognosis in melanoma patients34 and in patients with
advanced colorectal cancer treated with bevacizumab.35
Although baseline-circulating Ang-2 was not prognostic for
outcome in our mRCC patients, a decrease in circulating
Ang-2 appeared to be predictive for sunitinib-induced reduc-
tion in total tumor burden.
Levels of circulating Ang-2 and sTie-2 both declined after
sunitinib treatment. Previous studies have shown that suniti-
nib and bevacizumab cause downregulation of Ang-2 mRNA
in human tumor cells including glioma and rectal cancer
xenografts.36,37 These reports and this study suggest that
inhibitors of VEGF(R) signaling may decrease Ang-2 expres-
sion in tumors, which subsequently results in a decline of cir-
culating Ang-2. In addition, inhibition of VEGF(R) signaling
may reduce shedding of sTie-2, which is exclusively expressed
on endothelial cells as described for RCC,30 thereby decreas-
ing endothelial cell binding of Ang-2 to its receptor.
As conﬂicting data have been published on tissue localiza-
tion of Ang-2 expression in malignancies,30,35 we further
explored whether the changes in circulating Ang-2 were pos-
sibly of endothelial origin. Hence, HUVECS were treated
with sunitinib to determine changes in Ang-2 in supernatant.
Although sunitinib had an inhibitory effect on HUVEC pro-
liferation, secretion of Ang-2 by these cells was not affected
(unpublished data). Since plasma levels of vWF, which is also
stored in the Weibel–Palade bodies of endothelial cells, were
not affected in our patients, these ﬁndings suggest that suniti-
nib mostly reduced Ang-2 production from tumor cells. In
accordance, we found an association between the decrease
in circulating Ang-2 levels and a reduction in total tumor
burden in sunitinib-treated mRCC patients.
Apart from circulating Ang-2, sunitinib treatment resulted
in changes in plasma levels of VEGF and sVCAM-1. As
expected, VEGF levels increased after administration of suni-
tinib. A reactive rise in plasma VEGF is usually observed
upon treatment with TKIs targeting VEGFR.38 In a preclini-
cal study, sunitinib increased plasma VEGF levels in a dose-
dependent manner, which was caused by a tumor-dependent
response as well as a systemic tumor-independent response.39
Currently, the origin of the tumor-independent release of
VEGF has not been identiﬁed. In this study, sunitinib treat-
ment also induced a rise in sVCAM-1, while plasma levels of
the other soluble adhesion molecule, sICAM-1, remained
stable. Similarly, an increase in sVCAM-1 has been reported
after bevacizumab-based therapy,40,41 while sICAM-1 levels
were not notably affected.41 The increase of sVCAM-1 associ-
ated with inhibition of VEGF(R) has yet to be clariﬁed. It
has been described that nitric oxide (NO), which is produced
as a result of VEGFR-2 signaling,42 represses gene transcrip-
tion of VCAM-1 in human saphenous vein endothelial
cells.43 This observation suggests that sunitinib may promote
endothelial expression of VCAM-1 by inhibiting the repres-
sing function of NO. In contrast, it has been suggested that
the NO-dependent pathway is not involved in VEGF-induced
mRNA expression of VCAM-1 in human umbilical vein
endothelial cells (HUVECS).11
The results of this study indicate that sunitinib, a promis-
cuous drug against multiple tyrosine kinases, affects Ang-2
signaling, which may reﬂect an additional beneﬁcial effect of
sunitinib in patients with mRCC. In these patients, circulat-
ing Ang-2 levels are elevated and are associated with the
extent of disease. During sunitinib treatment, the decline in
circulating Ang-2 early predicts reduction in tumor burden.
Presently, antiangiogenic drugs that selectively target the
Ang-2 pathway are under development.44 Recently, AMG
386, a drug that selectively inhibits the interaction of Ang-1
and Ang-2 with Tie-2, has shown promising antitumor activ-
ity in patients with advanced solid tumors.45,46 These Ang-2
inhibitors may also be promising agents for the treatment of
RCC, as mRCC patients show increased levels of circulating
Ang-2.
In conclusion, sunitinib-induced changes in Ang-2, sTie-2,
sVCAM-1 and VEGF are related to the administration sched-
ule of the drug, while reduction in Ang-2 is also associated
with decrease in tumor burden. Our ﬁndings warrant further
studies in mRCC patients to clarify the role of the Ang-2
pathway in sunitinib treatment and efﬁcacy.
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Reduction in skin microvascular density and changes
in vessel morphology in patients treated with sunitinib
Astrid A.M. van der Veldta, Michiel P. de Boerb, Epie Bovena, Etto C. Eringac,
Alfons J.M. van den Eertwegha, Victor W. van Hinsberghc, Yvo M. Smuldersb
and Erik H. Serne´b
Hypertension is a common side effect in cancer patients
treated with inhibitors of vascular endothelial growth
factor/vascular endothelial growth factor receptor-2
signaling and may represent a marker of clinical benefit.
Functional rarefaction (a decrease in perfused
microvessels) or structural rarefaction (a reduction in
anatomic capillary density) may play an important role in
the development of hypertension. We investigated whether
sunitinib caused impairment of microvascular function
and/or reduction of capillary density in patients with
metastatic renal cell cancer (mRCC). Sixteen mRCC patients
were treated with sunitinib (50mg/day). Assessments of
24-h ambulatory blood pressure, microvascular endothelial
function by laser Doppler fluxmetry, and capillary density by
capillary microscopy were performed at baseline and days
14 and 28. Median blood pressure had increased on day 14
(systolic 10mmHg, P<0.01 and diastolic blood pressure
8mmHg, P<0.01). Capillary density had decreased from 69
to 61 capillaries/mm2 (P<0.01). This decrease was related
to the increase in systolic and diastolic blood pressure
(r= –0.57, P<0.05 and r= –0.68, P<0.01, respectively).
A more pronounced decrease in capillary density was
associated with increased visibility of the subpapillary
plexus (P=0.041). Preliminary findings indicated that
median progression-free survival was significantly
prolonged in patients with a greater than 6 capillaries/mm2
decrease in density as compared with patients with a
less pronounced decrease (P=0.044). In conclusion,
reduction in skin capillary density is associated with a rise
in blood pressure during sunitinib therapy and, by itself,
might be useful as a predictive marker of clinical
outcome. Anti-Cancer Drugs 21:439–446 	c 2010 Wolters
Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
The central role of angiogenesis in promoting tumor
progression and metastases formation is now well
appreciated and is governed by a balance between
stimulators and inhibitors of angiogenesis, a process by
which new capillaries are formed from preexisting
blood vessels [1]. Vascular endothelial growth factor
(VEGF)/VEGF receptor-2 (VEGFR-2) signaling constitu-
tes the predominant regulatory pathway for develop-
mental and tumor angiogenesis. Therapeutic targeting of
VEGF/VEGFR-2 signaling with bevacizumab, an anti-
VEGF monoclonal antibody, or sunitinib and sorafenib,
both receptor tyrosine kinase inhibitors targeting
VEGFR-2, have provided survival benefit in specified
cancer patients [1].
Arterial hypertension is a commonly reported side effect
in trials with inhibitors of VEGF/VEGFR-2 signaling,
such as bevacizumab and sunitinib [2,3]. Although con-
flicting data have been reported [4], the occurrence of
antiangiogenic treatment-related hypertension seems to
be a predictive marker for clinical outcome [5–8]. As an
example, bevacizumab-induced hypertension was asso-
ciated with favorable progression-free survival (PFS) in
advanced colorectal cancer patients [8]. In addition, the
occurrence of hypertension, particularly grade 3, was
associated with better treatment response to sunitinib in
metastatic renal cell cancer (mRCC) [7]. These findings
suggest that the increase in blood pressure (BP) or
underlying causative mechanisms may represent clinical
biomarkers of treatment efficacy.
The mechanisms by which antiangiogenic therapy can
increase BP are not yet fully understood. Proposed
mechanisms include reduced formation of nitric oxide
by endothelial cells, a reduced responsiveness of vas-
cular smooth muscle cells to nitric oxide, an increased
production of or reaction to vasoconstricting stimuli, and
a reduction in microvascular density (rarefaction)
[9–11]. Microvessels, that is, arterioles and capillaries,
are a major contributor to total peripheral vascular
resistance. Functional rarefaction (a decrease in perfused
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microvessels) or structural rarefaction (a reduction in
anatomic capillary density) may play an important role in
the development of hypertension [12,13].
We investigated in mRCC patients whether sunitinib,
a small molecule tyrosine kinase inhibitor of VEGFR-1,
2 and 3, platelet-derived growth factor receptor-a and b,
c-KIT, and FLT3, impairs microvascular function and
induces capillary rarefaction, which in turn might be
associated with BP rise and clinical outcome in patients
with mRCC.
Methods
Patients, treatment, and evaluation
Patients treated with sunitinib for mRCC from March
2006 to October 2007 were enrolled. Most patients had
been included in an expanded access program until
September 2006 [14] after which sunitinib was registered
and available on doctor’s prescription. Each participant
signed an institutional review board-approved protocol-
specific informed consent in accordance with national and
institutional guidelines. Sunitinib was administered orally
at a dose of 50mg daily, consisting of 4 weeks of treatment
followed by a 2-week rest period in cycles of 6 weeks.
Computed tomography was performed at baseline and
for every two to three cycles of treatment to assess clinical
response according to Response Evaluation Criteria in
Solid Tumors (RECIST) [15]. PFS was the time between
the first day of sunitinib and the date of progressive
disease on computed tomography, or clear clinical evi-
dence of progressive disease. Overall survival (OS) was
the time between the first day of treatment and the
date of death or the date at which patients were last
known to be alive.
Blood pressure measurements
At baseline, and days 14 and 28 ambulatory BP monitoring
(Spacelabs 90207, Redmond, Washington, District of
Columbia, USA) was performed to obtain 24-h recordings
of BP and heart rate [16]. Measurements were made at
the nondominant arm with appropriately sized cuffs. The
monitors measured BP and heart rate every 20min from
7:00 to 22:00 h and every 30min from 22:00 to 7:00 h.
Hypertension was graded according to National Cancer
Institute-Common Toxicity Criteria Version 3.0.
In patients with preexisting antihypertensive medication,
the dose and schedule of antihypertensive treatment
were not changed during the first 28 days of sunitinib
treatment unless the patients developed grade 3
hypertension requiring antihypertensive treatment. The
latter precluded patients from subsequent skin micro-
vascular measurements.
Skin microvascular measurements
Baseline, day-14 and day-28 skin microvascular measure-
ments were made as described earlier [16]. Microvascular
studies were carried out in the morning in a temperature-
controlled room (median: 22.91C, range: 21.3–25.11C)
after 30min of acclimatization. Patients had abstained
from caffeine, alcohol, smoking, and meals overnight.
Nail fold capillaries in the dorsal skin of the third finger
were visualized by a capillary microscope. Capillary density
was defined as the number of erythrocyte-perfused
capillaries per mm2. Baseline capillary density represented
the number of functional capillaries. The number of
capillaries was counted off-line by an experienced investi-
gator (MPdB.) from a videotape. The investigator count-
ing the capillaries was blinded to patients’ history and
clinical outcome. The day-to-day coefficient of variation of
baseline capillary density was 2.3±1.8% [17].
After baseline measurements, venous occlusion was
applied with the digital cuff inflated to 60mmHg for
60 s, to expose a maximal number of perfused capillaries.
Venous occlusion is supposed to reflect structural
capillary density.
Using the same visual fields as those used during baseline
measurements, the capillaries were counted in the 60-s
recordings. The day-to-day coefficient of variation of peak
capillary density during venous congestion was 9.5±
7.1% [12]. Venous occlusion at 60mmHg for 120 instead
of 60 s did not further increase the number of visible
capillaries [12].
Endothelium-dependent and endothelium-independent
vasodilatation of finger skin microcirculation were eval-
uated with laser Doppler fluxmetry combined with
iontophoresis of acetylcholine (Ach, for endothelium-
dependent vasodilatation) and sodium nitroprusside
(SNP, for endothelium-independent vasodilatation) as
described earlier [16]. ACh (1%, Miochol; Novartis, Basel,
Switzerland) mediates vasodilatation through the gen-
eration of nitric oxide and prostanoids in the endothe-
lium. SNP (0.1%, Nipride; Roche, Basel, Switzerland) is a
nitric oxide donor, acting directly on smooth muscle cells
to induce relaxation. Laser Doppler flux was measured on
the middle phalanx of the second and fourth digits with
the Periflux 4000 system (Perimed, Stockholm, Sweden)
and expressed as arbitrary perfusion units. A protocol of
multiple fixed doses (current intensity delivery time)
was used, resulting in an incremental dose–response
curve. Skin temperature was monitored. Day-to-day
reproducibility for iontophoresis of ACh and SNP was
15.9±8.4 and 13.9±9.0%, respectively [16].
Statistical analysis
Data are expressed as median with range. Statistical
analysis was performed using SPSS software (SPSS for
Windows 15.0; SPSS, Inc., Chicago, Illinois, USA). The
Wilcoxon signed-rank test was used to compare BP and
microvascular variables on days 14 and 28 with baseline.
The relationship between changes in these variables was
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assessed by the Spearman correlation test. In addition,
Fisher’s exact test was performed to determine asso-
ciations between categorical variables. The association
between BP rise and microvascular rarefaction on the one
hand and PFS and OS on the other were calculated with
the Kaplan–Meier method. For survival analysis, data
collection was closed on 1 March 2009. For Fisher’s exact
and Kaplan–Meier analyses, changes in vascular para-
meters on day 14 were dichotomized by median splitting.
A two-tailed probability value of P less than 0.05 was
considered significant.
Results
Patients’ characteristics and treatment effects
Patients’ characteristics and treatment effects are sum-
marized in Table 1.
During the first cycle, all 16 patients received 50mg
sunitinib daily. All patients underwent measurements
of BP and microvascular function at baseline and on
day 14, whereas 11 patients also had measurements on
day 28. Reasons for dropout were a temporary (n=3) or
permanent discontinuation (n=1) of treatment owing to
sunitinib-related adverse events. Another patient was
excluded from the analysis after day 14 because of grade 3
hypertension requiring antihypertensive medication.
Blood pressure increases during sunitinib treatment
During sunitinib treatment 24-h systolic BP (SBP),
diastolic BP (DBP) and mean arterial BP (MAP)
significantly increased on days 14 and 28, whereas the
24-h heart rate showed a significant decrease (Table 2).
On day 14, the median increase in SBP, DBP and
MAP were 10mmHg (range – 8 to +33mmHg), 8mmHg
(range – 7 to +24mmHg) and 9mmHg (range – 6 to
+27mmHg), respectively. Only one patient developed
grade 3 hypertension (170/107mmHg) and another two
patients had grade 2 hypertension (both 24-h DBP
increase by >20mmHg). On day 28, SBP, DBP and
MAP had further increased with a median increase
of 13mmHg (range, – 9 to +27mmHg), 10mmHg
(range – 7 to +22mmHg) and 12mmHg (range – 7 to
+24mmHg), respectively.
Capillary density decreases during sunitinib therapy
During sunitinib treatment, baseline capillary density
decreased on days 14 and 28 (Table 2). Capillary density
during venous occlusion significantly decreased on days
14 and 28 (P=0.005 and 0.003, respectively). Endo-
thelium-dependent (Ach mediated) and endothelium-
independent (SNP mediated) vasodilatation did not
change during treatment.
Changes in blood pressure are related to changes
in capillary density
On day 14, there were significant inverse correlations
between changes in BP and in capillary density at
baseline and during venous occlusion (Fig. 1) whereas
this was not the case for changes in microvascular
endothelium-dependent and endothelium-independent
vasodilatation. Analyses on day 28 were not substantially
different, although differences were not statistically
significant.
Changes in vessel morphology
An unexpected finding on day 14 was that capillary
microscopy revealed prominent visibility of the sub-
papillary plexus in eight out of 16 patients (Fig. 2). In all
patients, the subpapillary plexus was not visible at
baseline. Remarkably, seven out of eight patients with
a visible subpapillary plexus had a more pronounced
sunitinib-induced decrease in capillary density during
venous occlusion. The association between the in-
creased visibility of the subpapillary plexus and the more
Table 1 Patient characteristics
Characteristic N=16 (%) Median (range)
Male 9 (56)
Female 7 (44)
Age, years 60 (47–84)
Tumor type
Clear cell 15 (94)
Other 1 (6)
MSKCC risk groupsa
0 (favorable) 3 (19)
1–2 (intermediate) 10 (63)
Z3 (poor) 3 (19)
Prior treatment
First-line 7 (44)
Second-line 9 (56)
Best response according to RECIST
Partial response 3 (19)
Stable disease 8 (50)
Progressive disease 4 (25)
Not evaluable 1 (6)b
Median follow-up (months) 17 (2–35)
Median progression-free survival (months) 9 (1–29)
Median overall survival (months) 18 (2–35)
Cardiovascular related
Weight (kg) 83 (44–96)
BMI (kg/m2) 25 (16–30)
Fasting glucose (mmol/l) 5.3 (4.4–5.6)
Fasting serum total cholesterol (mmol/l) 4.3 (3.1–6.6)
Fasting LDL cholesterol (mmol/l) 2.7 (0.7–4.4)
Fasting HDL cholesterol (mmol/l) 1.1 (0.65–2.31)
Fasting serum triglycerides (mmol/l) 1.3 (0.7–3.9)
Preexistent cardiovascular risk factors
Hypertension 3 (19)
Diabetes mellitus 0 (0)
Smoker 4 (25)
Cardiovascular event 2 (12)c
Concomitant medication
Antihypertensive medication 4 (25)d
Cholesterol-lowering medication 3 (19)
BMI, body mass index; HDL, high density lipoprotein; LDL, low density
lipoprotein; RECIST, Response Evaluation Criteria in Solid Tumors.
aRisk groups according to Memorial Sloan-Kettering Cancer Center (MSKCC)
prognostic criteria [based on the five risk factors: low Karnofsky performance
status ( < 80%), high LDH ( >1.5 times the upper limit of normal), low serum
hemoglobin, high corrected serum calcium (>10mg/dl), and time from initial
diagnosis to treatment of less than 1 year] [18].
bBecause of early termination of sunitinib owing to sunitinib-related adverse
events.
cMyocardial infarction and coronary artery disease requiring percutaneous
transluminal coronary angioplasty, respectively 7 and 16 years before this study.
dOne patient without preexistent hypertension was treated with an angiotensin-
converting enzyme-inhibitor for nephropathy.
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Table 2 Blood pressure and microvascular measurements before and during sunitinib 50mg/day
During sunitinib
Baseline median (range) N=16 Day 14 median (range) N=16 Day 28 median (range) N=11
Blood pressure
24-h SBP (mmHg) 118 (98–141) 123 (108–170)** 123 (107–157)
24-h DBP (mmHg) 68 (55–86) 75 (63–107)** 79 (65–91)*
24-h MAP (mmHg) 87 (75–105) 93 (79–128)** 93 (80–113)*
24-h heart rate (bpm) 84 (55–98) 75 (56–97)* 77 (63–92)*
Capillary density
Baseline (capillaries/mm2) 50 (36–59) 46 (38–77) 43 (23–54)
Venous occlusion (capillaries/mm2)a 69 (51–99) 61 (44–88)** 65 (47–85)**
Temperature (1C) 31.5 (30.5–32.5) 30.2 (29.9–32.5) 30.4 (29.3–33.3)
ACh-mediated vasodilatation
Baseline skin perfusion (PU) 14 (5–34) 13 (4–35) 9 (6–27)
Plateau (PU) 59 (14–191) 60 (12–192) 73 (12–160)
Percentage increase (%) 295 (71–1032) 326 (1–1230) 448 (44–1803)
Temperature (1C) 31.2 (29.9–31.4) 30.8 (29.8–32.4) 30.4 (30.0–33.4)
SNP-mediated vasodilatation
Baseline skin perfusion (PU) 13 (4–25) 8 (5–87) 10 (3–28)
Plateau (PU) 63 (40–106) 69 (28–122) 68 (16–185)
Percentage increase (%) 468 (92–1838) 475 (34–1280) 483 (79–3482)
Temperature (1C) 31.1 (30.0–32.0) 31.2 (30.1–32.5) 30.2 (30.0–32.2)
ACh, acetylcholine; bpm, beats per minute; DBP, diastolic blood pressure; MAP, mean arterial pressure; PU, arbitrary perfusion unit; SBP, systolic blood pressure;
SNP, sodium nitroprusside.
aOne patient was excluded because of missing data.
*P<0.05, compared with baseline value by the Wilcoxon signed-rank test.
**P<0.01, compared with baseline value by the Wilcoxon signed-rank test.
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pronounced decrease in capillary density during venous
occlusion was significant (Fisher’s exact, P=0.041). At
later time points, a livedo reticularis-like disorder on the
fingers and arms could be observed in patients with an
increased visibility of the subpapillary plexus (Fig. 3).
Changes in capillary density and vessel morphology
predict clinical outcome
In our RCC patients treated with sunitinib we carried
out a preliminary analysis to know whether the vascular
changes were related to clinical outcome. On day 14,
changes in BP did not have a significant predictive value
for PFS and OS (SBP, P=0.87 and 0.34, respectively;
DBP, P=0.50 and 0.22, respectively). Patients with a
decrease in the number of capillaries greater than median
(2 capillaries/mm2) had a prolonged OS (P=0.033).
Patients with a decrease in the number of capillaries
during venous occlusion greater than median (6 capil-
laries/mm2) had a prolonged PFS and OS (P=0.044
and 0.008, respectively) (Fig. 4). In these patients
median PFS and OS were 11 and 32 months whereas
these values were 3 and 11 months for patients with
capillary rarefaction r 6/mm2. In addition, patients with
an increased visibility of the subpapillary plexus on
day 14 had a prolonged median PFS and OS compared with
patients without this microscopic skin pattern (P=0.015
and 0.013, respectively) (Fig. 4). There were no asso-
ciations between changes in BP and microvascular
function with tumor response according to RECIST.
Discussion
In this study we tested the hypothesis that the BP rise,
known to be induced by sunitinib, is associated with a
reduction in skin microvascular density. We report four
novel observations. First, sunitinib treatment is indeed
associated with capillary rarefaction, which in turn is
directly related to an increase in BP. Second, sunitinib
treatment is not associated with impaired microvascular
endothelium-dependent and endothelium-independent
vasodilatation. Third, the visibility of the subpapillary
plexus increased during sunitinib, which was associated
with a decrease in capillary density. Fourth, although
preliminary, sunitinib-induced capillary rarefaction is
predictive for PFS and OS.
Our study has several strengths. All measurements
were performed at relatively early time points (day 14).
Twenty-four-hour BP monitoring greatly improved the
Fig. 2
Skin capillaroscopy at baseline (a) and on day 14 (b) showing
increased visibility of the subpapillary plexus after 2 weeks of sunitinib
50mg/day. The skin fold in the left upper part of the figure (arrow)
indicates that the same capillary field was visualized.
Fig. 3
Patient showing a reticular pattern on fingers (a) and arms (b) during
sunitinib treatment.
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reliability of BP recordings. In addition, our patient
population was homogenous with regard to tumor type
and drug dose (50mg sunitinib per day), and we excluded
patients requiring anti-hypertensive treatment during
the study. Finally, the long follow-up enabled us to
evaluate possible associations between clinical outcome,
BP and microvascular function.
A rise in BP can be found in most patients treated with
sunitinib [19] with overt hypertension arising in approxi-
mately 20% of the patients [20]. Although sunitinib
targets several receptor tyrosine kinases, VEGF/VEGFR-2
signaling seems to be essential for the rise in BP. The role
for VEGF/VEGFR-2 in BP regulation is illustrated by the
extremely high prevalence of hypertension (92%) during
treatment with a combination of sunitinib and beva-
cizumab [21]. Two recent studies have suggested micro-
vascular rarefaction as a mechanism leading to high BP
when abrogating VEGF/VEGFR-2 signaling, but a possi-
ble relationship was not examined [10,11]. Microvascular
rarefaction was described to occur in the skin of patients
with advanced colorectal cancer receiving bevacizumab
[10] and in the mucosal surface of the inner lip of
patients with advanced solid tumors receiving telatinib, a
small molecule tyrosine kinase inhibitor of VEGFR-2
and 3, platelet-derived growth factor receptor-b, and c-KIT
[11]. Here, we not only measured the development of
capillary rarefaction during the inhibition of VEGF/
VEGFR-2 signaling, but we were also able to show the
presence of a direct association between the decrease in
capillary density and the rise in BP.
Although the cause-and-effect relationships of rarefaction
and hypertension are still under debate [9,13], mathe-
matical modeling of in-vivo microvascular networks
predicts an exponential relation between capillary and
arteriolar number and vascular resistance. Total vessel
rarefaction up to 42% can increase tissue vascular
resistance by 21% [22]. Indirect evidence suggests that
microvascular rarefaction, by affecting peripheral vascular
resistance, may indeed initiate the pathogenic sequence
in sunitinib-induced BP rise. Hypertension caused by an
increase in vascular resistance is characterized by a slight
decrease in circulating plasma volume, a decrease in
Fig. 4
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cardiac output and reduced sympathetic activity. In
accordance, hematocrit values and erythrocyte numbers
are increased in sunitinib-treated patients [19], possibly
reflecting a decreased circulating plasma volume. Simul-
taneously, cardiac output is decreased [23] and heart
rate is depressed ([2], this study), possibly reflecting
decreased sympathetic activity. Humoral factors, such as
catecholamines, endothelin-1 and urotensin-II, seem to
play a minor role in arterial hypertension during inhibi-
tion of VEGF/VEGFR-2 signaling [24]. Renal microvas-
cular dysfunction, accompanied by a shift in the renal
pressure–natriuresis relationship, is probably necessary to
maintain the initial elevation of BP [25].
Capillary nonperfusion may merely represent the down-
stream consequence of impaired nitric oxide synthesis
leading to reduced vasodilatation at the precapillary
arteriolar level. Indeed, Mourad et al. [10] have reported
a decrease in endothelium-dependent vasodilatation after
6 months of bevacizumab treatment. Endothelium-
independent vasodilatation, however, was not assessed and,
therefore, reduced formation of nitric oxide by endothe-
lial cells could not be distinguished from a decreased
responsiveness of vascular smooth muscle cells to nitric
oxide. Moreover, these findings may be secondary to a
chronic increase in BP instead of the cause of a rapid
rise in BP [13]. In this study both microvascular
endothelium-dependent and endothelium-independent
vasodilatation were unaffected by sunitinib therapy. It is
important to realize, however, that dermal vasodilatation
in response to iontophoresis of Ach is mediated not only
by nitric oxide, but also by prostanoids [26], which are
unaffected by antiangiogenic therapy [27]. Nevertheless,
the responsiveness of microvascular smooth muscle cells
to nitric oxide seems to be intact. Our methodology does
not preclude impaired endothelium-dependent and
endothelium-independent vasodilatation at the level of
the resistance vessels or conduit arteries. Impaired
endothelium-independent vasodilatation in conduit arteries
has been shown during telatinib therapy [11].
An unexpected, but related finding was the visibility of
the subpapillary plexus during sunitinib treatment. The
subpapillary plexus, which consists of an anastomosing
network of arterioles and venules and is located at a
depth of 400–500 mm from the surface, is not visible
in most healthy individuals (> 80%) [28]. At later time
points during sunitinib treatment, a livedo reticularis
pattern could be observed macroscopically on the fingers
and arms of the patients with a visible subpapillary
plexus. The visibility of the subpapillary plexus was
associated with a more marked decrease in capillary
density and, in addition, predictive of favorable clinical
outcome. In general, a reticular pattern can be caused by
several underlying factors that increase the visibility of
the venous network in the skin [29]. Venous stasis of
blood owing to slow flow in the draining veins secondary
to reduced arterial inflow is a hallmark feature of
vasospastic livedo reticularis [30] and may have caused
the change in vessel morphology during sunitinib
treatment. In addition, the increase in hematocrit and
erythrocyte numbers during sunitinib treatment [19,31]
may have contributed to the observed livedo reticularis
pattern, because this phenomenon is also associated with
polycythemia vera [29].
Capillary density, as a possible direct biomarker of the
antiangiogenic and BP increasing potential of sunitinib,
might be useful as a biomarker of efficacy. Although
preliminary, median PFS and OS were 11 and 32 months
for patients showing sunitinib-induced capillary rare-
faction greater than 6/mm2 whereas these values were
3 and 11 months for patients with a capillary rarefaction
r 6/mm2. As expected, three patients who developed
Z grade 2 hypertension showed capillary rarefaction
greater than 6/mm2 associated with a better clinical
outcome. Whether sunitinib-induced capillary rarefaction
may indeed constitute an early indicator of antitumor
activity needs to be confirmed in a larger series of mRCC
patients. In addition, it needs to be investigated whether
sunitinib-induced capillary rarefaction in the skin is
indicative of changes in microvascular perfusion at the
site of the tumor. In conclusion, early measurements of
microvascular parameters in mRCC patients treated with
the VEGFR-2 inhibitor, sunitinib, showed a reduction
in capillary density whereas endothelium-dependent
and endothelium-independent vasodilatations were un-
affected. Reduction in skin capillary density was directly
related to a rise in BP. Patients with a marked decrease in
capillary density and/or increased visibility of the sub-
papillary plexus seemed to have a significantly prolonged
PFS and OS, suggesting that these microvascular para-
meters may constitute an early indicator of antitumor
activity.
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Sunitinib-induced reduction in
skin microvascular density is
a reversible phenomenon
Arterial hypertension is a well-recognized adverse event in
cancer patients treated with inhibitors that target vascular
endothelial growth factor (VEGF) or its receptors (VEGFR).
Rarefaction (a decrease in perfused microvessels) is suggested
to play an important role in the development of this side-
effect [1]. A reduction in capillary density has been
demonstrated in patients treated with bevacizumab [2],
sunitinib [3], and telatinib [4]. In the April issue of
Annals of Oncology, Steeghs et al. [5] have demonstrated that
the reduction in capillary density induced by bevacizumab
was reversible as measured over 3 months upon
discontinuation of the drug. Preclinical data in the adult
mouse showed rapid reversibility of capillary regression in
normal organs within 2 weeks after cessation of VEGF
inhibition [6]. Whether this is true in humans remains to be
demonstrated. We here report rapid and full reversibility of
microvessel perfusion upon discontinuation of sunitinib.
The tyrosine kinase inhibitor sunitinib targets VEGFR and is
administered in a 4 weeks on 2 weeks off schedule. We have
demonstrated earlier that the rise in blood pressure in patients
with metastatic renal cell cancer (mRCC) during sunitinib was
related with a decrease in capillary density [3]. We have also
described that the blood pressure rise disappeared promptly
during the drug holiday [7]. To investigate whether sunitinib-
induced reduction in microvascular density is readily reversible
within the 2 weeks off treatment, we measured 24-h ambulatory
blood pressure and nailfold capillary density [3] at baseline, 14
days after the start of sunitinib 50 mg/day and 14 days after
discontinuation of the drug in three consecutive patients with
mRCC. As reported by us before [3], blood pressure increased,
whereas the capillary density decreased. On day 42, 2 weeks
after discontinuation of sunitinib, not only blood pressure but
also capillary density fully recovered to baseline values in two of
three patients (Figure 1). During the ﬁrst treatment cycle, the
third patient experienced objective sunitinib-induced grade 1–3
toxic effects. At the time of cycle 2, she still suffered from
a series of grade 1 side-effects, which was reason to reduce the
sunitinib dose to 37.5 mg/day. Apart from hypertension grade
2, cycle 2 was tolerated well. One week after discontinuation
of sunitinib in the 2 weeks off period, antihypertensive
medication could be stopped. Measurements of 24-h
ambulatory blood pressure and nailfold capillary density were
repeated on day 84 (2 weeks after discontinuation of sunitinib
at 37.5 mg/day) and promptly showed recovery to baseline
values (Figure 1).
Although the effects of VEGF/VEGFR inhibitors on blood
pressure and microcirculation appear to be reversible, it is not
known whether prolonged treatment with these drugs will
cause permanent damage to the vascular system or even cause
structural rarefaction and hypertension as a secondary
phenomenon. Currently, these angiogenesis inhibitors are only
administered in the palliative setting, but their prolonged
administration in the curative setting is under investigation.
Therefore, insight is required into potential long-lasting adverse
Figure 1. Measurement of capillary density (A) and blood pressure (B)
during the ﬁrst treatment cycle of sunitinib 50 mg/day in a 4 weeks on 2
weeks off schedule in three individual patients with advanced renal cell
cancer. Capillary density is expressed as baseline capillary density in
number (n) per square millimeter. In one patient, the sunitinib dose was
reduced during the second cycle and additional measurements were
carried out after the second off period (= day 84). MAP, mean arterial
blood pressure.
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events in normal capillaries that are caused by chronic
treatment with these drugs.
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Chapter 14 
Summary 
 
 
 
 
       
  
The development of targeted therapy has significantly improved the outcome of patients 
with metastatic renal cell cancer (mRCC). Among the approved targeted agents, sunitinib 
has achieved an important place in the treatment of this disease. In this thesis, several 
clinical and pharmacodynamic aspects regarding sunitinib treatment in mRCC patients 
are described. Chapter 1 provided an introduction on the treatment of mRCC with a 
particular focus on sunitinib. Thereafter, the contents of this thesis are divided in three 
parts.  
 
Part I: Efficacy of sunitinib in renal cell cancer 
In Chapter 2, the efficacy of sunitinib in primary renal cell cancer (RCC) tumors in 
seventeen patients who presented with primary metastatic disease was described. 
Although primary tumors are usually refractory to cytokine-based therapy, sunitinib 
induced a significant reduction in tumor volume with concomitant development of 
extensive tumor necrosis. As the drug was capable of inducing an important tumor 
response in primary tumors, this might result in improved surgical resection.  
In Chapter 3A, the clinical impact of neoadjuvant sunitinib was explored on surgical 
management of primary tumors with surgery-limiting features which included complex 
primaries and/or bulky locoregional metastases. Although six out of ten surgery-limiting 
tumor sites showed a reduction in tumor size, the extent of downsizing by neoadjuvant 
sunitinib was limited and cytoreductive surgery was reconsidered in only three patients. 
In addition, in Chapter 3B it was demonstrated that neoadjuvant sunitinib for resectable 
primary tumors can have a negative impact on surgical management. Two mRCC 
patients were described who developed a progressive caval vein thrombus during 
sunitinib treatment, consequently impeding the initially planned surgery.  
Since localization of metastatic disease in the brain represents another RCC tumor 
location difficult to treat, the occurrence of brain metastases during sunitinib treatment 
was reported in Chapter 4. In a period of two years, nine out of 91 sunitinib-treated 
mRCC patients developed symptomatic brain metastases, which represented the first 
sign of progressive disease. Remarkably, six out of nine patients developed central 
nervous system (CNS) symptoms in the 2-week rest period. Lesions may have been 
masked by an anti-edema effect of sunitinib during the 4 weeks-on period of the 
treatment cycle. These findings suggest that sunitinib is inadequate for control of brain 
metastases and may temporarily suppress their existence. After radiotherapy or surgery 
for brain metastases, sunitinib could be safely continued and showed persisting efficacy 
in the extra-cerebral tumor sites. Therefore, new and isolated progression of RCC in CNS 
is no indication for permanent discontinuation of sunitinib.  
In Chapter 5, it was examined whether genetic polymorphisms have predictive value for 
sunitinib efficacy in mRCC patients. To that end, a retrospective multicenter pharmaco-
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genetic association study was performed in 136 clear cell mRCC patients treated with 
sunitinib. Thirty polymorphisms related to the pharmacokinetics and pharmacodynamics 
of the drug were investigated for a possible association with progression-free survival 
(PFS) and overall survival (OS). Apart from three clinical characteristics [Memorial Sloan-
Kettering Cancer Center (MSKCC) prognostic criteria, number of metastatic sites and 
age], genetic polymorphisms in three genes involved in the pharmacokinetics of sunitinib 
(CYP3A5, NR1I3 and ABCB1) were predictive factors for PFS. The results of this study 
warrant prospective validation and further clarification of the role of these genetic 
determinants in sunitinib exposure and efficacy. 
 
Part II: Side-effects of sunitinib 
In Chapter 6, the toxicity and efficacy of sunitinib were described in 82 mRCC patients 
included in a compassionate use programme. To this end, adverse events were graded 
according to Common Terminology Criteria for Adverse Events (CTCAE). The observed 
efficacy of sunitinib was comparable with that reported in previous phase III trials. 
However, the observed toxicity seemed to be more severe, as almost half of the group of 
patients needed a dose reduction because of treatment-related side-effects. Most 
important toxicities requiring a lower dose included stomatitis, fatigue, hand-foot 
syndrome and a combination of grade 1-2 side-effects. Severe toxicity, defined as dose 
reduction or permanent discontinuation, was highly related to low body surface area, 
high age and female gender. On the basis of these patient characteristics, a model could 
be developed to predict the probability of severe toxicity in patients treated with 
sunitinib.  
In Chapter 7, the occurrence of severe cognitive disorders induced by sunitinib was 
reported. Three elderly patients with mRCC developed cognitive and behavioral changes 
while on sunitinib which were reversible upon discontinuation. Brain metastases were 
excluded and the neurological symptoms disappeared after discontinuation of the drug. 
All three patients had preexisting arteriosclerotic leukoencephalopathy which most likely 
has contributed to the development of these cognitive side-effects. Therefore, physicians 
should be aware of cognitive disorders in elderly patients who are treated with sunitinib. 
In case such cognitive disorders develop, brain metastases should be excluded and 
sunitinib should temporarily be discontinued. As described earlier, sunitinib-induced side-
effects can be severe. Hence, tools are warranted to predict the toxicity of sunitinib in 
individual patients in order to select patients for alternative dosing.  
In Chapter 8, genetic polymorphisms in the pharmacokinetic and pharmacodynamic 
pathways of sunitinib were identified that predispose for the development of sunitinib-
induced side-effects. In 219 patients treated with sunitinib, several genetic variants were 
associated with the development of leucopenia, mucosal inflammation, hand-foot syn-
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drome and any toxicity higher than grade 2. The identified genetic polymorphisms 
encoded for metabolizing enzymes, efflux transporters, and drug targets of sunitinib. 
Development of leucopenia was associated with genetic polymorphisms in CYP1A1 
2455A/G, FLT3 738T/C and the NR1I3 haplotype. In addition, mucosal inflammation and 
hand-foot syndrome were associated with genetic polymorphisms in CYP1A1 2455A/G 
and the ABCB1 haplotype, respectively. Any toxicity higher than grade 2 prevalence was 
increased when the T allele of vascular endothelial growth factor receptor (VEGFR)-2 
1191C/T or a copy of TT in the ABCG2 haplotype were present. Validation of the 
importance of specific genetic polymorphisms in the development of sunitinib-induced 
side-effects should be carried out in an independent patient population.   
 
Part III: Potential biomarkers  
In Chapter 9, new response criteria that incorporate the development of tumor necrosis 
were evaluated for early prediction of sunitinib efficacy. To that end, criteria defined by 
Choi et al were used in the evaluation of computed tomography (CT) scans in 55 
sunitinib-treated mRCC patients. According to these criteria, a partial response (PR) was 
defined as a ?? ???? ????????? ??? ????? ??? ? ?? ???? ????????? ??? ????????????? At first 
evaluation after a median period of 1.9 months, the Choi criteria were significantly better 
predictive for PFS and OS than the standard Response Evaluation Criteria In Solid 
Tumors (RECIST). However, the predictive value of the Choi criteria was similar to that of 
RECIST at later time points. Although the Choi criteria could be useful to early identify 
mRCC patients who benefit from sunitinib, these criteria were not able to early select 
patients without benefit from the drug. Therefore, the use of the Choi criteria will not 
change the management of sunitinib-treated mRCC patients.  
In Chapter 10, the remarkable changes in hemoglobin levels during sunitinib treatment 
were reported. In 82 mRCC patients, a zig-zag pattern was observed in hemoglobin 
levels and erythrocyte numbers. During the 4 weeks-on treatment, a transient increase 
in hemoglobin and erythrocyte count occurred, which diminished rapidly during the 2-
week rest period. Although the increase in erythrocyte numbers was accompanied by a 
rise in plasma erythropoietin, an erythropoietin-induced rise in erythrocytes is not 
expected to diminish rapidly within the 2 weeks of rest. On the basis of previous studies 
and our findings, it was hypothesized that the cyclic kinetics of hemoglobin and 
erythrocytes were not caused by an increase in erythropoiesis, but are likely the result of 
a temporary loss of intravascular fluid caused by inhibition of VEGFR-2 and subsequent 
reduction of nitric oxide.  
In Chapter 11, the effects of sunitinib were measured on mature circulating endothelial 
cells (CEC) and hematopoietic progenitor cells (HPCs) in blood obtained from mRCC 
patients. Changes in circulating levels of CECs and HPCs may reflect sunitinib activity on 
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tumor neovasculature. In particular, the kinetics of specific populations of small VEGFR2-
expressing CECs [CD45neg)/CD34bright)] and HPCs [CD45dim)/CD34bright)] were analyzed. 
These populations showed opposite kinetics; the CECs increased, whereas the HPCs 
decreased. This increase in CECs is likely the result of sunitinib activity in immature 
tumor vessels. In addition, an increased number of CECs after 14 days of sunitinib 
treatment was associated with a longer PFS when compared with patients with a 
decreased number of CECs.  
To further investigate the effects of sunitinib on tumor endothelium, a study, reported in 
Chapter 12, was performed to measure changes in plasma proteins associated with 
activated tumor endothelium. To that end, plasma samples from sunitinib-treated mRCC 
patients were investigated for levels of the vascular endothelial growth factor (VEGF), 
soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular cell adhesion 
molecule-1 (sICAM-1), von Willebrand factor (vWF), circulating angiopoietin-2 (Ang-2) 
and soluble Tie-2 (sTie-2). This study showed that tumor burden was positively 
associated with baseline circulating Ang-2. Sunitinib induced a decrease in circulating 
Ang-2 and sTie-2 levels, whereas levels of sVCAM-1 and VEGF significantly increased. 
The decrease in circulating Ang-2 was positively associated with the percentage decrease 
in tumor burden after sunitinib treatment. Hence, the decline in circulating Ang-2 may 
represent a biomarker of sunitinib activity in RCC tumors.  
Finally, in Chapter 13 the effects of sunitinib on the systemic vasculature were reported. 
Sunitinib treatment is associated with systemic hypertension, which may be caused by 
the development of functional rarefaction (a decrease in perfused microvessels) or 
structural rarefaction (a reduction in anatomic capillary density). In Chapter 13A, it was 
investigated whether sunitinib treatment leads to impairment of microvascular function 
and/or reduction of capillary density in the dorsal skin of the finger. In mRCC patients, 
sunitinib induced a rise in systolic and diastolic blood pressure, whereas the capillary 
density in the skin decreased. This decrease was associated with an increase in systolic 
and diastolic blood pressure. In Chapter 13B, it was demonstrated that these effects 
were reversible after discontinuation of sunitinib. Patients with a greater reduction in 
capillary density had a prolonged PFS. Therefore, reduction in skin capillary density might 
be a predictive marker of clinical outcome in sunitinib-treated mRCC patients. 
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Part I:  Efficacy of sunitinib in renal cell cancer (RCC) 
 
I.1 Drug of choice in the era of targeted therapy 
The development of targeted therapy, including sunitinib, has proven to be effective in 
patients with metastatic renal cell cancer (mRCC; Figure 1) and has significantly 
improved their perspectives (Chapter 1). Nevertheless, it is not yet clear on how to 
decide on the optimal treatment regimen for an individual patient with mRCC (1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. An example of a mRCC patient who had a partial response (PR) during sunitinib 
treatment. Metastasis to the lip prior to sunitinib treatment (A) and after two weeks of sunitinib 
treatment (B). Computed tomography (CT) scans showing metastases (arrows) to lungs, pleura 
and subcutis before the start of sunitinib (C) and at fourteen weeks after initiation of sunitinib (D).  
 
In mRCC, several factors should be taken into account for the appropriate choice of drug. 
First, it is important to determine whether the histology of the tumor mainly consists of 
the clear cell subtype. In case of dominant clear cell histology, patients are further 
stratified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria, extent 
of disease, and presence of a primary tumor in the first-line setting. Based on the 
currently available data, sunitinib is justified as first-line standard of care for each patient 
with clear cell mRCC (2;3). Sunitinib has shown high efficacy in these patients even in 
the presence of poor risk factors (2). In case patients might not tolerate sunitinib, 
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pazopanib can be considered as choice (4). In addition, phase III data justify the 
combination of bevacizumab plus interferon-????? ?????-line treatment (5-8). However, it 
can be considered to restrict the latter combination to patients in the favorable risk group 
and limited disease in the lungs, since complete remission may occur for a prolonged 
period of time [Chapter 1; (9;10)]. Temsirolimus is recommended as first-line treatment 
in patients with poor risk factors (11). Besides the MSKCC-related criteria, other factors 
such as genetic polymorphisms (Chapter 5) and specific tumor features, may contribute 
to appropriate selection of targeted therapy, as optimal stratification of mRCC patients 
may further improve the efficacy of these drugs. It is also important to unravel 
mechanisms of primary (intrinsic) and secondary (acquired) resistance which is inevitable 
to occur in the course of the disease. Recently, lysosomal sequestration has been 
identified as a mechanism of sunitinib resistance (12). 
 
I.2 Sunitinib treatment for localized disease 
mRCC patients with potentially resectable primary tumors and/or a solitary metastasis 
are still candidates for nephrectomy and/or metastasectomy, as long-term survival has 
been reported in some patients (13). In the cytokine era, responses of the primary tumor 
were very rare (14) and patients presenting with primary metastatic disease and a 
resectable primary tumor usually underwent cytoreductive nephrectomy. This strategy 
was based on the results of two randomized phase III trials, which had shown that 
nephrectomy followed by interferon-??? ???????overall survival (OS) as compared with 
interferon-?? ?????? (15;16). Currently, this treatment strategy is under debate since 
targeted therapy (17;18) can induce impressive responses in primary tumors (Chapter 
2). Targeted therapy may even contribute to downsizing of primary tumors, thereby 
facilitating cytoreductive surgery [Chapter 3A; (19-21). However, mixed responses in the 
primary tumor and metastases may occur. It has been described that an initially 
resectable primary tumor may increase in size despite a treatment-induced response in 
the metastases (Chapter 3B). Therefore, early identification of progression of a 
resectable primary tumor is important to avoid a missed opportunity for cytoreductive 
nephrectomy. Patients with lung metastases only and a favorable prognostic score are 
most likely to benefit from cytoreductive surgery. The selection of mRCC patients for 
cytoreductive nephrectomy needs to be optimized. Recently, two randomized controlled 
trials have been initiated to determine the current role and optimal timing of removal of 
the primary tumor in patients with primary metastatic disease. Therefore, participation in 
a clinical trial is currently considered as the best management of mRCC patients 
presenting with a resectable primary and synchronous metastases.  
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I.3 Second-line treatment 
After progression on a previous systemic treatment, several drugs can be considered as 
second-line therapy in mRCC patients. After failure of cytokine-based therapy, sunitinib, 
pazopanib, and sorafenib can be recommended (4;22;23). In addition, phase III data 
support second-line treatment with everolimus after failure of a receptor tyrosine kinase 
inhibitor (TKI) (11). In clinical practice however, another TKI is frequently given after 
failure of a TKI. For example, sunitinib-induced tumor response can still be observed 
after disease progression upon sorafenib treatment. However, the optimal treatment 
sequence of targeted agents after failure in first-line setting has not been defined yet. 
Therefore, clinical trials in the second-line and third-line setting are warranted in order to 
determine the optimal treatment strategy and drug sequence in individual patients with 
mRCC.  
 
I.4 Sunitinib for patients with non-clear cell histology 
Although efficacy of sunitinib is observed in patients with non-clear cell histology, 
evidence for use of sunitinib in this patient population is limited. In the majority of phase 
III trials on targeted drugs, mRCC patients with a predominant clear cell histology have 
been included. Temsirolimus has proven activity in patients with non-clear cell histology 
as observed in a subset analysis of the phase III trial (11). In addition, a few 
retrospective studies have reported minor efficacy of sunitinib and sorafenib in patients 
with non-clear cell histology [Chapter 6; (24;25)]. However, a recent phase II trial could 
not demonstrate significant efficacy of sunitinib in mRCC patients with non-clear cell 
histologies (26). In fact, there is no established effective therapy for patients with non-
clear cell histology. Presently, treatment in a clinical trial is the preferred strategy for 
mRCC patients with non-clear cell histologies, because effective drugs need to be 
developed for this heterogeneous group (27). To that end, broad international 
collaboration is required, as non-clear histology accounts for a very small patient 
population. 
 
Part II: Side-effects of sunitinib 
 
II.1 Prediction of side-effects 
In clinical practice, sunitinib treatment is associated with a wide range of grade 1-2 
toxicities, frequently requiring dose reduction and/or discontinuation of treatment 
(Chapter 6). Therefore, patients should be monitored closely, in particular during the first 
weeks of sunitinb treatment. Early identification of patients who might develop severe 
toxicity may be helpful in order to reduce the standard dose of sunitinib prior to the start 
189
   
 
of treatment. In Chapter 6, it was demonstrated that there was a significant correlation 
between severe sunitinib-related toxicity and patient characteristics including small body 
surface area, high age, and female gender. In addition, the data presented in Chapter 8 
show that several genetic polymorphisms in the pharmacokinetic and pharmacodynamic 
pathways of sunitinib are associated with sunitinib-induced toxicity including leucopenia, 
mucosal inflammation, hand-foot syndrome, and any toxicity higher than grade 2. The 
high incidence of dose reduction and discontinuation of treatment, together with the 
findings in Chapters 6 and 8, suggest that the standard dosing schedule of sunitinib, 
which is 50 mg daily in a 4 weeks-on/2 weeks-off schedule, is not always optimal for 
unselected mRCC patients. Considering a relation between exposure of sunitinib and 
some toxicities (28), it is conceivable that patients with severe toxicity are overtreated, 
whereas patients who do not experience any toxicity may be undertreated. In that case, 
some side-effects such as hypertension may be an easy read-out of sufficiently reached 
plasma concentrations of sunitinib and its active metabolite SU12622. As an alternative, 
pharmacokinetic studies with intensive monitoring of plasma levels of sunitinib and its 
active metabolite SU12622 may be beneficial to further reveal the relationship between 
sunitinib exposure and sunitinib-induced toxicities. The need for pharmacokinetic studies 
is also supported by the findings in Chapter 5 in which genetic polymorphisms in three 
genes involved in the pharmacokinetics of sunitinib (CYP3A5, NR1I3 and ABCB1) were 
found to be associated with progression-free survival (PFS). In the future, these genetic 
variants may be useful to optimize dosing and scheduling of sunitinib in individual 
patients. 
 
II.2 Palliation of side-effects 
As sunitinib has proven efficacy in mRCC, optimal dosing, i.e. the highest tolerable dose, 
and adherence to sunitinib treatment are essential for palliation of disease-related 
symptoms and prolongation of survival. However, sunitinib frequently causes the 
accumulation of a series of grade 1 and 2 adverse events. As a result, sunitinib-induced 
toxicities can have a profound impact on daily life, thereby invalidating patients. For 
example, fatigue interferes excessively with daily life, mucositis and taste alteration 
require changes in food habits, hand-foot syndrome limits walking and the urgent pattern 
of diarrhea has a high risk of soiling. However, the evidence for adequate palliation of 
sunitinib-induced toxicities is rather limited, as these toxicities are completely different 
from those caused by traditional chemotherapy. More insight into the underlying 
mechanisms of sunitinib-induced side-effects may improve the palliation of these 
frequently observed symptoms. This is particularly important since sunitinib is considered 
palliative instead of curative for treatment of patients with mRCC.  
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II.2.1 Dose modifications 
In general, sunitinib-induced toxicities will recover after dose reduction or temporarily 
discontinuation of treatment. When necessary, a 12.5 mg dose reduction is recom-
mended from the regular dose of 50 mg (29). After discontinuation of sunitinib, recovery 
to acceptable levels of toxicity should occur within four weeks to allow sunitinib 
continuation. In the absence of hematological ????????????????-hematological ??????????
toxicities in the previous cycle, re-escalation to the previous dose level can be considered 
(29). However, dose reduction or interruption of sunitinib treatment should be prevented 
in order to achieve sufficient efficacy. If patients have symptoms of progressive disease 
(PD) during the rest period, continuous dosing of sunitinib at 37.5 mg per day is advised. 
Early detection and management reduces the severity of the side-effects, thereby 
improving quality of life and treatment adherence. To this end, frequent contact between 
patient and his/her treating physician is important, in particular during the first treatment 
cycle. In the paragraphs below, the current management of the most frequently reported 
toxicities associated with sunitinib treatment will be shortly discussed.  
 
II.2.2 Fatigue 
Fatigue is one of the most common side-effects associated with sunitinib treatment (2). 
Dose interruption or at least dose adjustment is usually required for grade 3 or 4 fatigue. 
Fatigue may be caused by other sunitinib-related toxicities, such as hypothyroidism (30) 
and anemia. Therefore, thyroid function and hemoglobin level should be monitored on a 
regular basis, as patients can be easily treated for these symptoms. Of note, onset of 
fatigue or its worsening could also indicate disease progression, as cancer-related fatigue 
is often perceived by mRCC patients.  
 
II.2.3 Hypothyroidism 
For all patients treated with sunitinib, it has been recommended that thyroid function 
tests are performed on days 1 and 28 of the first four cycles (31). Levels of the thyroid-
stimulating hormone (TSH) should ideally be checked prior to start of sunitinib. By 
applying this intensive initial screening, patients at risk of developing sunitinib-induced 
thyroid dysfunction can be early detected following drug initiation. In addition, when 
patients do not have thyroid function test abnormalities within the first four cycles, 
monitoring of thyroid function tests can be subsequently performed less frequently, e.g. 
every three cycles, unless clinically indicated (31). Hormone replacement therapy should 
be initiated in patients with persistent TSH > 10 mIU/mL, even in the presence of normal 
T4 levels (31).  
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II.2.4 Hand-foot syndrome 
Management of hand-foot syndrome can be initiated before symptoms develop. 
Complaints can be partly prevented by regular manicures and pedicures (32). Excessive 
pressure on bony prominences should be prevented by wearing appropriate footwear and 
by avoiding activities that place undue stress to the hands and feet. In addition, patients 
should be advised to avoid exposure of their hands and feet to hot water, as it is believed 
that hot water may exacerbate the symptoms (33). If hand-foot syndrome develops 
(Figure 2), moisturizing creams are recommended for relief.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Examples of grade 3 hand-foot syndrome in patients treated with sunitinib.  
(A) Painful skin changes of the hand consisting of blisters and peeling, interfering with activities of 
daily living (ADL). 
(B) Painful blister on the right foot of another patient, interfering with ADL.  
 
In addition, keratolytics (e.g. urea 20-40% or salicylic acid 6%) can be given (33). In 
case of grade 2 hand-foot syndrome, topical analgesics such lidocaine 2% and pain killers 
may be given for pain control. Grade 3 hand-foot syndrome often requires interruption of 
treatment until hand-foot syndrome reaches grade 0 or 1. Thereafter, the treatment can 
be resumed at a reduced dose. Then, if toxicity does not occur, re-escalation of the dose 
can be attempted (33).  
 
II.2.5 Oral mucositis and stomatitis              
In clinical practice, the terms oral mucositis and stomatitis are often used inter-
changeable. Rigorous hygiene consisting of baking soda mouthwash or sodium chloride 
solutions may partly prevent oral mucositis and stomatitis (29). Treatment of ??????????
requires mixtures of mucosal coating agents and local anesthetics, whereas oral 
candidiasis requires oral nystatin or fluconazole. Of note, ketoconazole, which is a 
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selective inhibitor of CYP3A, is contraindicated as it may increase plasma concentrations 
of sunitinib. Development of grade 3 mucositis or stomatitis requires dose modification of 
sunitinib.    
 
II.2.6 Gastrointestinal toxicity 
Anorexia, nausea, vomiting and diarrhea are frequently reported side-effects of sunitinib 
(2). Symptomatic medications include megestrol acetate for anorexia, metoclopramide 
and ondansetron for nausea and/or vomiting, and loperamide for diarrhea (29;34). In 
case of nausea or vomiting, small amounts of food and drinks are advised. When patients 
have diarrhea, they are advised to avoid food that would aggravate this complaint (spicy 
fatty foods, caffeine) and to drink plenty of liquids for oral hydration (29).  
 
II.2.7 Hypertension 
The exact mechanism by which VEGF inhibitors induce hypertension has not yet been 
completely clarified. Previous studies have shown that VEGFR-2 is involved in the 
regulation of the vascular tone. Activation of VEGFR-2 via phosphoinositide-3 kinase 
(PI3K) and its downstream serine protein kinase Akt stimulates endothelium-derived 
nitric oxide synthase (eNOS), subsequently leading to the production of the potent 
vasodilator nitric oxide (NO) (Figure 3A). In addition, decreased NO bioavailability favors 
the production and/or activity of endothelin-1 (ET-1) through the loss of inhibitory effects 
of NO on ET-1 (35;36). Indeed, plasma ET-1 concentrations have been described to 
increase in subjects treated with sunitinib (37;38). Consequently, it could be 
hypothesized that inhibition of VEGFR-2 causes an imbalance between the vasodilator NO 
and the vasoconstrictor ET-1, favoring ET-1 and thereby resulting in the development of 
hypertension (Figure 3B). The recognition and management of hypertension by drugs 
affecting VEGF(R) signaling is important, as poorly controlled hypertension may lead to 
serious adverse events. Therefore, blood pressure should be monitored on a regular 
basis, in particularly in patients at high cardiovascular risk such as patients with pre-
existent hypertension, diabetes mellitus and a history of cardiovascular disease. 24-hour 
ambulatory blood pressure measurements during the first treatment cycle can be used to 
early detect undiagnosed or uncontrolled hypertension (39). In line with the Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC7) (40), it is currently recommended to apply 
behavioral and pharmacological interventions in order to achieve a blood pressure lower 
than 140/90 mmHg in patients treated with angiogenesis inhibitors (34;41). However, no 
clear recommendation can be made for anti-hypertensive drugs, as there is a lack of 
studies on treatment of this drug-induced hypertension (34;41). In fact, efficacy has 
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been observed for all types of anti-hypertensive drugs including diuretics, beta-blockers, 
angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. 
Therefore, drug selection should be based on the comorbidity, contraindications and drug 
interactions in an individual patient. As previously tested in a human colorectal tumor 
xenograft in nude rats, it has been demonstrated that anti-hypertensive treatment does 
not negatively affect the antitumor activity of the TKI cediranib (42). Recently, it has 
been reported that the development of hypertension during sunitinib treatment is 
associated with improved clinical outcome in mRCC, indicating that hypertension may be 
a biomarker of efficacy in sunitinib-treated mRCC patients (43-45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  
(A) Role of VEGFR-2 in regulation of the vascular tone.  
(B) Inhibition of VEGFR-2 by sunitinib might result in a dysbalance between vasodilatation and 
vasoconstriction, leading to increased peripheral resistance and subsequent hypertension. 
 R, receptor (extracellular domain); TK, tyrosine kinase; P, phosphorylation site (intracellular 
domain); PI-3K, phosphoinositide-3 kinase; eNOS, endothelium-derived nitric oxide synthase; NO, 
nitric oxide; ET-1, endothelin-1. 
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Part III: Potential biomarkers  
 
III.1 Imaging of mRCC 
As targeted therapy causes disease stabilization rather than substantial tumor 
regression, new response criteria and imaging techniques are being investigated for 
improved evaluation of the efficacy of these molecules in mRCC patients. Response 
Evaluation Criteria in Solid Tumors (RECIST) are usually applied to assess tumor 
response in mRCC and are able to identify patients with clinical benefit. However, RECIST 
is not able to early identify mRCC patients with a poor PFS during targeted therapy 
(Chapter 9). Incorporation of treatment-induced changes in tumor attenuation on 
contrast-enhanced computed tomography (CT) scans may have additional value to 
assess tumor response, but it is not clear whether inclusion of these changes in decision-
making have significant impact on the current management of mRCC patients. Other 
imaging techniques including dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI), dynamic contrast-enhanced ultrasonography (DCE-US), and positron 
emission tomography (PET) are also under study for response evaluation of targeted 
therapy in mRCC patients (46).  
Functional imaging, such as DCE-MRI and dynamic PET scans, is increasingly 
incorporated in the evaluation of anticancer drugs. These imaging techniques usually 
have a limited field of view, which may be a disadvantage. For example, the field of view 
of a dynamic PET scan is currently < 20 cm. Therefore, functional imaging can usually 
not be applied to evaluate the disease in the whole patient. However, the recent trend is 
towards a reduction of lesions to be measured, as RECIST version 1.1 has reduced the 
maximum number of target lesions from 10 to 5 lesions (47). In addition, Hillman et al 
(48) have reported that measurement of > two metastatic lesions when compared with 
two lesions did not alter the definitive response in solid tumors. However, functional 
imaging may fail to detect new lesions outside the field of view in case of progressive 
disease (PD), which is a potential limitation for routine use. In addition, functional 
imaging techniques may be significantly influenced by the hemodynamic changes that 
are caused by targeted agents, which hold especially for inhibitors of VEGF(R) signaling. 
As treatment with these drugs is associated with an increase in blood pressure (49), a 
decrease in heart rate (50), and a reduction in capillary density of the normal 
microcirculation (Chapter 13), these hemodynamic effects may affect the kinetic 
parameters that are obtained by functional imaging, such as PET and DCE-MRI. 
Therefore, methods need to be developed that correct for blood pressure and cardiac 
output in the kinetic modeling of functional imaging techniques.  
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As the PET technique is able to quantify tracer concentrations in absolute units, 
radiolabeling of targeted agents with short-lived positron emitting radionuclides, such as 
carbon-11 (11C; half-life, 20.3 min) and fluorine-18 (18F; half-life, 109.8 min), is an 
attractive approach to assess their uptake in tumor lesions. In dynamic PET studies, the 
optimal kinetic model of an injected tracer can be developed to quantify the tumor 
uptake of the radiolabeled drug. Currently, several targeted drugs have been radio-
labeled as PET tracers and their number is still increasing (51). These specific PET tracers 
provide a unique opportunity for personalized treatment planning, since they may be able 
to predict tumor response before initiation of therapy. Of the approved targeted agents 
for treatment of mRCC, [89Zr]bevacizumab and [18F]sunitinib have been developed as 
PET tracers (52-54). Such PET studies using radiolabeled drugs may not only be used to 
explore a potential relationship between pretreatment uptake and response, but might 
also give insight into drug uptake during treatment and the development of tumor 
resistance.  
Before implementation of new imaging tools and new response evaluation criteria to 
determine the efficacy of targeted therapies in the clinic, the feasibility, accuracy and 
reproducibility of the new methods should be determined. For the assessment of tumor 
response, the test-retest reproducibility of the method needs to be known in order to 
determine the minimal change in the variable that represents a true treatment effect. In 
particular, when relatively small changes are already considered as tumor response, the 
test-retest reproducibility needs to be high. In addition, there is a need for standardized 
protocols including timing of response evaluation, acquisition of imaging data and data 
analysis in order to optimally compare the results in individual patients at different time-
points, but also to enable exchange of data among different institutes. With regard to the 
timing of response assessment, specific attention should be paid to sunitinib, as this TKI 
is usually administered in a schedule consisting of 4 weeks-on treatment followed by a 2-
week rest period. Since temporarily discontinuation of sunitinib may result in flare-up 
mimicking PD (55), response measurements should not be performed during the rest 
period. As the new criteria and techniques have not yet been optimally validated, RECIST 
can still be considered as the preferred method to assess response to targeted therapy.   
 
III.2 Circulating factors  
Apart from imaging techniques, markers in blood may have promise as surrogate 
endpoints for sunitinib efficacy in mRCC patients. In comparison with imaging techniques, 
blood parameters are usually less expensive and less time-consuming. In Chapters 10, 
11 and 12, it is demonstrated that changes in blood values including hemoglobin, 
circulating endothelial cells (CECs), hematopoietic progenitor cells (HPCs), and circulating 
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proteins are partly reversible and related to the dosing schedule of sunitinib. The 
reversible pattern of these changes in blood values, however, suggests that the 
investigated markers rather reflect systemic exposure to sunitinib than a surrogate 
endpoint for tumor response. Among the investigated blood-based parameters in the 
present thesis, only CECs and circulating Ang-2 hold promise as surrogate markers, as 
changes in these blood parameters were associated with treatment outcome. An 
increased number of CECs after 14 days of sunitinib treatment was associated with a 
longer PFS in mRCC patients (Chapter 11), whereas the decrease in circulating Ang-2 
was positively associated with the percentage decrease in tumor burden after sunitinib 
treatment (Chapter 12).  
 
III.2.1 Circulating endothelial cells and progenitor cells 
To date, the origin and phenotype of CECs and progenitor cells is not well defined. CECs 
are thought to be shed from mature blood vessels (56), whereas progenitor cells are 
considered to be bone marrow-derived cells, contributing to tumor angiogenesis (57). In 
sunitinib-treated mRCC patients, the increase in CECs may be caused by endothelial cell 
detachment and may reflect antivascular effects of sunitinib in tumors (Chapter 11). In a 
more recent study by Farace et al (58), baseline CD45dimCD34+VEGFR2+ progenitor cells 
were associated with PFS and OS in 55 mRCC patients treated with sunitinib or sorafenib. 
In that study, levels of CD45dimCD34+VEGFR2+ progenitor cells showed an increase on 
day 14 after start of treatment as compared with baseline levels, but this change was not 
significant (58). In addition, patients with stable or increased levels of CD45dim-
CD34+VEGFR2+ progenitor cells between baseline and day 14 had a lower risk of disease 
progression compared with patients whose CD45dimCD34+VEGFR2+ progenitor cell levels 
decreased over the same period (58). These results by Farace et al (58) are in contrast 
to the results described in Chapter 11, as a significant decrease in the level of 
CD45dim/CD34bright/VEGFR2+ HPCs was found in Chapter 11. This decrease in the level of 
CD45dim/CD34bright/VEGFR2+ HPCs may be caused by sunitinib-induced bone marrow 
suppression associated with FLT-3 inhibition of sunitinib (59). The discrepancy between 
the study by Farace et al (58) and our study may be explained by the fact that the 
CD45dim/CD34bright/VEGFR2+ HPCs in Chapter 11 are presented in absolute counts, 
whereas Farace et al presented the results as the percentage of VEGFR2+ cells among 
the circulating progenitor cells (CD45dimCD34+). This difference in presentation of results 
on progenitor cells illustrates the lack of agreement on the methodology of studies 
investigating CECs and progenitor cells. Currently, identification and enumeration of CECs 
and progenitor cells remain difficult and are performed by non-standardized methods. As 
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agreement on the phenotypic differentiation of CECs and progenitor cells is still lacking, 
there is a need for consensus on the characterization of these cells.  
 
III.2.2 Circulating Ang-2 
The role of angiopoietin-2 (Ang-2) in tumor angiogenesis remains controversial and 
poorly defined. During sunitinib treatment, levels of circulating Ang-2 and sTie-2 
decreased. The reduction in circulating Ang-2 was positively associated with the 
percentage decrease in tumor burden after sunitinib treatment (Chapter 12). Targeting 
Ang-2 may represent an additional beneficial effect of sunitinib in patients with mRCC. 
However, it is currently not known whether sunitinib directly targets Ang-2 or whether 
the decrease in circulating Ang-2 reflects an indirect effect of sunitinib on another target. 
As Ang-2 and von Willebrand factor (vWF) are both stored in the Weibel-Palade bodies of 
endothelial cells (EC) and plasma levels of vWF did not change in mRCC patients treated 
with sunitinib, it was suggested that sunitinib mostly reduced Ang-2 production from 
tumor cells (Chapter 12).  
Presently, the interest in the Ang-2/Tie-2 pathway as an important factor for tumor 
angiogenesis is rapidly growing and drugs that selectively target the Ang-2/Tie-2 
pathway have been developed (60). There is evidence that targeting the Ang-2/Tie-2 
signaling pathway may inhibit the functions of Tie-2-expressing macrophages (TEM), 
which is a subset of tumor-associated macrophages having proangiogenic activity (61). 
Mazzieri et al (62) have shown that inhibition of Ang-2 regresses the tumor vasculature 
and inhibits progression of late-stage, metastatic MMTV-PyMT mammary carcinomas in a 
mouse tumor model. In that study, Ang-2 blockade did not inhibit recruitment of 
MRC1(+)TEMs, but inhibited their upregulation of Tie-2 and ability to restore 
angiogenesis in tumors. After a conditional knockdown of Tie-2 in hematopoietic-lineage 
cells, a lack of association was observed between TEMs and ECs in MMTV-PyMT tumors. 
Together, these findings suggest that Ang-2/Tie-2 signaling, or the upregulation of Tie-2 
receptors on the surface of TEMs, is important to enable TEM interacting with angiogenic 
blood vessels [Figure 4, (61)]. This suggests that activated ECs in tumors release Ang-2, 
which in turn induces TEMs to interact with sprouting blood vessels through upregulation 
of Tie-2 on TEM as well as the formation of EC-TEM cell-to-cell contacts mediated by 
Ang-2 and Tie-2 (61). Although Ang-2 expression by tumor cells is not considered in the 
above described interactions between ECs and TEMs, it is conceivable that expression of 
Ang-2 by tumor cells, which has been observed for RCC tumor cells (63), can lead to 
interactions between tumor cells and TEMs. Since sunitinib treatment reduces levels of 
circulating Ang-2 and Tie-2 (Chapter 12), sunitinib may inhibit both ECs-TEMs and tumor 
cells-TEMs interactions. In addition, the inhibitory activity of sunitinib on bone marrow 
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may reduce the recruitment of TEMs and consequently their availability in tumors. As 
TEMs are known to have protumoral and proangiogenic activity that can counteract the 
efficacy of both anti-angiogenic and radiation therapy (61), the combined targeting of 
angiogenic ECs and proangiogenic TEMs by selective inhibition of the Ang-2/Tie-2-
pathway is promising for the treatment of mRCC patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Modeling the effects of angiopoietin (Ang) inhibition on angiogenesis and TEMs in mouse 
mammary tumors. In mature blood vessels, Ang-1 is constitutively expressed by perivascular cells, 
such as pericytes and smooth muscle cells, and promotes EC quiescence by interacting with Tie-2 
on ECs. In these conditions, ECs release little or no Ang-2 (not shown). (A) In growing tumors, ECs 
proliferate and form new blood vessels. This process is accompanied by the dissociation of 
pericytes from, and association of TEMs with, the sprouting ECs. At sites of sprouting angiogenesis 
(inset in A and B), activated ECs upregulate and release Ang-2 (which competes with Ang-1 for 
binding to Tie-2) in the peri-EC spaces, making it available for binding to Tie-2 on ECs and 
perivascular TEMs. The net outcome of the process, which occurs in the presence of VEGF and 
other proangiogenic factors, is stimulation of angiogenesis. (C) Ang-2 specific inhibition leads to 
regression of tumor blood vessels. This is accompanied by enhanced pericyte coverage of, and 
displacement of TEMs from, the remaining blood vessels. The former effect may be mediated, at 
least in part, by Ang-1, which outcompetes Ang-2 for binding to Tie-2. Note that TEMs express 
much lower Tie-2 levels in Ang-2 depleted tumors than in untreated tumors, suggesting that Ang-2 
directly stimulates Tie-2 expression by TEMs.  
TEM, Tie-2 expressing macrophages; Ang-1, angiopoietin-1; Ang-2, angiopoietin-1; EC, endothelial 
cell [reprinted with permission from reference (61)]. 
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III.2.3 Capillary density and blood pressure 
As described in Chapter 13, sunitinib treatment induced a decrease in capillary density in 
the dorsal finger of the skin, whereas blood pressure increased. These effects were 
related and probably reflect inhibition of VEGFR-2 signaling, leading to a decreased 
production of nitric oxide (NO) and subsequently peripheral vasoconstriction and 
hypertension (64). In this respect, polymorphisms in genes of the VEGFR-2/NO pathway 
may be useful to predict the development of hypertension in sunitinib-treated patients 
(65). As mentioned above (see paragraph II.2.7), retrospective studies have shown that 
the development of hypertension may be a simple surrogate marker for outcome in 
mRCC patients treated with sunitinib (43-45). However, it should be excluded that the 
observed relation between the development of hypertension and clinical outcome is not 
confounded by patient characteristics such preexistent hypertension and age. In addition, 
prospective studies with adequate blood pressure measurements are warranted to 
confirm the usefulness of hypertension as a surrogate marker of sunitinib efficacy. The 
mechanism of the relation between drug-induced hypertension and clinical outcome in 
patients treated with anti-angiogenic drugs has not yet been clarified. On the one hand, 
earlier studies have shown that the vasoconstrictor angiotensin II can enhance blood flow 
in hepatic tumors (66;67), suggesting increased drug delivery to tumors. On the other 
hand, a previous PET study using radioactive water and a radiolabeled anticancer drug 
([11C]docetaxel) has shown that bevacizumab induces a rapid decrease in tumor 
perfusion and drug delivery to tumors in patients with non-small cell lung cancer (68). 
These findings indicate that more insight into the relation between drug-induced 
hypertension and clinical outcome is warranted, as it may also provide insight into the 
effects of anti-hypertensive medication on the efficacy of VEGF(R) inhibitors.   
 
Conclusions 
As multiple systemic treatment modalities arise, a further refinement is needed to 
identify mRCC patients who are likely to benefit from sunitinib treatment and patients 
who do not. Although the MSKCC criteria may be useful for risk stratification, more 
specific tools are required to select individual patients for a specific treatment. Since 
targeted drugs may fail in a number of patients and are associated with a wide range of 
toxicities, tools are needed for prediction of efficacy and drug-induced toxicity in order to 
personalize treatment planning in individual patients. To this end, prediction models, 
pharmacogenetic variables and radiolabeled drugs for PET may be useful to predict the 
efficacy and toxicity of targeted agents, including sunitinib, prior to the start of 
treatment. Furthermore, evaluation of tumor response needs to be improved in order to 
switch early from an ineffective drug to another one. Besides response evaluation by 
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tumor imaging, circulating biomarkers in blood may be promising surrogate markers for 
this purpose. To that end, extensive studies in larger numbers of cancer patients are 
required to validate markers for routine clinical use. In addition, it has become 
increasingly important to define the best sequence of drugs in order to maximize patient 
outcome. Finally, there is still a need for new active molecules since most mRCC patients 
will eventually acquire drug resistance and die from progressive disease. Therefore, 
participation in clinical trials should still be encouraged for patients with mRCC. 
201
   
 
References 
 
 1.  Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 
2009;27:3225-34. 
 
 2.  Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib 
versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. 
 3.  Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall 
survival and updated results for sunitinib compared with interferon alfa in patients with 
metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90. 
 4.  Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally 
advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin 
Oncol 2010;28:1061-8. 
 5.  Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. 
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a 
randomised, double-blind phase III trial. Lancet 2007;370:2103-11. 
 6.  Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of 
bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma 
(AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2137-43. 
 7.  Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus 
interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal 
cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8. 
 8.  Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of 
bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with 
metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-
43. 
 9.  Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, et al. Number of metastatic 
sites rather than location dictates overall survival of patients with node-negative metastatic 
renal cell carcinoma. Urology 2003;61:314-9. 
 10.  Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. 
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal 
cancer. J Clin Oncol 2003;21:3127-32. 
 11.  Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, 
interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-
81.   
 12.  Gotink KJ, Broxterman HJ, Labots M, De Haas RR, Dekker H, Honeywell RJ, et al. 
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer 
Res 2011;17:7337-46. 
 13.  Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of 
metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6. 
 14.  Bex A, Horenblas S, Meinhardt W, Verra N, De Gast GC. The role of initial immunotherapy 
as selection for nephrectomy in patients with metastatic renal cell carcinoma and the 
primary tumor in situ. Eur Urol 2002;42:570-4. 
 15.  Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. 
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for 
metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9. 
202
   
 
 16.  Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R. Radical nephrectomy plus 
interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic 
renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70. 
 17.  Biswas S, Kelly J, Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell 
carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 2009;14(1):52-9. 
 18.  Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target 
Oncol 2010;5(2):113-8. 
 19.  Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine 
kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008;72(4):864-8. 
 20.  Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, et al. Neoadjuvant clinical 
trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 
2010;28:1502-7. 
 21.  Rodriguez Faba O, Breda A, Rosales A, Palou J, Algaba F, Maroto Rey P, et al. Neoadjuvant 
temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. 
Eur Urol 2010;58:307-10. 
 22.  Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in 
advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. 
 23.  Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in 
patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24. 
 24.  Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib 
and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 
2008;26:127-31. 
 25.  Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and 
efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet 
Oncol 2009;10:757-63. 
 26.  Molina A, Feldman D, Ginsberg M, Kroog G, Tickoo S, Jia X, et al. Phase II trial of sunitinib 
in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 
2012;30:335-40.  
 27.  Singer E, Bratslavsky G, Linehan W, Srinivasan R. Targeted therapies for non-clear renal 
cell carcinoma. Target Oncol 2010;5:119-29. 
 28.  Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between 
exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results 
of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 
2010;66:357-71.  
 29.  Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and 
temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 
2009;3:170-9. 
 30.  Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after 
sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 
2006;145:660-4. 
 31.  Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, et al. The clinical 
implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 
2008;99:448-54. 
203
   
 
 32.  Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects 
of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500. 
 33.  Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for 
the management of hand-foot skin reaction associated with the multitargeted kinase 
inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-11. 
 34.  Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, et al. Toxicities of 
targeted therapy and their management in kidney cancer. Eur Urol 2011;59:526-40. 
 35.  Merkus D, Sorop O, Houweling B, Boomsma F, Van den Meiracker AH, Duncker DJ. NO and 
prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising 
swine. Am J Physiol Heart Circ Physiol 2006;291:H2075-H2081. 
 36.  Wiley KE, Davenport AP. Physiological antagonism of endothelin-1 in human conductance 
and resistance coronary artery. Br J Pharmacol 2001;133:568-74. 
 37.  Kappers MH, Van Esch JH, Sluiter W, Sleijfer S, Danser AHJ, Van den Meiracker AH. 
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased 
circulating endothelin-1 levels. Hypertension 2010;56:675-81. 
 38.  Kappers MH, Smedts FM, Horn T, Van Esch JH, Sleijfer S, Leijten F, et al. The vascular 
endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome 
with activation of the endothelin system. Hypertension 2011;58:295-302. 
 39.  Bamias A, Manios E, Karadimou A, Michas F, Lainakis G, Constantinidis C, et al. The use of 
24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib 
improves the diagnostic accuracy and management of hypertension in patients with 
advanced renal cancer. Eur J Cancer 2011;47:1660-8. 
 40.  Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report 
of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure. Hypertension 2003;42:1206-52. 
 
 41.  Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of 
hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15. 
 42.  Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. Inhibition of 
vascular endothelial growth factor-a signaling induces hypertension: examining the effect 
of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of 
concomitant antihypertensive therapy. Clin Cancer Res 2008;14:3124-31. 
 43.  Szmit S, Langiewicz P, Zlnierek J, Nurzynski P, Zaborowska M, Filipiak KJ, et al. 
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal 
cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 
2011;35:18-25. 
 44.  Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a 
biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. 
J Natl Cancer Inst 2011;103:763-73. 
 45.  Bono P, Rautiola J, Utriainen T, Joensuu H. Hypertension as predictor of sunitinib treatment 
outcome in metastatic renal cell carcinoma. Acta Oncol 2011;50:569-73. 
 46.  Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Boven E. Targeted therapies in renal 
cell cancer: recent developments in imaging. Target Oncol. 2010;5:95-112. 
 47.  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J 
Cancer 2009;45:228-47. 
204
   
 
 48.  Hillman SL, An MW, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC, et al. Evaluation 
of the optimal number of lesions needed for tumor evaluation using the response 
evaluation criteria in solid tumors: a North Central Cancer Treatment Group Investigation. J 
Clin Oncol 2009;27:3205-10. 
 49.  Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 
24:1329-31. 
 50.  Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving 
sunitinib. N Engl J Med 2008;358:95-7. 
 
 51.  Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. 
Individualized treatment planning in oncology: role of PET and radiolabelled anticancer 
drugs in predicting tumour resistance. Curr Pharm Des 2008;14:2914-31. 
 52.  Nagengast WB, De Korte MA, Oude Munnink TH, Timmer-Bosscha H, Den Dunnen WF, 
Hollema H, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to 
treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010;51:761-7. 
 53.  Nagengast WB, De Vries EG, Hospers GA, Mulder NH, De Jong JR, Hollema H, et al. In vivo 
VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl 
Med 2007;48:1313-9. 
 54.  Wang JQ, Miller KD, Sledge GW, Zheng QH. Synthesis of [18F]SU11248, a new potential 
PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 2005;15:4380-4. 
 55.  Desar IM, Mulder SF, Stillebroer AB, Van Spronsen DJ, Van der Graaf WT, Mulders PF, et al. 
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or 
sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 2009;48:927-31. 
 56.  Duda DG, Cohen KS, Di Tomaso E, Au P, Klein RJ, Scadden DT, et al. Differential CD146 
expression on circulating versus tissue endothelial cells in rectal cancer patients: 
implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic 
therapy. J Clin Oncol 2006;24:1449-53. 
 57.  Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of 
bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor 
angiogenesis and growth. Nat Med 2001;7:1194-201. 
 58.  Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, et al. Levels of 
circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in 
metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 
2011;104:1144-50. 
 59.  Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, et al. 
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 
2009;101:1717-23. 
 60.  Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, 
pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in 
adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-65. 
 61.  De Palma M, Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin 
Cancer Res 2011;17:5226-32. 
 62.  Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 
axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling 
rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512-26. 
205
   
 
 63.  Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, et al. Expression of 
the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation 
by the von Hippel-Lindau gene and hypoxia. J Pathol 2002;198:502-10. 
 64.  Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. 
Hypertension and rarefaction during treatment with telatinib, a small molecule angio-
genesis inhibitor. Clin Cancer Res 2008;14:3470-6. 
 65.  Van der Veldt AA, Eechoute K, Oosting, S, Kappers MH, Haanen JB, Reyners  AK, et al. 
Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) 
and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced 
hypertension. J Clin Oncol 2011;29:abstract 4611.  
  
 66.  Burke D, Davies MM, Zweit J, Flower MA, Ott RJ, Dworkin MJ, et al. Continuous angiotensin 
II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases. Br J 
Cancer 2001;85:1640-5. 
 67.  Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, et al. Angiotensin-
II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 
PET. J Nucl Med 1996;37:1522-3. 
 68.  Van der Veldt AA, Lubberink M, Bahce I, Walraven M, De Boer MP, Greuter HN, et al. Rapid 
decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for 
scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82-91.  
 
 
206
 
 
 
 
Nederlandse samenvatting 
 
 
 
 
       
 
De ontwikkeling van medicamenten die beter gericht zijn tegen de kankercel, ook wel 
targeted therapie genoemd, heeft het perspectief van de patiënt met gemetastaseerd 
niercelcarcinoom significant verbeterd. Voor niercelcarcinoom is de vasculaire 
endotheliale groeifactor (VEGF) een belangrijk target voor therapie. Van de nieuwe 
medicamenten heeft sunitinib een belangrijke plaats verworven bij de behandeling van 
het niercelcarcinoom. Hoewel behandeling met sunitinib heeft geleid tot een betere 
overleving van patiënten met deze ziekte, was er enkele jaren geleden nog veel 
onduidelijk over de eigenschappen van dit middel. In dit proefschrift worden 
verscheidene klinische en farmacodynamische aspecten van sunitinib beschreven bij 
patiënten met gemetastaseerd niercelcarcinoom. Hoofdstuk 1 bevat een introductie tot 
de behandeling van gemetastaseerd niercelcarcinoom in het algemeen, met daarbij 
speciale aandacht voor sunitinib. Vervolgens is de inhoud van dit proefschrift opgedeeld 
in drie delen.  
 
Deel I: Effectiviteit van sunitinib voor niercelcarcinoom 
In Hoofdstuk 2 is de effectiviteit van sunitinib voor primaire tumoren van het niercel-
carcinoom beschreven. Er werden zeventien patiënten met een primair gemetastaseerde 
ziekte behandeld met sunitinib. Hoewel primaire tumoren meestal refractair zijn voor een 
behandeling met cytokines, induceerde sunitinib zowel een significante verkleining in de 
tumorgrootte als een uitgebreide tumornecrose. Aangezien een klinisch indrukwekkende 
respons in primaire tumoren werd waargenomen, zou een voorbehandeling met sunitinib 
de chirurgische resectie van primaire tumoren sterk kunnen vereenvoudigen.  
Hoofdstuk 3A is gewijd aan de mogelijke waarde van een neoadjuvante behandeling 
met sunitinib voor inoperabele primaire tumoren. Tot deze inoperabele primaire tumoren 
werden complexe primaire tumoren en/of uitgebreide locoregionale metastasen 
gerekend. Hoewel zes van de tien inoperabele tumoren een afname in tumorgrootte 
toonden, kon slechts bij drie patiënten cytoreductieve chirurgie worden uitgevoerd. 
Verder werd duidelijk  dat neoadjuvante behandeling met sunitinib een negatief effect 
kan hebben op mogelijk operabele primaire tumoren (Hoofdstuk 3B). Twee patiënten 
met gemetastaseerd niercelcarcinoom en een primaire tumor in situ toonden progressie 
van de ziekte tijdens neoadjuvante behandeling met sunitinib. Deze progressieve ziekte 
uitte zich in een trombus in de vena cava. Dit leidde ertoe dat de oorspronkelijk geplande 
operatie niet kon doorgaan. Aangezien metastasering naar de hersenen ook een moeilijk 
te behandelen tumorlocalisatie van niercelcarcinoom is, werd de incidentie van 
hersenmetastasen tijdens behandeling met sunitinib besproken in Hoofdstuk 4. 
Gedurende een periode van twee jaar kregen negen van 91 patiënten met 
gemetastaseerd niercelcarcinoom, die werden behandeld met sunitinib, symptomatische 
hersenmetastasen. Deze hersenmetastasen waren het eerste teken van progressie van 
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 de ziekte tijdens sunitinib. Het was opmerkelijk dat bij zes van de negen patiënten de 
symptomen ontstonden gedurende de tweewekelijkse rustperiode in het behandel-
schema. Deze observatie doet vermoeden dat hersenmetastasen in eerste instantie 
gemaskeerd worden door het anti-oedeem effect van sunitinib. Sunitinib lijkt dus 
onvoldoende effectief te zijn voor locale controle van hersenmetastasen, maar kan 
mogelijk wel tijdelijk de symptomen van hersenmetastasen onderdrukken. Na 
radiotherapie of chirurgische behandeling van de hersenmetastasen kon de behandeling 
met sunitinib weer veilig worden voortgezet en bleek dit medicament nog langdurig 
effectief te zijn voor de behandeling van de extra-cerebrale tumorgebieden. Daarom is 
progressieve ziekte van het niercelcarcinoom in het centrale zenuwstelsel, mits deze 
progressie nieuw en geïsoleerd is, zeker geen reden om de behandeling met sunitinib 
definitief te stoppen.  
Vervolgens is in Hoofdstuk 5 beschreven in hoeverre genetische polymorfismen de 
effectiviteit van sunitinib bij patiënten met gemetastaseerd niercelcarcinoom kunnen 
voorspellen. Daartoe werd een retrospectieve multicentrum studie verricht bij 136 
patiënten met gemetastaseerd heldercellig niercelcarcinoom, die werden behandeld met 
sunitinib. Er werden dertig polymorfismen, die geassocieerd worden met de 
farmacokinetiek en de farmacodynamiek van sunitinib, onderzocht voor een mogelijke 
relatie met de progressievrije overleving en de totale overleving. Naast de drie klinische 
karakteristieken [Memorial Sloan-Kettering Cancer Center (MSKCC) prognostische 
criteria, aantal locaties met metastasen en leeftijd] bleken genetische polymorfismen in 
drie genen(CYP3A5, NR1I3 en ABCB1), die betrokken zijn bij de farmacokinetiek van 
sunitinib, voorspellend te zijn voor de progressievrije overleving. Toekomstige studies 
zijn nodig om deze genetische determinanten prospectief te valideren teneinde hun rol 
bij de blootstelling aan en de effectiviteit van sunitinib te verduidelijken. 
 
Deel II: Bijwerkingen van sunitinib 
In Hoofdstuk 6 zijn de toxiciteit en de effectiviteit van sunitinib beschreven bij 82 
patiënten met gemetastaseerd niercelcarcinoom die werden behandeld in een 
‘compassionate use programme’. In dit ‘compassionate use programme’ waren de in- en 
exclusie criteria minder streng dan die in fase III studies. Op deze manier kon een beter 
beeld worden verkregen van het voordeel van sunitinib bij patiënten uit de dagelijkse 
oncologische praktijk. In deze studie bleek de effectiviteit van sunitinib vergelijkbaar met 
die in eerdere fase III studies. De geobserveerde toxiciteit, welke werd gegradeerd 
volgens de Common Terminology Criteria for Adverse Events (CTCAE), was echter veel 
ernstiger, aangezien bijna de helft van de patiënten een verlaging van de dosis nodig had 
om de ontstane bijwerkingen van sunitinib te verminderen. Stomatitis, vermoeidheid, 
hand-voet syndroom en een combinatie van verschillende graad 1-2 bijwerkingen waren 
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de belangrijkste redenen voor een dosisverlaging. Vervolgens werd nagegaan of kon 
worden voorspeld, bij wie ernstige toxiciteit zou optreden. Ernstige toxiciteit werd 
gedefinieerd als de noodzaak tot dosisreductie of een definitieve beëindiging van de 
behandeling. Deze bleek sterk gerelateerd aan een klein lichaamsoppervlak, een hoge 
leeftijd en het vrouwelijke geslacht. Gebaseerd op deze drie karakteristieken kon een 
model worden ontwikkeld waarmee de kans op ernstige toxiciteit door sunitinib kon 
worden voorspeld.  
Hoofdstuk 7 is gewijd aan het ontstaan van ernstige cognitieve symptomen tijdens 
behandeling met sunitinib. Drie bejaarde patiënten met gemetastaseerd niercelcarcinoom 
kregen cognitieve klachten en gedragsveranderingen tijdens het gebruik van sunitinib. 
Hersenmetastasen werden uitgesloten en na het staken van de behandeling verdwenen 
de cognitieve symptomen vanzelf. Alle drie patiënten had voorafgaande aan de 
behandeling met sunitinib reeds een arteriosclerotische leukoencefalopathie, hetgeen 
waarschijnlijk heeft bijgedragen aan het ontstaan van de cognitieve bijwerkingen. 
Daarom is het belangrijk dat artsen aandacht hebben voor cognitieve veranderingen in 
bejaarde patiënten aan wie sunitinib wordt voorgeschreven. Wanneer patiënten 
dergelijke symptomen ervaren, dienen hersenmetastasen te worden uitgesloten en dient 
de behandeling met sunitinib (tijdelijk) te worden gestaakt. Zoals eerder beschreven 
kunnen de bijwerkingen tijdens een behandeling met sunitinib ernstig zijn. Daarom is er 
een dringende behoefte aan hulpmiddelen die de toxiciteit van sunitinib bij individuele 
patiënten kunnen voorspellen, zodat de dosering zo nodig kan worden aangepast.   
In Hoofdstuk 8 is beschreven of specifieke genetische polymorfismen, die belangrijk zijn 
bij de farmacokinetiek en farmacodynamiek van sunitinib, kunnen worden geïdenti-
ficeerd. Deze genetische polymorfismen zouden patiënten gevoeliger kunnen maken voor 
de bijwerkingen van sunitinib. Bij 219 met sunitinib behandelde patiënten bleken 
verscheidene genetische polymorfismen aangewezen te kunnen worden, die geassocieerd 
waren met het ontstaan van leucopenie, mucositis, hand-voet syndroom en elke 
bijwerking ernstiger dan graad 2. Deze genetische polymorfismen codeerden voor 
metaboliserende enzymen, efflux transporters en specifieke targets van sunitinib. Zo was 
het ontstaan van leucopenie geassocieerd met genetische polymorfismen in CYP1A1 
2455A/G, FLT3 738T/C en het NR1I3 haplotype. Het optreden van mucositis en het hand-
voet syndroom was geassocieerd met genetische polymorfismen in respectievelijk 
CYP1A1 2455A/G en het ABCB1 haplotype. De prevalentie van bijwerkingen die ernstiger 
waren dan graad 2 was verhoogd, wanneer het T allel van de vasculaire endotheliale 
groeifactorreceptor (VEGFR)-2 1191C/T of een kopie van TT in het ABCG2 haplotype 
aanwezig was. Het belang van deze specifieke genetische polymorfismen voor het 
ontstaan van bijwerkingen van sunitinib zal in een onafhankelijke patiëntenpopulatie 
moeten worden gevalideerd.  
213
 Deel III: Potentiële biomarkers 
Om de effectiviteit van sunitinib te kunnen voorspellen werden nieuwe criteria voor het 
beoordelen van computertomografie (CT) scans geëvalueerd, zoals is beschreven in 
Hoofdstuk 9. Deze nieuwe criteria houden rekening met het ontstaan van tumornecrose 
en werden eerder door Choi en medewerkers ontwikkeld. In deze studie werden de 
criteria volgens Choi gebruikt voor de evaluatie van CT scans van 55 patiënten met 
gemetastaseerd niercelcarcinoom, die werden behandeld met sunitinib. Volgens Choi’s 
criteria is er sprake van een partiële remissie als de grootte van de tumor in één 
dimensie afneemt met tenminste 10% óf als de attenuatie van de tumor (uitgedrukt in 
Hounsfield Units) afneemt met tenminste 15%. Wanneer de grootte van de tumor 
toeneemt met tenminste 10% en er geen sprake is van een partiële respons op basis van 
de verandering in attenuatie, is er volgens Choi en medewerkers sprake van progressieve 
ziekte. Tijdens de eerste evaluatie na een mediane periode van 1,9 maanden hadden de 
Choi criteria voor de progressievrije overleving en voor de totale overleving een 
significant betere voorspellende waarde dan de gebruikelijke Response Evaluation 
Criteria In Solid Tumors (RECIST). Gedurende de verdere behandeling met sunitinib was 
de voorspellende waarde echter niet beter dan die van RECIST. De Choi criteria zouden 
kunnen worden toegepast om vroegtijdig patiënten met gemetastaseerd niercel-
carcinoom te herkennen die baat hebben bij behandeling met sunitinib, maar ze zijn niet 
geschikt om patiënten die progressieve ziekte ontwikkelen vroegtijdig te identificeren. 
Daarom zal het gebruik van de respons criteria ontwikkeld door Choi en medewerkers 
geen invloed hebben op de beslissing of behandeling met sunitinib bij deze patiënten 
moet worden gestopt. 
In Hoofdstuk 10 zijn de veranderingen in het hemoglobinegehalte tijdens de 
behandeling met sunitinib beschreven. Bij 82 patiënten met gemetastaseerd niercel-
carcinoom werd een zig-zag patroon in het hemoglobinegehalte en het aantal erytrocyten 
waargenomen. Gedurende de vier weken behandeling ontstond een tijdelijke stijging in 
het hemoglobinegehalte en het erytrocytengetal welke verdween gedurende de 
rustperiode van twee weken. Hoewel de toename in het aantal erytrocyten gepaard ging 
met ???????????????????????????????????????het plasma, was vanwege de prompte daling in 
de rustperiode een causaal verband minder waarschijnlijk. Gebaseerd op eerdere studies 
en onze bevindingen was een betere hypothese, dat de stijging in het hemoglobine-
gehalte meer het gevolg is van een tijdelijk verlies aan intravasculaire vloeistof door 
remming van VEGFR-2.  
Hoofdstuk 11 is gewijd aan de effecten van sunitinib op rijpe circulerende endotheel 
cellen (CECs) en hemat????etische stamcellen (HPCs) in het bloed van patiënten met 
gemetastaseerd niercelcarcinoom. De veranderingen in circulerende CECs en HPCs 
zouden de activiteit van sunitinib op de tumorvasculatuur kunnen weerspiegelen. In het 
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bijzonder werd de kinetiek geanalyseerd van specifieke populaties CECs 
[CD45neg)/CD34bright)] en HPCs [CD45dim)/CD34bright)] die VEGFR-2 tot expressie brengen. 
Deze twee celpopulaties toonden een tegenovergestelde kinetiek: de CECs stegen terwijl 
de HPCs daalden. Deze stijging in CECs is waarschijnlijk het gevolg van de activiteit van 
sunitinib in onrijpe tumorvaten. Na veertien dagen behandeling met sunitinib hadden 
patiënten met een gestegen aantal CECs een langere progressievrije overleving dan 
patiënten met een gedaald aantal CECs.   
Om de effecten van sunitinib op het endotheel van tumoren verder te onderzoeken werd 
een studie, beschreven in Hoofdstuk 12, verricht om eiwitten in plasma te meten die 
geassocieerd zijn met geactiveerd tumorendotheel. Daartoe werd het plasma van 
patiënten met gemetastaseerd niercelcarcinoom, die werden behandeld met sunitinib, 
onderzocht op de hoeveelheid VEGF, soluble vascular cell adhesion molecule-1 (sVCAM-
1), soluble intercellular cell adhesion molecule-1 (sICAM-1), von Willebrand factor (vWF), 
circulerend angiopoietin-2 (Ang-2) en soluble Tie-2 (sTie-2). Voor het starten van de 
behandeling met sunitinib bleek de omvang van het ziekteproces positief geassocieerd te 
zijn met de hoeveelheid circulerend Ang-2. Behandeling met sunitinib leidde tot een 
daling van het circulerende Ang-2 en sTie-2, terwijl de hoeveelheden sVCAM-1 en VEGF 
juist significant toenamen. De daling in circulerend Ang-2 was positief geassocieerd met 
het totale percentage afname in alle tumorgebieden. Daarom zou de afname van 
circulerend Ang-2 een biomarker kunnen zijn voor de activiteit van sunitinib bij 
niercelcarcinoom.  
Tenslotte werden in Hoofdstuk 13 de effecten van sunitinib op de systemische 
vasculatuur besproken. Behandeling met sunitinib is geassocieerd met het ontstaan van 
hypertensie, die toegeschreven wordt aan functionele rarefactie (een vermindering in 
geperfundeerde microvaatjes) of structurele rarefactie (een afname in de anatomische 
capillaire dichtheid). Bij patiënten met een gemetastaseerd niercelcarcinoom werd 
onderzocht of behandeling met sunitinib leidde tot een vermindering van de 
microvasculaire functie en/of afname van de capillaire dichtheid in de dorsale huid van de 
vinger (Hoofdstuk 13A). Bij deze patiënten werd een stijging van de systolische en 
diastolische bloeddruk waargenomen, die was geassocieerd met een afname van de 
capillaire dichtheid in de huid. In Hoofdstuk 13B werd beschreven dat deze effecten 
omkeerbaar zijn na het staken van de behandeling met sunitinib. Aangezien patiënten 
met een grotere afname in capillaire dichtheid tijdens het gebruik van sunitinib een 
langere progressievrije overleving hadden, zou deze waarneming voorspellend kunnen 
zijn voor een langere overleving.  
 
In dit proefschrift zijn verscheidene klinische en farmacodynamische aspecten van de 
behandeling met sunitinib beschreven die belangrijk zijn voor patiënten met 
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 gemetastaseerd niercelcarcinoom. De verschillende studies hebben meer inzicht 
verschaft in het vakkundig voorschrijven van sunitinib, het vermijden van ernstige 
bijwerkingen en het begrijpen van de effecten in het tumorproces en de vasculatuur. De 
gegevens bieden handvatten voor vervolgonderzoek om de behandeling voor patiënten 
met gemetastaseerd niercelcarcinoom verder te verbeteren.  
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